id	sid	tid	token	lemma	pos
aji-137	1	1	_	_	PUNCT
aji-137	2	1	_	_	PUNCT
aji-137	3	1	_	_	PUNCT
aji-137	4	1	_	_	PUNCT
aji-137	5	1	_	_	PUNCT
aji-137	6	1	_	_	PUNCT
aji-137	7	1	_	_	PUNCT
aji-137	8	1	_	_	PUNCT
aji-137	9	1	_	_	PUNCT
aji-137	10	1	_	_	PUNCT
aji-137	11	1	_	_	PUNCT
aji-137	12	1	_	_	PUNCT
aji-137	13	1	_	_	PUNCT
aji-137	14	1	_	_	PUNCT
aji-137	15	1	_	_	PUNCT
aji-137	16	1	_	_	PUNCT
aji-137	17	1	_	_	PUNCT
aji-137	18	1	_	_	PUNCT
aji-137	19	1	_	_	PUNCT
aji-137	20	1	_	_	PUNCT
aji-137	21	1	_	_	PUNCT
aji-137	22	1	_	_	PUNCT
aji-137	23	1	_	_	PUNCT
aji-137	24	1	_	_	PUNCT
aji-137	25	1	_	_	PUNCT
aji-137	26	1	_	_	PUNCT
aji-137	27	1	_	_	PUNCT
aji-137	28	1	_	_	PUNCT
aji-137	29	1	_	_	PUNCT
aji-137	30	1	_	_	PUNCT
aji-137	31	1	_	_	PUNCT
aji-137	32	1	_	_	PUNCT
aji-137	33	1	_	_	PUNCT
aji-137	34	1	_	_	PUNCT
aji-137	35	1	_	_	PUNCT
aji-137	36	1	_	_	PUNCT
aji-137	37	1	_	_	PUNCT
aji-137	38	1	_	_	PUNCT
aji-137	39	1	_	_	PUNCT
aji-137	40	1	_	_	PUNCT
aji-137	41	1	_	_	PUNCT
aji-137	42	1	_	_	PUNCT
aji-137	43	1	_	_	PUNCT
aji-137	44	1	_	_	PUNCT
aji-137	45	1	_	_	PUNCT
aji-137	46	1	_	_	PUNCT
aji-137	47	1	_	_	PUNCT
aji-137	48	1	_	_	PUNCT
aji-137	49	1	_	_	PUNCT
aji-137	50	1	_	_	PUNCT
aji-137	51	1	_	_	PUNCT
aji-137	52	1	_	_	PUNCT
aji-137	53	1	_	_	PUNCT
aji-137	54	1	_	_	PUNCT
aji-137	55	1	_	_	PUNCT
aji-137	56	1	_	_	PUNCT
aji-137	57	1	_	_	PUNCT
aji-137	58	1	_	_	PUNCT
aji-137	59	1	_	_	PUNCT
aji-137	60	1	_	_	PUNCT
aji-137	61	1	_	_	PUNCT
aji-137	62	1	_	_	PUNCT
aji-137	63	1	_	_	PUNCT
aji-137	64	1	_	_	PUNCT
aji-137	65	1	_	_	PUNCT
aji-137	66	1	_	_	PUNCT
aji-137	67	1	_	_	PUNCT
aji-137	68	1	_	_	PUNCT
aji-137	69	1	_	_	PUNCT
aji-137	70	1	_	_	PUNCT
aji-137	71	1	_	_	PUNCT
aji-137	72	1	_	_	PUNCT
aji-137	73	1	_	_	PUNCT
aji-137	74	1	_	_	PUNCT
aji-137	75	1	_	_	PUNCT
aji-137	76	1	_	_	PUNCT
aji-137	77	1	_	_	PUNCT
aji-137	78	1	_	_	PUNCT
aji-137	79	1	_	_	PUNCT
aji-137	80	1	_	_	PUNCT
aji-137	81	1	_	_	PUNCT
aji-137	82	1	_	_	PUNCT
aji-137	83	1	_	_	PUNCT
aji-137	84	1	_	_	PUNCT
aji-137	85	1	_	_	PUNCT
aji-137	86	1	_	_	PUNCT
aji-137	87	1	_	_	PUNCT
aji-137	88	1	_	_	PUNCT
aji-137	89	1	_	_	PUNCT
aji-137	90	1	_	_	PUNCT
aji-137	91	1	_	_	PUNCT
aji-137	92	1	_	_	PUNCT
aji-137	93	1	_	_	PUNCT
aji-137	94	1	_	_	PUNCT
aji-137	95	1	_	_	PUNCT
aji-137	96	1	_	_	PUNCT
aji-137	97	1	_	_	PUNCT
aji-137	98	1	_	_	PUNCT
aji-137	99	1	_	_	PUNCT
aji-137	100	1	_	_	PUNCT
aji-137	101	1	_	_	PUNCT
aji-137	102	1	+	+	ADJ
aji-137	102	2	+	+	NUM
aji-137	102	3	assistant	assistant	ADJ
aji-137	102	4	professor	professor	NOUN
aji-137	102	5	;	;	PUNCT
aji-137	102	6	#	#	NOUN
aji-137	102	7	pharm	pharm	NOUN
aji-137	102	8	d	d	PROPN
aji-137	102	9	iii	iii	NOUN
aji-137	102	10	year	year	NOUN
aji-137	102	11	;	;	PUNCT
aji-137	102	12	*	*	PUNCT
aji-137	102	13	corresponding	correspond	VERB
aji-137	102	14	author	author	NOUN
aji-137	102	15	:	:	PUNCT
aji-137	102	16	e	e	NOUN
aji-137	102	17	-	-	NOUN
aji-137	102	18	mail	mail	NOUN
aji-137	102	19	:	:	PUNCT
aji-137	102	20	keshapallysrijareddy@gmail.com	keshapallysrijareddy@gmail.com	X
aji-137	102	21	;	;	PUNCT
aji-137	102	22	cite	cite	VERB
aji-137	102	23	as	as	ADP
aji-137	102	24	:	:	PUNCT
aji-137	102	25	gupta	gupta	PROPN
aji-137	102	26	,	,	PUNCT
aji-137	102	27	nikita	nikita	PROPN
aji-137	102	28	,	,	PUNCT
aji-137	102	29	sai	sai	PROPN
aji-137	102	30	rama	rama	PROPN
aji-137	102	31	konda	konda	PROPN
aji-137	102	32	,	,	PUNCT
aji-137	102	33	k.	k.	PROPN
aji-137	102	34	srija	srija	PROPN
aji-137	102	35	,	,	PUNCT
aji-137	102	36	and	and	CCONJ
aji-137	102	37	g.	g.	PROPN
aji-137	102	38	pooja	pooja	PROPN
aji-137	102	39	reddy	reddy	PROPN
aji-137	102	40	.	.	PUNCT
aji-137	103	1	2024	2024	NUM
aji-137	103	2	.	.	PUNCT
aji-137	104	1	“	"	PUNCT
aji-137	104	2	the	the	DET
aji-137	104	3	mechanism	mechanism	NOUN
aji-137	104	4	and	and	CCONJ
aji-137	104	5	efficacy	efficacy	NOUN
aji-137	104	6	of	of	ADP
aji-137	104	7	baricitinib	baricitinib	NOUN
aji-137	104	8	as	as	ADP
aji-137	104	9	a	a	DET
aji-137	104	10	novel	novel	ADJ
aji-137	104	11	therapeutic	therapeutic	ADJ
aji-137	104	12	option	option	NOUN
aji-137	104	13	for	for	ADP
aji-137	104	14	rheumatoid	rheumatoid	NOUN
aji-137	104	15	arthritis	arthritis	NOUN
aji-137	104	16	:	:	PUNCT
aji-137	104	17	a	a	DET
aji-137	104	18	review	review	NOUN
aji-137	104	19	”	"	PUNCT
aji-137	104	20	.	.	PUNCT
aji-137	105	1	asian	asian	ADJ
aji-137	105	2	journal	journal	NOUN
aji-137	105	3	of	of	ADP
aji-137	105	4	immunology	immunology	NOUN
aji-137	105	5	7	7	NUM
aji-137	105	6	(	(	PUNCT
aji-137	105	7	1):123	1):123	NUM
aji-137	105	8	-	-	SYM
aji-137	105	9	30	30	NUM
aji-137	105	10	.	.	PUNCT
aji-137	106	1	https://journalaji.com/index.php/aji/article/view/137	https://journalaji.com/index.php/aji/article/view/137	X
aji-137	106	2	.	.	PUNCT
aji-137	107	1	asian	asian	ADJ
aji-137	107	2	journal	journal	PROPN
aji-137	107	3	of	of	ADP
aji-137	107	4	immunology	immunology	NOUN
aji-137	107	5	volume	volume	NOUN
aji-137	107	6	7	7	NUM
aji-137	107	7	,	,	PUNCT
aji-137	107	8	issue	issue	NOUN
aji-137	107	9	1	1	NUM
aji-137	107	10	,	,	PUNCT
aji-137	107	11	page	page	NOUN
aji-137	107	12	123	123	NUM
aji-137	107	13	-	-	SYM
aji-137	107	14	130	130	NUM
aji-137	107	15	,	,	PUNCT
aji-137	107	16	2024	2024	NUM
aji-137	107	17	;	;	PUNCT
aji-137	107	18	article	article	NOUN
aji-137	107	19	no.aji.120135	no.aji.120135	VERB
aji-137	107	20	the	the	DET
aji-137	107	21	mechanism	mechanism	NOUN
aji-137	107	22	and	and	CCONJ
aji-137	107	23	efficacy	efficacy	NOUN
aji-137	107	24	of	of	ADP
aji-137	107	25	baricitinib	baricitinib	NOUN
aji-137	107	26	as	as	ADP
aji-137	107	27	a	a	DET
aji-137	107	28	novel	novel	ADJ
aji-137	107	29	therapeutic	therapeutic	ADJ
aji-137	107	30	option	option	NOUN
aji-137	107	31	for	for	ADP
aji-137	107	32	rheumatoid	rheumatoid	NOUN
aji-137	107	33	arthritis	arthritis	NOUN
aji-137	107	34	:	:	PUNCT
aji-137	107	35	a	a	DET
aji-137	107	36	review	review	NOUN
aji-137	107	37	nikita	nikita	X
aji-137	107	38	gupta	gupta	PROPN
aji-137	107	39	a++	a++	NOUN
aji-137	107	40	,	,	PUNCT
aji-137	107	41	sai	sai	PROPN
aji-137	107	42	rama	rama	PROPN
aji-137	108	1	konda	konda	PROPN
aji-137	108	2	b	b	PROPN
aji-137	108	3	#	#	PROPN
aji-137	108	4	,	,	PUNCT
aji-137	108	5	k.	k.	PROPN
aji-137	108	6	srija	srija	PROPN
aji-137	108	7	b	b	PROPN
aji-137	108	8	#	#	NOUN
aji-137	108	9	*	*	ADJ
aji-137	108	10	and	and	CCONJ
aji-137	108	11	g.	g.	PROPN
aji-137	108	12	pooja	pooja	PROPN
aji-137	108	13	reddy	reddy	PROPN
aji-137	109	1	b	b	PROPN
aji-137	109	2	#	#	PROPN
aji-137	109	3	a	a	DET
aji-137	109	4	department	department	NOUN
aji-137	109	5	of	of	ADP
aji-137	109	6	pharmacy	pharmacy	NOUN
aji-137	109	7	practice	practice	NOUN
aji-137	109	8	,	,	PUNCT
aji-137	109	9	st	st	PROPN
aji-137	109	10	.	.	PROPN
aji-137	109	11	pauls	pauls	PROPN
aji-137	109	12	college	college	PROPN
aji-137	109	13	of	of	ADP
aji-137	109	14	pharmacy	pharmacy	NOUN
aji-137	109	15	,	,	PUNCT
aji-137	109	16	turkayamjal	turkayamjal	PROPN
aji-137	109	17	,	,	PUNCT
aji-137	109	18	hyderabad	hyderabad	PROPN
aji-137	109	19	,	,	PUNCT
aji-137	109	20	telangana	telangana	PROPN
aji-137	109	21	,	,	PUNCT
aji-137	109	22	india	india	PROPN
aji-137	109	23	.	.	PUNCT
aji-137	110	1	b	b	PROPN
aji-137	110	2	st	st	PROPN
aji-137	110	3	.	.	PROPN
aji-137	110	4	pauls	pauls	PROPN
aji-137	110	5	college	college	PROPN
aji-137	110	6	of	of	ADP
aji-137	110	7	pharmacy	pharmacy	NOUN
aji-137	110	8	,	,	PUNCT
aji-137	110	9	turkayamjal	turkayamjal	PROPN
aji-137	110	10	,	,	PUNCT
aji-137	110	11	hyderabad	hyderabad	PROPN
aji-137	110	12	,	,	PUNCT
aji-137	110	13	telangana	telangana	PROPN
aji-137	110	14	,	,	PUNCT
aji-137	110	15	india	india	PROPN
aji-137	110	16	.	.	PUNCT
aji-137	111	1	authors	author	NOUN
aji-137	111	2	’	’	PART
aji-137	111	3	contributions	contribution	NOUN
aji-137	111	4	this	this	DET
aji-137	111	5	work	work	NOUN
aji-137	111	6	was	be	AUX
aji-137	111	7	carried	carry	VERB
aji-137	111	8	out	out	ADP
aji-137	111	9	in	in	ADP
aji-137	111	10	collaboration	collaboration	NOUN
aji-137	111	11	among	among	ADP
aji-137	111	12	all	all	DET
aji-137	111	13	authors	author	NOUN
aji-137	111	14	.	.	PUNCT
aji-137	112	1	all	all	DET
aji-137	112	2	authors	author	NOUN
aji-137	112	3	read	read	VERB
aji-137	112	4	and	and	CCONJ
aji-137	112	5	approved	approve	VERB
aji-137	112	6	the	the	DET
aji-137	112	7	final	final	ADJ
aji-137	112	8	manuscript	manuscript	NOUN
aji-137	112	9	.	.	PUNCT
aji-137	113	1	article	article	NOUN
aji-137	113	2	information	information	PROPN
aji-137	113	3	doi	doi	PROPN
aji-137	113	4	:	:	PUNCT
aji-137	113	5	https://doi.org/10.9734/aji/2024/v7i1137	https://doi.org/10.9734/aji/2024/v7i1137	PROPN
aji-137	113	6	open	open	ADJ
aji-137	113	7	peer	peer	NOUN
aji-137	113	8	review	review	NOUN
aji-137	113	9	history	history	NOUN
aji-137	113	10	:	:	PUNCT
aji-137	113	11	this	this	DET
aji-137	113	12	journal	journal	NOUN
aji-137	113	13	follows	follow	VERB
aji-137	113	14	the	the	DET
aji-137	113	15	advanced	advance	VERB
aji-137	113	16	open	open	ADJ
aji-137	113	17	peer	peer	NOUN
aji-137	113	18	review	review	NOUN
aji-137	113	19	policy	policy	NOUN
aji-137	113	20	.	.	PUNCT
aji-137	114	1	identity	identity	NOUN
aji-137	114	2	of	of	ADP
aji-137	114	3	the	the	DET
aji-137	114	4	reviewers	reviewer	NOUN
aji-137	114	5	,	,	PUNCT
aji-137	114	6	editor(s	editor(s	NOUN
aji-137	114	7	)	)	PUNCT
aji-137	114	8	and	and	CCONJ
aji-137	114	9	additional	additional	ADJ
aji-137	114	10	reviewers	reviewer	NOUN
aji-137	114	11	,	,	PUNCT
aji-137	114	12	peer	peer	NOUN
aji-137	114	13	review	review	NOUN
aji-137	114	14	comments	comment	NOUN
aji-137	114	15	,	,	PUNCT
aji-137	114	16	different	different	ADJ
aji-137	114	17	versions	version	NOUN
aji-137	114	18	of	of	ADP
aji-137	114	19	the	the	DET
aji-137	114	20	manuscript	manuscript	NOUN
aji-137	114	21	,	,	PUNCT
aji-137	114	22	comments	comment	NOUN
aji-137	114	23	of	of	ADP
aji-137	114	24	the	the	DET
aji-137	114	25	editors	editor	NOUN
aji-137	114	26	,	,	PUNCT
aji-137	114	27	etc	etc	X
aji-137	114	28	are	be	AUX
aji-137	114	29	available	available	ADJ
aji-137	114	30	here	here	ADV
aji-137	114	31	:	:	PUNCT
aji-137	114	32	https://www.sdiarticle5.com/review-history/120135	https://www.sdiarticle5.com/review-history/120135	NOUN
aji-137	114	33	received	receive	VERB
aji-137	114	34	:	:	PUNCT
aji-137	114	35	03/06/2024	03/06/2024	NUM
aji-137	114	36	accepted	accept	VERB
aji-137	114	37	:	:	PUNCT
aji-137	114	38	05/08/2024	05/08/2024	NUM
aji-137	114	39	published	publish	VERB
aji-137	114	40	:	:	PUNCT
aji-137	114	41	23/08/2024	23/08/2024	NUM
aji-137	114	42	abstract	abstract	ADJ
aji-137	114	43	rheumatoid	rheumatoid	NOUN
aji-137	114	44	arthritis	arthritis	NOUN
aji-137	114	45	(	(	PUNCT
aji-137	114	46	ra	ra	NOUN
aji-137	114	47	)	)	PUNCT
aji-137	114	48	is	be	AUX
aji-137	114	49	characterized	characterize	VERB
aji-137	114	50	by	by	ADP
aji-137	114	51	systemic	systemic	ADJ
aji-137	114	52	synovitis	synovitis	PROPN
aji-137	114	53	,	,	PUNCT
aji-137	114	54	which	which	PRON
aji-137	114	55	destroys	destroy	VERB
aji-137	114	56	joints	joint	NOUN
aji-137	114	57	.	.	PUNCT
aji-137	115	1	with	with	ADP
aji-137	115	2	the	the	DET
aji-137	115	3	discovery	discovery	NOUN
aji-137	115	4	of	of	ADP
aji-137	115	5	biological	biological	ADJ
aji-137	115	6	disease	disease	NOUN
aji-137	115	7	-	-	PUNCT
aji-137	115	8	modifying	modify	VERB
aji-137	115	9	anti	anti	ADJ
aji-137	115	10	-	-	ADJ
aji-137	115	11	rheumatic	rheumatic	ADJ
aji-137	115	12	medicines	medicine	NOUN
aji-137	115	13	(	(	PUNCT
aji-137	115	14	bdmards	bdmard	NOUN
aji-137	115	15	)	)	PUNCT
aji-137	115	16	and	and	CCONJ
aji-137	115	17	the	the	DET
aji-137	115	18	combination	combination	NOUN
aji-137	115	19	of	of	ADP
aji-137	115	20	traditional	traditional	ADJ
aji-137	115	21	dmards	dmard	NOUN
aji-137	115	22	,	,	PUNCT
aji-137	115	23	clinical	clinical	ADJ
aji-137	115	24	remission	remission	NOUN
aji-137	115	25	is	be	AUX
aji-137	115	26	now	now	ADV
aji-137	115	27	seen	see	VERB
aji-137	115	28	as	as	ADP
aji-137	115	29	a	a	DET
aji-137	115	30	reasonable	reasonable	ADJ
aji-137	115	31	and	and	CCONJ
aji-137	115	32	achievable	achievable	ADJ
aji-137	115	33	aim	aim	NOUN
aji-137	115	34	for	for	ADP
aji-137	115	35	many	many	ADJ
aji-137	115	36	patients	patient	NOUN
aji-137	115	37	.	.	PUNCT
aji-137	116	1	however	however	ADV
aji-137	116	2	,	,	PUNCT
aji-137	116	3	bdmards	bdmard	NOUN
aji-137	116	4	must	must	AUX
aji-137	116	5	be	be	AUX
aji-137	116	6	administered	administer	VERB
aji-137	116	7	via	via	ADP
aji-137	116	8	intravenous	intravenous	ADJ
aji-137	116	9	or	or	CCONJ
aji-137	116	10	subcutaneous	subcutaneous	ADJ
aji-137	116	11	injection	injection	NOUN
aji-137	116	12	,	,	PUNCT
aji-137	116	13	and	and	CCONJ
aji-137	116	14	some	some	DET
aji-137	116	15	patients	patient	NOUN
aji-137	116	16	may	may	AUX
aji-137	116	17	not	not	PART
aji-137	116	18	react	react	VERB
aji-137	116	19	or	or	CCONJ
aji-137	116	20	lose	lose	VERB
aji-137	116	21	their	their	PRON
aji-137	116	22	main	main	ADJ
aji-137	116	23	response	response	NOUN
aji-137	116	24	.	.	PUNCT
aji-137	117	1	under	under	ADP
aji-137	117	2	these	these	DET
aji-137	117	3	conditions	condition	NOUN
aji-137	117	4	,	,	PUNCT
aji-137	117	5	targeted	target	VERB
aji-137	117	6	synthetic	synthetic	ADJ
aji-137	117	7	dmards	dmard	NOUN
aji-137	117	8	(	(	PUNCT
aji-137	117	9	tsdmards	tsdmard	NOUN
aji-137	117	10	)	)	PUNCT
aji-137	117	11	,	,	PUNCT
aji-137	117	12	which	which	PRON
aji-137	117	13	are	be	AUX
aji-137	117	14	low	low	ADJ
aji-137	117	15	.	.	PUNCT
aji-137	118	1	review	review	NOUN
aji-137	118	2	article	article	NOUN
aji-137	118	3	https://doi.org/10.9734/aji/2024/v7i1137	https://doi.org/10.9734/aji/2024/v7i1137	PROPN
aji-137	118	4	https://www.sdiarticle5.com/review-history/120135	https://www.sdiarticle5.com/review-history/120135	PROPN
aji-137	118	5	gupta	gupta	PROPN
aji-137	118	6	et	et	PROPN
aji-137	118	7	al	al	PROPN
aji-137	118	8	.	.	PROPN
aji-137	118	9	;	;	PUNCT
aji-137	118	10	asian	asian	PROPN
aji-137	118	11	j.	j.	PROPN
aji-137	118	12	immunol	immunol	PROPN
aji-137	118	13	.	.	PROPN
aji-137	118	14	,	,	PUNCT
aji-137	118	15	vol	vol	NOUN
aji-137	118	16	.	.	PROPN
aji-137	118	17	7	7	NUM
aji-137	118	18	,	,	PUNCT
aji-137	118	19	no	no	INTJ
aji-137	118	20	.	.	NOUN
aji-137	118	21	1	1	NUM
aji-137	118	22	,	,	PUNCT
aji-137	118	23	pp	pp	ADJ
aji-137	118	24	.	.	PUNCT
aji-137	119	1	123	123	NUM
aji-137	119	2	-	-	SYM
aji-137	119	3	130	130	NUM
aji-137	119	4	,	,	PUNCT
aji-137	119	5	2024	2024	NUM
aji-137	119	6	;	;	PUNCT
aji-137	119	7	article	article	NOUN
aji-137	119	8	no.aji.120135	no.aji.120135	VERB
aji-137	119	9	124	124	NUM
aji-137	119	10	molecular	molecular	ADJ
aji-137	119	11	-	-	PUNCT
aji-137	119	12	weight	weight	NOUN
aji-137	119	13	molecules	molecule	NOUN
aji-137	119	14	that	that	PRON
aji-137	119	15	may	may	AUX
aji-137	119	16	be	be	AUX
aji-137	119	17	taken	take	VERB
aji-137	119	18	orally	orally	ADV
aji-137	119	19	,	,	PUNCT
aji-137	119	20	have	have	AUX
aji-137	119	21	emerged	emerge	VERB
aji-137	119	22	.	.	PUNCT
aji-137	120	1	five	five	NUM
aji-137	120	2	phase	phase	NOUN
aji-137	120	3	3	3	NUM
aji-137	120	4	studies	study	NOUN
aji-137	120	5	of	of	ADP
aji-137	120	6	baricitinib	baricitinib	NOUN
aji-137	120	7	,	,	PUNCT
aji-137	120	8	a	a	DET
aji-137	120	9	jak1(janus	jak1(janus	X
aji-137	120	10	kinase1	kinase1	NOUN
aji-137	120	11	)	)	PUNCT
aji-137	120	12	and	and	CCONJ
aji-137	120	13	jak2(janus	jak2(janus	X
aji-137	120	14	kinase	kinase	PROPN
aji-137	120	15	2	2	NUM
aji-137	120	16	)	)	PUNCT
aji-137	120	17	inhibitor	inhibitor	NOUN
aji-137	120	18	,	,	PUNCT
aji-137	120	19	demonstrated	demonstrate	VERB
aji-137	120	20	good	good	ADJ
aji-137	120	21	clinical	clinical	ADJ
aji-137	120	22	effectiveness	effectiveness	NOUN
aji-137	120	23	in	in	ADP
aji-137	120	24	patients	patient	NOUN
aji-137	120	25	with	with	ADP
aji-137	120	26	active	active	ADJ
aji-137	120	27	ra	ra	PROPN
aji-137	120	28	who	who	PRON
aji-137	120	29	were	be	AUX
aji-137	120	30	naïve	naïve	ADJ
aji-137	120	31	to	to	AUX
aji-137	120	32	sdmards	sdmard	NOUN
aji-137	120	33	or	or	CCONJ
aji-137	120	34	had	have	VERB
aji-137	120	35	an	an	DET
aji-137	120	36	unsatisfactory	unsatisfactory	ADJ
aji-137	120	37	response	response	NOUN
aji-137	120	38	to	to	ADP
aji-137	120	39	sdmards	sdmard	NOUN
aji-137	120	40	,	,	PUNCT
aji-137	120	41	mtx(methotrexate	mtx(methotrexate	NUM
aji-137	120	42	)	)	PUNCT
aji-137	120	43	or	or	CCONJ
aji-137	120	44	bdmards	bdmard	NOUN
aji-137	120	45	.	.	PUNCT
aji-137	121	1	in	in	ADP
aji-137	121	2	patients	patient	NOUN
aji-137	121	3	with	with	ADP
aji-137	121	4	rheumatoid	rheumatoid	NOUN
aji-137	121	5	arthritis	arthritis	NOUN
aji-137	121	6	who	who	PRON
aji-137	121	7	had	have	AUX
aji-137	121	8	not	not	PART
aji-137	121	9	previously	previously	ADV
aji-137	121	10	been	be	AUX
aji-137	121	11	treated	treat	VERB
aji-137	121	12	with	with	ADP
aji-137	121	13	biologic	biologic	ADJ
aji-137	121	14	disease	disease	NOUN
aji-137	121	15	-	-	PUNCT
aji-137	121	16	modifying	modify	VERB
aji-137	121	17	antirheumatic	antirheumatic	ADJ
aji-137	121	18	medications	medication	NOUN
aji-137	121	19	(	(	PUNCT
aji-137	121	20	dmards	dmard	NOUN
aji-137	121	21	)	)	PUNCT
aji-137	121	22	,	,	PUNCT
aji-137	121	23	baricitinib	baricitinib	NOUN
aji-137	121	24	,	,	PUNCT
aji-137	121	25	an	an	DET
aji-137	121	26	oral	oral	ADJ
aji-137	121	27	inhibitor	inhibitor	NOUN
aji-137	121	28	of	of	ADP
aji-137	121	29	janus	janus	PROPN
aji-137	121	30	kinase	kinase	PROPN
aji-137	121	31	1	1	NUM
aji-137	121	32	and	and	CCONJ
aji-137	121	33	2	2	NUM
aji-137	121	34	,	,	PUNCT
aji-137	121	35	decreased	decrease	VERB
aji-137	121	36	disease	disease	NOUN
aji-137	121	37	activity	activity	NOUN
aji-137	121	38	.	.	PUNCT
aji-137	122	1	keywords	keyword	NOUN
aji-137	122	2	:	:	PUNCT
aji-137	122	3	rheumatoid	rheumatoid	VERB
aji-137	122	4	arthritis	arthritis	NOUN
aji-137	122	5	;	;	PUNCT
aji-137	122	6	baericitinib	baericitinib	NOUN
aji-137	122	7	;	;	PUNCT
aji-137	122	8	bdmards	bdmard	NOUN
aji-137	122	9	;	;	PUNCT
aji-137	122	10	tsdmards	tsdmard	NOUN
aji-137	122	11	;	;	PUNCT
aji-137	122	12	jak1	jak1	PROPN
aji-137	122	13	inhibitor	inhibitor	NOUN
aji-137	122	14	;	;	PUNCT
aji-137	122	15	jak2	jak2	NOUN
aji-137	122	16	inhibitors	inhibitor	NOUN
aji-137	122	17	;	;	PUNCT
aji-137	122	18	mtx	mtx	NOUN
aji-137	122	19	.	.	NOUN
aji-137	122	20	1	1	NUM
aji-137	122	21	.	.	X
aji-137	123	1	introduction	introduction	NOUN
aji-137	123	2	“	"	PUNCT
aji-137	123	3	rheumatoid	rheumatoid	VERB
aji-137	123	4	arthritis	arthritis	NOUN
aji-137	123	5	(	(	PUNCT
aji-137	123	6	ra	ra	NOUN
aji-137	123	7	)	)	PUNCT
aji-137	123	8	is	be	AUX
aji-137	123	9	a	a	DET
aji-137	123	10	systemic	systemic	ADJ
aji-137	123	11	autoimmune	autoimmune	ADJ
aji-137	123	12	illness	illness	NOUN
aji-137	123	13	linked	link	VERB
aji-137	123	14	to	to	ADP
aji-137	123	15	a	a	DET
aji-137	123	16	persistent	persistent	ADJ
aji-137	123	17	inflammatory	inflammatory	ADJ
aji-137	123	18	process	process	NOUN
aji-137	123	19	that	that	PRON
aji-137	123	20	can	can	AUX
aji-137	123	21	harm	harm	VERB
aji-137	123	22	extraarticular	extraarticular	ADJ
aji-137	123	23	organs	organ	NOUN
aji-137	123	24	such	such	ADJ
aji-137	123	25	as	as	ADP
aji-137	123	26	the	the	DET
aji-137	123	27	kidney	kidney	NOUN
aji-137	123	28	,	,	PUNCT
aji-137	123	29	lung	lung	NOUN
aji-137	123	30	,	,	PUNCT
aji-137	123	31	heart	heart	NOUN
aji-137	123	32	,	,	PUNCT
aji-137	123	33	digestive	digestive	ADJ
aji-137	123	34	tract	tract	NOUN
aji-137	123	35	,	,	PUNCT
aji-137	123	36	eyes	eye	NOUN
aji-137	123	37	,	,	PUNCT
aji-137	123	38	skin	skin	NOUN
aji-137	123	39	,	,	PUNCT
aji-137	123	40	and	and	CCONJ
aji-137	123	41	nervous	nervous	ADJ
aji-137	123	42	system	system	NOUN
aji-137	123	43	in	in	ADP
aji-137	123	44	addition	addition	NOUN
aji-137	123	45	to	to	ADP
aji-137	123	46	joints	joint	NOUN
aji-137	123	47	.	.	PUNCT
aji-137	124	1	to	to	PART
aji-137	124	2	categorise	categorise	VERB
aji-137	124	3	arthritis	arthritis	NOUN
aji-137	124	4	into	into	ADP
aji-137	124	5	noninflammatory	noninflammatory	ADJ
aji-137	124	6	(	(	PUNCT
aji-137	124	7	osteoarthritis	osteoarthritis	NOUN
aji-137	124	8	)	)	PUNCT
aji-137	124	9	and	and	CCONJ
aji-137	124	10	inflammatory	inflammatory	ADJ
aji-137	124	11	(	(	PUNCT
aji-137	124	12	pseudogout	pseudogout	ADJ
aji-137	124	13	,	,	PUNCT
aji-137	124	14	basic	basic	ADJ
aji-137	124	15	calcium	calcium	NOUN
aji-137	124	16	phosphate	phosphate	NOUN
aji-137	124	17	disease	disease	NOUN
aji-137	124	18	,	,	PUNCT
aji-137	124	19	gout	gout	NOUN
aji-137	124	20	)	)	PUNCT
aji-137	124	21	types	type	NOUN
aji-137	124	22	,	,	PUNCT
aji-137	124	23	as	as	ADV
aji-137	124	24	well	well	ADV
aji-137	124	25	as	as	ADP
aji-137	124	26	bacterial	bacterial	ADJ
aji-137	124	27	and	and	CCONJ
aji-137	124	28	viral	viral	ADJ
aji-137	124	29	infections	infection	NOUN
aji-137	124	30	(	(	PUNCT
aji-137	124	31	staphylococcus	staphylococcus	NOUN
aji-137	124	32	aureus	aureus	NOUN
aji-137	124	33	,	,	PUNCT
aji-137	124	34	neisseria	neisseria	PROPN
aji-137	124	35	gonorrhoeae	gonorrhoeae	PROPN
aji-137	124	36	,	,	PUNCT
aji-137	124	37	complications	complication	NOUN
aji-137	124	38	of	of	ADP
aji-137	124	39	lyme	lyme	NOUN
aji-137	124	40	disease	disease	NOUN
aji-137	124	41	,	,	PUNCT
aji-137	124	42	parvovirus	parvovirus	NOUN
aji-137	124	43	,	,	PUNCT
aji-137	124	44	enterovirus	enterovirus	NOUN
aji-137	124	45	)	)	PUNCT
aji-137	124	46	,	,	PUNCT
aji-137	124	47	and	and	CCONJ
aji-137	124	48	autoimmune	autoimmune	ADJ
aji-137	124	49	processes	process	NOUN
aji-137	124	50	,	,	PUNCT
aji-137	124	51	a	a	DET
aji-137	124	52	great	great	ADJ
aji-137	124	53	deal	deal	NOUN
aji-137	124	54	of	of	ADP
aji-137	124	55	research	research	NOUN
aji-137	124	56	and	and	CCONJ
aji-137	124	57	description	description	NOUN
aji-137	124	58	has	have	AUX
aji-137	124	59	been	be	AUX
aji-137	124	60	done	do	VERB
aji-137	124	61	on	on	ADP
aji-137	124	62	arthritis	arthritis	NOUN
aji-137	124	63	”	"	PUNCT
aji-137	125	1	[	[	X
aji-137	125	2	1	1	NUM
aji-137	125	3	]	]	PUNCT
aji-137	125	4	.	.	PUNCT
aji-137	126	1	“	"	PUNCT
aji-137	126	2	systemic	systemic	ADJ
aji-137	126	3	synovitis	synovitis	ADV
aji-137	126	4	-	-	PUNCT
aji-137	126	5	induced	induce	VERB
aji-137	126	6	joint	joint	ADJ
aji-137	126	7	degradation	degradation	NOUN
aji-137	126	8	is	be	AUX
aji-137	126	9	a	a	DET
aji-137	126	10	characteristic	characteristic	ADJ
aji-137	126	11	feature	feature	NOUN
aji-137	126	12	of	of	ADP
aji-137	126	13	rheumatoid	rheumatoid	NOUN
aji-137	126	14	arthritis	arthritis	NOUN
aji-137	126	15	(	(	PUNCT
aji-137	126	16	ra	ra	NOUN
aji-137	126	17	)	)	PUNCT
aji-137	126	18	”	"	PUNCT
aji-137	127	1	[	[	X
aji-137	127	2	1	1	NUM
aji-137	127	3	]	]	PUNCT
aji-137	127	4	.	.	PUNCT
aji-137	128	1	“	"	PUNCT
aji-137	128	2	when	when	SCONJ
aji-137	128	3	chondrocytes	chondrocyte	NOUN
aji-137	128	4	and	and	CCONJ
aji-137	128	5	fibroblasts	fibroblast	NOUN
aji-137	128	6	are	be	AUX
aji-137	128	7	stimulated	stimulate	VERB
aji-137	128	8	,	,	PUNCT
aji-137	128	9	cartilage	cartilage	NOUN
aji-137	128	10	and	and	CCONJ
aji-137	128	11	bone	bone	NOUN
aji-137	128	12	are	be	AUX
aji-137	128	13	broken	break	VERB
aji-137	128	14	down	down	ADP
aji-137	128	15	,	,	PUNCT
aji-137	128	16	leading	lead	VERB
aji-137	128	17	to	to	ADP
aji-137	128	18	the	the	DET
aji-137	128	19	production	production	NOUN
aji-137	128	20	of	of	ADP
aji-137	128	21	osteoclasts	osteoclast	NOUN
aji-137	128	22	and	and	CCONJ
aji-137	128	23	metalloproteinases	metalloproteinase	NOUN
aji-137	128	24	and	and	CCONJ
aji-137	128	25	joint	joint	ADJ
aji-137	128	26	injury	injury	NOUN
aji-137	128	27	”	"	PUNCT
aji-137	129	1	[	[	X
aji-137	129	2	2,3	2,3	NUM
aji-137	129	3	]	]	PUNCT
aji-137	129	4	.	.	PUNCT
aji-137	130	1	“	"	PUNCT
aji-137	130	2	these	these	DET
aji-137	130	3	processes	process	NOUN
aji-137	130	4	are	be	AUX
aji-137	130	5	facilitated	facilitate	VERB
aji-137	130	6	by	by	ADP
aji-137	130	7	the	the	DET
aji-137	130	8	overproduction	overproduction	NOUN
aji-137	130	9	of	of	ADP
aji-137	130	10	pro	pro	ADJ
aji-137	130	11	-	-	ADJ
aji-137	130	12	inflammatory	inflammatory	ADJ
aji-137	130	13	cytokines	cytokine	NOUN
aji-137	130	14	by	by	ADP
aji-137	130	15	immune	immune	ADJ
aji-137	130	16	cells	cell	NOUN
aji-137	130	17	in	in	ADP
aji-137	130	18	the	the	DET
aji-137	130	19	synovium	synovium	NOUN
aji-137	130	20	,	,	PUNCT
aji-137	130	21	such	such	ADJ
aji-137	130	22	as	as	ADP
aji-137	130	23	macrophage	macrophage	ADJ
aji-137	130	24	colony	colony	NOUN
aji-137	130	25	stimulating	stimulate	VERB
aji-137	130	26	factor	factor	NOUN
aji-137	130	27	,	,	PUNCT
aji-137	130	28	interleukins-6	interleukins-6	NOUN
aji-137	130	29	and-17	and-17	NOUN
aji-137	130	30	,	,	PUNCT
aji-137	130	31	and	and	CCONJ
aji-137	130	32	tumor	tumor	NOUN
aji-137	130	33	necrosis	necrosis	NOUN
aji-137	130	34	factorα	factorα	NOUN
aji-137	130	35	”	"	PUNCT
aji-137	131	1	[	[	X
aji-137	131	2	2,4	2,4	NUM
aji-137	131	3	]	]	PUNCT
aji-137	131	4	.	.	PUNCT
aji-137	132	1	“	"	PUNCT
aji-137	132	2	this	this	DET
aji-137	132	3	medication	medication	NOUN
aji-137	132	4	has	have	AUX
aji-137	132	5	been	be	AUX
aji-137	132	6	authorized	authorize	VERB
aji-137	132	7	by	by	ADP
aji-137	132	8	the	the	DET
aji-137	132	9	fda	fda	PROPN
aji-137	132	10	for	for	ADP
aji-137	132	11	use	use	NOUN
aji-137	132	12	in	in	ADP
aji-137	132	13	adult	adult	NOUN
aji-137	132	14	patients	patient	NOUN
aji-137	132	15	with	with	ADP
aji-137	132	16	moderately	moderately	ADV
aji-137	132	17	to	to	PART
aji-137	132	18	severely	severely	ADV
aji-137	132	19	active	active	ADJ
aji-137	132	20	rheumatoid	rheumatoid	NOUN
aji-137	132	21	arthritis	arthritis	NOUN
aji-137	132	22	when	when	SCONJ
aji-137	132	23	other	other	ADJ
aji-137	132	24	dmards	dmard	NOUN
aji-137	132	25	,	,	PUNCT
aji-137	132	26	such	such	ADJ
aji-137	132	27	as	as	ADP
aji-137	132	28	tumor	tumor	NOUN
aji-137	132	29	necrosis	necrosis	NOUN
aji-137	132	30	factor	factor	NOUN
aji-137	132	31	antagonist	antagonist	NOUN
aji-137	132	32	therapies	therapy	NOUN
aji-137	132	33	,	,	PUNCT
aji-137	132	34	have	have	AUX
aji-137	132	35	not	not	PART
aji-137	132	36	proven	prove	VERB
aji-137	132	37	to	to	PART
aji-137	132	38	be	be	AUX
aji-137	132	39	helpful	helpful	ADJ
aji-137	132	40	”	"	PUNCT
aji-137	133	1	[	[	X
aji-137	133	2	5	5	NUM
aji-137	133	3	]	]	PUNCT
aji-137	133	4	.	.	PUNCT
aji-137	134	1	“	"	PUNCT
aji-137	134	2	baricitinib	baricitinib	NOUN
aji-137	134	3	is	be	AUX
aji-137	134	4	an	an	DET
aji-137	134	5	oral	oral	ADJ
aji-137	134	6	selective	selective	ADJ
aji-137	134	7	inhibitor	inhibitor	NOUN
aji-137	134	8	of	of	ADP
aji-137	134	9	jak1	jak1	PROPN
aji-137	134	10	and	and	CCONJ
aji-137	134	11	jak2	jak2	PROPN
aji-137	134	12	,	,	PUNCT
aji-137	134	13	specifically	specifically	ADV
aji-137	134	14	formulated	formulate	VERB
aji-137	134	15	to	to	PART
aji-137	134	16	treat	treat	VERB
aji-137	134	17	patients	patient	NOUN
aji-137	134	18	with	with	ADP
aji-137	134	19	active	active	ADJ
aji-137	134	20	rheumatoid	rheumatoid	NOUN
aji-137	134	21	arthritis	arthritis	NOUN
aji-137	134	22	”	"	PUNCT
aji-137	134	23	[	[	X
aji-137	134	24	6	6	NUM
aji-137	134	25	]	]	PUNCT
aji-137	134	26	.	.	PUNCT
aji-137	135	1	“	"	PUNCT
aji-137	135	2	baricitinib	baricitinib	NOUN
aji-137	135	3	,	,	PUNCT
aji-137	135	4	a	a	DET
aji-137	135	5	jak1	jak1	NOUN
aji-137	135	6	and	and	CCONJ
aji-137	135	7	jak2	jak2	PROPN
aji-137	135	8	inhibitor	inhibitor	NOUN
aji-137	135	9	,	,	PUNCT
aji-137	135	10	has	have	AUX
aji-137	135	11	been	be	AUX
aji-137	135	12	subjected	subject	VERB
aji-137	135	13	to	to	ADP
aji-137	135	14	five	five	NUM
aji-137	135	15	phase	phase	NOUN
aji-137	135	16	3	3	NUM
aji-137	135	17	trials	trial	NOUN
aji-137	135	18	that	that	PRON
aji-137	135	19	have	have	AUX
aji-137	135	20	demonstrated	demonstrate	VERB
aji-137	135	21	excellent	excellent	ADJ
aji-137	135	22	clinical	clinical	ADJ
aji-137	135	23	efficacy	efficacy	NOUN
aji-137	135	24	in	in	ADP
aji-137	135	25	patients	patient	NOUN
aji-137	135	26	with	with	ADP
aji-137	135	27	active	active	ADJ
aji-137	135	28	ra	ra	PROPN
aji-137	135	29	who	who	PRON
aji-137	135	30	have	have	AUX
aji-137	135	31	not	not	PART
aji-137	135	32	responded	respond	VERB
aji-137	135	33	well	well	ADV
aji-137	135	34	to	to	ADP
aji-137	135	35	sdmards	sdmard	NOUN
aji-137	135	36	,	,	PUNCT
aji-137	135	37	mtx	mtx	NOUN
aji-137	135	38	,	,	PUNCT
aji-137	135	39	or	or	CCONJ
aji-137	135	40	bdmards	bdmard	NOUN
aji-137	135	41	.	.	PUNCT
aji-137	136	1	adalimumab	adalimumab	PROPN
aji-137	136	2	,	,	PUNCT
aji-137	136	3	mtx	mtx	NOUN
aji-137	136	4	,	,	PUNCT
aji-137	136	5	and	and	CCONJ
aji-137	136	6	placebo	placebo	NOUN
aji-137	136	7	were	be	AUX
aji-137	136	8	used	use	VERB
aji-137	136	9	as	as	ADP
aji-137	136	10	comparators	comparator	NOUN
aji-137	136	11	in	in	ADP
aji-137	136	12	studies	study	NOUN
aji-137	136	13	where	where	SCONJ
aji-137	136	14	there	there	PRON
aji-137	136	15	was	be	VERB
aji-137	136	16	a	a	DET
aji-137	136	17	positive	positive	ADJ
aji-137	136	18	response	response	NOUN
aji-137	136	19	for	for	ADP
aji-137	136	20	clinical	clinical	ADJ
aji-137	136	21	and	and	CCONJ
aji-137	136	22	functional	functional	ADJ
aji-137	136	23	criteria	criterion	NOUN
aji-137	136	24	.	.	PUNCT
aji-137	137	1	additionally	additionally	ADV
aji-137	137	2	,	,	PUNCT
aji-137	137	3	it	it	PRON
aji-137	137	4	is	be	AUX
aji-137	137	5	stated	state	VERB
aji-137	137	6	that	that	SCONJ
aji-137	137	7	safety	safety	NOUN
aji-137	137	8	was	be	AUX
aji-137	137	9	bearable	bearable	ADJ
aji-137	137	10	within	within	ADP
aji-137	137	11	the	the	DET
aji-137	137	12	short	short	ADJ
aji-137	137	13	trial	trial	NOUN
aji-137	137	14	duration	duration	NOUN
aji-137	137	15	”	"	PUNCT
aji-137	138	1	[	[	X
aji-137	138	2	1,7,8	1,7,8	NUM
aji-137	138	3	]	]	PUNCT
aji-137	138	4	.	.	PUNCT
aji-137	139	1	“	"	PUNCT
aji-137	139	2	jak	jak	PROPN
aji-137	139	3	inhibitors	inhibitor	NOUN
aji-137	139	4	provide	provide	VERB
aji-137	139	5	an	an	DET
aji-137	139	6	alternative	alternative	NOUN
aji-137	139	7	to	to	ADP
aji-137	139	8	traditional	traditional	ADJ
aji-137	139	9	ra	ra	PROPN
aji-137	139	10	treatments	treatment	NOUN
aji-137	139	11	by	by	ADP
aji-137	139	12	targeting	target	VERB
aji-137	139	13	cytokine	cytokine	NOUN
aji-137	139	14	signaling	signal	VERB
aji-137	139	15	pathways	pathway	NOUN
aji-137	139	16	linked	link	VERB
aji-137	139	17	to	to	ADP
aji-137	139	18	the	the	DET
aji-137	139	19	pathophysiology	pathophysiology	NOUN
aji-137	139	20	of	of	ADP
aji-137	139	21	ra	ra	PROPN
aji-137	139	22	.	.	PUNCT
aji-137	140	1	in	in	ADP
aji-137	140	2	clinical	clinical	ADJ
aji-137	140	3	studies	study	NOUN
aji-137	140	4	including	include	VERB
aji-137	140	5	individuals	individual	NOUN
aji-137	140	6	with	with	ADP
aji-137	140	7	ra	ra	PROPN
aji-137	140	8	1–5	1–5	NUM
aji-137	140	9	,	,	PUNCT
aji-137	140	10	the	the	DET
aji-137	140	11	oral	oral	ADJ
aji-137	140	12	,	,	PUNCT
aji-137	140	13	selective	selective	ADJ
aji-137	140	14	jak1	jak1	NOUN
aji-137	140	15	and	and	CCONJ
aji-137	140	16	jak2	jak2	PROPN
aji-137	140	17	inhibitor	inhibitor	NOUN
aji-137	140	18	baricitinib	baricitinib	NOUN
aji-137	140	19	has	have	AUX
aji-137	140	20	demonstrated	demonstrate	VERB
aji-137	140	21	clinical	clinical	ADJ
aji-137	140	22	effectiveness	effectiveness	NOUN
aji-137	140	23	and	and	CCONJ
aji-137	140	24	tolerability	tolerability	NOUN
aji-137	140	25	.	.	PUNCT
aji-137	141	1	adults	adult	NOUN
aji-137	141	2	with	with	ADP
aji-137	141	3	moderately	moderately	ADV
aji-137	141	4	-	-	PUNCT
aji-137	141	5	to	to	PART
aji-137	141	6	severely	severely	ADV
aji-137	141	7	active	active	ADJ
aji-137	141	8	ra	ra	PROPN
aji-137	141	9	are	be	AUX
aji-137	141	10	eligible	eligible	ADJ
aji-137	141	11	to	to	PART
aji-137	141	12	receive	receive	VERB
aji-137	141	13	baricitinib	baricitinib	NOUN
aji-137	141	14	therapy	therapy	NOUN
aji-137	141	15	in	in	ADP
aji-137	141	16	over	over	ADP
aji-137	141	17	50	50	NUM
aji-137	141	18	countries	country	NOUN
aji-137	141	19	,	,	PUNCT
aji-137	141	20	including	include	VERB
aji-137	141	21	the	the	DET
aji-137	141	22	us	us	PROPN
aji-137	141	23	,	,	PUNCT
aji-137	141	24	japan	japan	PROPN
aji-137	141	25	,	,	PUNCT
aji-137	141	26	and	and	CCONJ
aji-137	141	27	several	several	ADJ
aji-137	141	28	european	european	ADJ
aji-137	141	29	nations	nation	NOUN
aji-137	141	30	”	"	PUNCT
aji-137	142	1	[	[	X
aji-137	142	2	9	9	NUM
aji-137	142	3	]	]	PUNCT
aji-137	142	4	.	.	PUNCT
aji-137	143	1	the	the	DET
aji-137	143	2	main	main	ADJ
aji-137	143	3	therapy	therapy	NOUN
aji-137	143	4	goal	goal	NOUN
aji-137	143	5	for	for	ADP
aji-137	143	6	individuals	individual	NOUN
aji-137	143	7	with	with	ADP
aji-137	143	8	established	establish	VERB
aji-137	143	9	ra	ra	PROPN
aji-137	143	10	is	be	AUX
aji-137	143	11	to	to	PART
aji-137	143	12	achieve	achieve	VERB
aji-137	143	13	minimal	minimal	ADJ
aji-137	143	14	disease	disease	NOUN
aji-137	143	15	activity	activity	NOUN
aji-137	143	16	[	[	X
aji-137	143	17	10,11	10,11	NOUN
aji-137	143	18	]	]	PUNCT
aji-137	143	19	.	.	PUNCT
aji-137	144	1	“	"	PUNCT
aji-137	144	2	many	many	ADJ
aji-137	144	3	dmard	dmard	ADJ
aji-137	144	4	treatments	treatment	NOUN
aji-137	144	5	have	have	AUX
aji-137	144	6	been	be	AUX
aji-137	144	7	tried	try	VERB
aji-137	144	8	by	by	ADP
aji-137	144	9	a	a	DET
aji-137	144	10	sizable	sizable	ADJ
aji-137	144	11	portion	portion	NOUN
aji-137	144	12	of	of	ADP
aji-137	144	13	patients	patient	NOUN
aji-137	144	14	with	with	ADP
aji-137	144	15	established	establish	VERB
aji-137	144	16	ra	ra	PROPN
aji-137	144	17	,	,	PUNCT
aji-137	144	18	but	but	CCONJ
aji-137	144	19	they	they	PRON
aji-137	144	20	have	have	AUX
aji-137	144	21	not	not	PART
aji-137	144	22	been	be	AUX
aji-137	144	23	successful	successful	ADJ
aji-137	144	24	in	in	ADP
aji-137	144	25	reaching	reach	VERB
aji-137	144	26	a	a	DET
aji-137	144	27	low	low	ADJ
aji-137	144	28	disease	disease	NOUN
aji-137	144	29	activity	activity	NOUN
aji-137	144	30	state	state	NOUN
aji-137	144	31	.	.	PUNCT
aji-137	145	1	according	accord	VERB
aji-137	145	2	to	to	ADP
aji-137	145	3	clinical	clinical	ADJ
aji-137	145	4	research	research	NOUN
aji-137	145	5	,	,	PUNCT
aji-137	145	6	response	response	NOUN
aji-137	145	7	rates	rate	NOUN
aji-137	145	8	to	to	ADP
aji-137	145	9	all	all	DET
aji-137	145	10	presently	presently	ADV
aji-137	145	11	prescribed	prescribe	VERB
aji-137	145	12	medications	medication	NOUN
aji-137	145	13	decline	decline	NOUN
aji-137	145	14	as	as	ADP
aji-137	145	15	cdmard	cdmard	NOUN
aji-137	145	16	and	and	CCONJ
aji-137	145	17	bdmard	bdmard	NOUN
aji-137	145	18	experience	experience	NOUN
aji-137	145	19	increases	increase	NOUN
aji-137	145	20	”	"	PUNCT
aji-137	146	1	[	[	X
aji-137	146	2	12	12	NUM
aji-137	146	3	]	]	PUNCT
aji-137	146	4	.	.	PUNCT
aji-137	147	1	“	"	PUNCT
aji-137	147	2	studies	study	NOUN
aji-137	147	3	involving	involve	VERB
aji-137	147	4	patients	patient	NOUN
aji-137	147	5	who	who	PRON
aji-137	147	6	have	have	AUX
aji-137	147	7	not	not	PART
aji-137	147	8	responded	respond	VERB
aji-137	147	9	to	to	ADP
aji-137	147	10	prior	prior	ADJ
aji-137	147	11	bdmards	bdmard	NOUN
aji-137	147	12	are	be	AUX
aji-137	147	13	especially	especially	ADV
aji-137	147	14	significant	significant	ADJ
aji-137	147	15	since	since	SCONJ
aji-137	147	16	this	this	DET
aji-137	147	17	cohort	cohort	NOUN
aji-137	147	18	is	be	AUX
aji-137	147	19	growing	grow	VERB
aji-137	147	20	and	and	CCONJ
aji-137	147	21	has	have	VERB
aji-137	147	22	the	the	DET
aji-137	147	23	biggest	big	ADJ
aji-137	147	24	unmet	unmet	NOUN
aji-137	147	25	demand	demand	NOUN
aji-137	147	26	in	in	ADP
aji-137	147	27	the	the	DET
aji-137	147	28	ra	ra	PROPN
aji-137	147	29	field	field	NOUN
aji-137	147	30	.	.	PUNCT
aji-137	148	1	the	the	DET
aji-137	148	2	ra	ra	PROPN
aji-137	148	3	-	-	PUNCT
aji-137	148	4	beacon	beacon	NOUN
aji-137	148	5	trial	trial	NOUN
aji-137	148	6	did	do	AUX
aji-137	148	7	not	not	PART
aji-137	148	8	previously	previously	ADV
aji-137	148	9	evaluate	evaluate	VERB
aji-137	148	10	the	the	DET
aji-137	148	11	degree	degree	NOUN
aji-137	148	12	to	to	PART
aji-137	148	13	which	which	PRON
aji-137	148	14	patient	patient	ADJ
aji-137	148	15	variables	variable	NOUN
aji-137	148	16	,	,	PUNCT
aji-137	148	17	such	such	ADJ
aji-137	148	18	as	as	ADP
aji-137	148	19	age	age	NOUN
aji-137	148	20	,	,	PUNCT
aji-137	148	21	illness	illness	NOUN
aji-137	148	22	duration	duration	NOUN
aji-137	148	23	,	,	PUNCT
aji-137	148	24	serological	serological	ADJ
aji-137	148	25	status	status	NOUN
aji-137	148	26	,	,	PUNCT
aji-137	148	27	or	or	CCONJ
aji-137	148	28	history	history	NOUN
aji-137	148	29	of	of	ADP
aji-137	148	30	using	use	VERB
aji-137	148	31	certain	certain	ADJ
aji-137	148	32	bdmards	bdmard	NOUN
aji-137	148	33	,	,	PUNCT
aji-137	148	34	impact	impact	VERB
aji-137	148	35	the	the	DET
aji-137	148	36	response	response	NOUN
aji-137	148	37	to	to	ADP
aji-137	148	38	baricitinib	baricitinib	NOUN
aji-137	148	39	”	"	PUNCT
aji-137	149	1	[	[	X
aji-137	149	2	13	13	NUM
aji-137	149	3	]	]	PUNCT
aji-137	149	4	.	.	PUNCT
aji-137	150	1	these	these	DET
aji-137	150	2	crucial	crucial	ADJ
aji-137	150	3	queries	query	NOUN
aji-137	150	4	are	be	AUX
aji-137	150	5	covered	cover	VERB
aji-137	150	6	in	in	ADP
aji-137	150	7	the	the	DET
aji-137	150	8	present	present	ADJ
aji-137	150	9	analysis	analysis	NOUN
aji-137	150	10	[	[	X
aji-137	150	11	14	14	NUM
aji-137	150	12	]	]	PUNCT
aji-137	150	13	.	.	PUNCT
aji-137	151	1	“	"	PUNCT
aji-137	151	2	this	this	DET
aji-137	151	3	article	article	NOUN
aji-137	151	4	aims	aim	VERB
aji-137	151	5	to	to	PART
aji-137	151	6	compile	compile	VERB
aji-137	151	7	and	and	CCONJ
aji-137	151	8	summarize	summarize	VERB
aji-137	151	9	the	the	DET
aji-137	151	10	available	available	ADJ
aji-137	151	11	information	information	NOUN
aji-137	151	12	about	about	ADP
aji-137	151	13	the	the	DET
aji-137	151	14	impact	impact	NOUN
aji-137	151	15	of	of	ADP
aji-137	151	16	baricitinib	baricitinib	NOUN
aji-137	151	17	on	on	ADP
aji-137	151	18	the	the	DET
aji-137	151	19	development	development	NOUN
aji-137	151	20	of	of	ADP
aji-137	151	21	structural	structural	ADJ
aji-137	151	22	joint	joint	ADJ
aji-137	151	23	damage	damage	NOUN
aji-137	151	24	as	as	ADV
aji-137	151	25	well	well	ADV
aji-137	151	26	as	as	ADP
aji-137	151	27	the	the	DET
aji-137	151	28	underlying	underlying	ADJ
aji-137	151	29	mechanisms	mechanism	NOUN
aji-137	151	30	of	of	ADP
aji-137	151	31	these	these	DET
aji-137	151	32	effects	effect	NOUN
aji-137	151	33	.	.	PUNCT
aji-137	152	1	results	result	NOUN
aji-137	152	2	measured	measure	VERB
aji-137	152	3	by	by	ADP
aji-137	152	4	magnetic	magnetic	ADJ
aji-137	152	5	resonance	resonance	NOUN
aji-137	152	6	imaging	imaging	NOUN
aji-137	152	7	(	(	PUNCT
aji-137	152	8	mri	mri	NOUN
aji-137	152	9	)	)	PUNCT
aji-137	152	10	or	or	CCONJ
aji-137	152	11	radiographic	radiographic	ADJ
aji-137	152	12	progression	progression	NOUN
aji-137	152	13	of	of	ADP
aji-137	152	14	joint	joint	ADJ
aji-137	152	15	erosion	erosion	NOUN
aji-137	152	16	and	and	CCONJ
aji-137	152	17	joint	joint	ADJ
aji-137	152	18	space	space	NOUN
aji-137	152	19	narrowing	narrow	VERB
aji-137	152	20	in	in	ADP
aji-137	152	21	clinical	clinical	ADJ
aji-137	152	22	studies	study	NOUN
aji-137	152	23	and	and	CCONJ
aji-137	152	24	post	post	VERB
aji-137	152	25	analyses	analysis	NOUN
aji-137	152	26	of	of	ADP
aji-137	152	27	patients	patient	NOUN
aji-137	152	28	with	with	ADP
aji-137	152	29	ra	ra	PROPN
aji-137	152	30	who	who	PRON
aji-137	152	31	are	be	AUX
aji-137	152	32	naive	naive	ADJ
aji-137	152	33	to	to	ADP
aji-137	152	34	diseasemodifying	diseasemodifye	VERB
aji-137	152	35	antirheumatic	antirheumatic	ADJ
aji-137	152	36	drugs	drug	NOUN
aji-137	152	37	(	(	PUNCT
aji-137	152	38	dmards	dmard	NOUN
aji-137	152	39	)	)	PUNCT
aji-137	152	40	or	or	CCONJ
aji-137	152	41	who	who	PRON
aji-137	152	42	gupta	gupta	VERB
aji-137	152	43	et	et	PROPN
aji-137	152	44	al	al	PROPN
aji-137	152	45	.	.	PROPN
aji-137	152	46	;	;	PUNCT
aji-137	152	47	asian	asian	PROPN
aji-137	152	48	j.	j.	PROPN
aji-137	152	49	immunol	immunol	PROPN
aji-137	152	50	.	.	PROPN
aji-137	152	51	,	,	PUNCT
aji-137	152	52	vol	vol	NOUN
aji-137	152	53	.	.	PROPN
aji-137	152	54	7	7	NUM
aji-137	152	55	,	,	PUNCT
aji-137	152	56	no	no	INTJ
aji-137	152	57	.	.	NOUN
aji-137	152	58	1	1	NUM
aji-137	152	59	,	,	PUNCT
aji-137	152	60	pp	pp	ADJ
aji-137	152	61	.	.	PUNCT
aji-137	153	1	123	123	NUM
aji-137	153	2	-	-	SYM
aji-137	153	3	130	130	NUM
aji-137	153	4	,	,	PUNCT
aji-137	153	5	2024	2024	NUM
aji-137	153	6	;	;	PUNCT
aji-137	153	7	article	article	NOUN
aji-137	153	8	no.aji.120135	no.aji.120135	PROPN
aji-137	153	9	125	125	NUM
aji-137	153	10	do	do	AUX
aji-137	153	11	not	not	PART
aji-137	153	12	respond	respond	VERB
aji-137	153	13	well	well	ADV
aji-137	153	14	to	to	ADP
aji-137	153	15	conventional	conventional	ADJ
aji-137	153	16	synthetic	synthetic	ADJ
aji-137	153	17	dmards	dmard	NOUN
aji-137	153	18	(	(	PUNCT
aji-137	153	19	csdmards	csdmard	NOUN
aji-137	153	20	)	)	PUNCT
aji-137	153	21	are	be	AUX
aji-137	153	22	presented	present	VERB
aji-137	153	23	.	.	PUNCT
aji-137	154	1	these	these	DET
aji-137	154	2	results	result	NOUN
aji-137	154	3	were	be	AUX
aji-137	154	4	obtained	obtain	VERB
aji-137	154	5	with	with	ADP
aji-137	154	6	approved	approve	VERB
aji-137	154	7	doses	dose	NOUN
aji-137	154	8	of	of	ADP
aji-137	154	9	baricitinib	baricitinib	NOUN
aji-137	154	10	(	(	PUNCT
aji-137	154	11	2	2	NUM
aji-137	154	12	mg	mg	NOUN
aji-137	154	13	or	or	CCONJ
aji-137	154	14	4	4	NUM
aji-137	154	15	mg	mg	NOUN
aji-137	154	16	once	once	ADV
aji-137	154	17	daily	daily	ADV
aji-137	154	18	,	,	PUNCT
aji-137	154	19	except	except	SCONJ
aji-137	154	20	in	in	ADP
aji-137	154	21	the	the	DET
aji-137	154	22	usa	usa	PROPN
aji-137	154	23	,	,	PUNCT
aji-137	154	24	canada	canada	PROPN
aji-137	154	25	,	,	PUNCT
aji-137	154	26	and	and	CCONJ
aji-137	154	27	china	china	PROPN
aji-137	154	28	,	,	PUNCT
aji-137	154	29	where	where	SCONJ
aji-137	154	30	the	the	DET
aji-137	154	31	approved	approve	VERB
aji-137	154	32	dose	dose	NOUN
aji-137	154	33	is	be	AUX
aji-137	154	34	2	2	NUM
aji-137	154	35	mg	mg	NOUN
aji-137	154	36	once	once	ADV
aji-137	154	37	daily	daily	ADV
aji-137	154	38	)	)	PUNCT
aji-137	154	39	.	.	PUNCT
aji-137	155	1	furthermore	furthermore	ADV
aji-137	155	2	,	,	PUNCT
aji-137	155	3	preclinical	preclinical	ADJ
aji-137	155	4	baricitinib	baricitinib	NOUN
aji-137	155	5	study	study	NOUN
aji-137	155	6	results	result	NOUN
aji-137	155	7	are	be	AUX
aji-137	155	8	discussed	discuss	VERB
aji-137	155	9	”	"	PUNCT
aji-137	155	10	[	[	X
aji-137	155	11	2	2	NUM
aji-137	155	12	]	]	PUNCT
aji-137	155	13	.	.	PUNCT
aji-137	156	1	“	"	PUNCT
aji-137	156	2	when	when	SCONJ
aji-137	156	3	traditional	traditional	ADJ
aji-137	156	4	dmards	dmard	NOUN
aji-137	156	5	are	be	AUX
aji-137	156	6	insufficient	insufficient	ADJ
aji-137	156	7	for	for	ADP
aji-137	156	8	treating	treat	VERB
aji-137	156	9	rheumatoid	rheumatoid	NOUN
aji-137	156	10	arthritis	arthritis	NOUN
aji-137	156	11	,	,	PUNCT
aji-137	156	12	baricitinib	baricitinib	NOUN
aji-137	156	13	,	,	PUNCT
aji-137	156	14	a	a	DET
aji-137	156	15	disease	disease	NOUN
aji-137	156	16	-	-	PUNCT
aji-137	156	17	modifying	modify	VERB
aji-137	156	18	anti	anti	ADJ
aji-137	156	19	-	-	ADJ
aji-137	156	20	rheumatic	rheumatic	ADJ
aji-137	156	21	medication	medication	NOUN
aji-137	156	22	,	,	PUNCT
aji-137	156	23	may	may	AUX
aji-137	156	24	be	be	AUX
aji-137	156	25	used	use	VERB
aji-137	156	26	.	.	PUNCT
aji-137	157	1	adult	adult	NOUN
aji-137	157	2	patients	patient	NOUN
aji-137	157	3	with	with	ADP
aji-137	157	4	moderately	moderately	ADV
aji-137	157	5	to	to	PART
aji-137	157	6	severely	severely	ADV
aji-137	157	7	active	active	ADJ
aji-137	157	8	rheumatoid	rheumatoid	NOUN
aji-137	157	9	arthritis	arthritis	NOUN
aji-137	157	10	who	who	PRON
aji-137	157	11	have	have	AUX
aji-137	157	12	not	not	PART
aji-137	157	13	reacted	react	VERB
aji-137	157	14	well	well	ADV
aji-137	157	15	to	to	ADP
aji-137	157	16	previous	previous	ADJ
aji-137	157	17	dmards	dmard	NOUN
aji-137	157	18	,	,	PUNCT
aji-137	157	19	including	include	VERB
aji-137	157	20	tumor	tumor	NOUN
aji-137	157	21	necrosis	necrosis	NOUN
aji-137	157	22	factor	factor	NOUN
aji-137	157	23	antagonist	antagonist	NOUN
aji-137	157	24	treatments	treatment	NOUN
aji-137	157	25	,	,	PUNCT
aji-137	157	26	may	may	AUX
aji-137	157	27	use	use	VERB
aji-137	157	28	this	this	DET
aji-137	157	29	medicine	medicine	NOUN
aji-137	157	30	,	,	PUNCT
aji-137	157	31	according	accord	VERB
aji-137	157	32	to	to	ADP
aji-137	157	33	approval	approval	NOUN
aji-137	157	34	from	from	ADP
aji-137	157	35	the	the	DET
aji-137	157	36	u.s	u.s	PROPN
aji-137	157	37	.	.	PROPN
aji-137	157	38	food	food	PROPN
aji-137	157	39	and	and	CCONJ
aji-137	157	40	drug	drug	PROPN
aji-137	157	41	administration	administration	PROPN
aji-137	157	42	(	(	PUNCT
aji-137	157	43	fda	fda	PROPN
aji-137	157	44	)	)	PUNCT
aji-137	157	45	.	.	PUNCT
aji-137	158	1	moreover	moreover	ADV
aji-137	158	2	,	,	PUNCT
aji-137	158	3	baricitinib	baricitinib	NOUN
aji-137	158	4	is	be	AUX
aji-137	158	5	fda	fda	PROPN
aji-137	158	6	approved	approve	VERB
aji-137	158	7	for	for	ADP
aji-137	158	8	the	the	DET
aji-137	158	9	treatment	treatment	NOUN
aji-137	158	10	of	of	ADP
aji-137	158	11	covid-19	covid-19	PROPN
aji-137	158	12	,	,	PUNCT
aji-137	158	13	making	make	VERB
aji-137	158	14	it	it	PRON
aji-137	158	15	a	a	DET
aji-137	158	16	viable	viable	ADJ
aji-137	158	17	option	option	NOUN
aji-137	158	18	for	for	ADP
aji-137	158	19	hospitalized	hospitalize	VERB
aji-137	158	20	patients	patient	NOUN
aji-137	158	21	when	when	SCONJ
aji-137	158	22	combined	combine	VERB
aji-137	158	23	with	with	ADP
aji-137	158	24	other	other	ADJ
aji-137	158	25	medications	medication	NOUN
aji-137	158	26	.	.	PUNCT
aji-137	159	1	this	this	PRON
aji-137	159	2	includes	include	VERB
aji-137	159	3	pediatric	pediatric	ADJ
aji-137	159	4	instances	instance	NOUN
aji-137	159	5	that	that	PRON
aji-137	159	6	require	require	VERB
aji-137	159	7	extracorporeal	extracorporeal	ADJ
aji-137	159	8	membrane	membrane	NOUN
aji-137	159	9	oxygenation	oxygenation	NOUN
aji-137	159	10	,	,	PUNCT
aji-137	159	11	invasive	invasive	ADJ
aji-137	159	12	mechanical	mechanical	ADJ
aji-137	159	13	ventilation	ventilation	NOUN
aji-137	159	14	,	,	PUNCT
aji-137	159	15	or	or	CCONJ
aji-137	159	16	supplemental	supplemental	ADJ
aji-137	159	17	oxygen	oxygen	NOUN
aji-137	159	18	.	.	PUNCT
aji-137	160	1	reviewing	review	VERB
aji-137	160	2	all	all	DET
aji-137	160	3	the	the	DET
aji-137	160	4	important	important	ADJ
aji-137	160	5	information	information	NOUN
aji-137	160	6	on	on	ADP
aji-137	160	7	baricitinib	baricitinib	NOUN
aji-137	160	8	therapy	therapy	NOUN
aji-137	160	9	in	in	ADP
aji-137	160	10	the	the	DET
aji-137	160	11	clinical	clinical	ADJ
aji-137	160	12	setting	setting	NOUN
aji-137	160	13	,	,	PUNCT
aji-137	160	14	including	include	VERB
aji-137	160	15	mechanisms	mechanism	NOUN
aji-137	160	16	,	,	PUNCT
aji-137	160	17	side	side	NOUN
aji-137	160	18	effects	effect	NOUN
aji-137	160	19	,	,	PUNCT
aji-137	160	20	and	and	CCONJ
aji-137	160	21	contraindications	contraindication	NOUN
aji-137	160	22	,	,	PUNCT
aji-137	160	23	is	be	AUX
aji-137	160	24	the	the	DET
aji-137	160	25	aim	aim	NOUN
aji-137	160	26	of	of	ADP
aji-137	160	27	this	this	DET
aji-137	160	28	exercise	exercise	NOUN
aji-137	160	29	.	.	PUNCT
aji-137	161	1	this	this	DET
aji-137	161	2	exercise	exercise	NOUN
aji-137	161	3	is	be	AUX
aji-137	161	4	specifically	specifically	ADV
aji-137	161	5	designed	design	VERB
aji-137	161	6	to	to	PART
aji-137	161	7	fulfill	fulfill	VERB
aji-137	161	8	the	the	DET
aji-137	161	9	requirements	requirement	NOUN
aji-137	161	10	of	of	ADP
aji-137	161	11	an	an	DET
aji-137	161	12	interdisciplinary	interdisciplinary	ADJ
aji-137	161	13	medical	medical	ADJ
aji-137	161	14	team	team	NOUN
aji-137	161	15	that	that	PRON
aji-137	161	16	treats	treat	VERB
aji-137	161	17	patients	patient	NOUN
aji-137	161	18	with	with	ADP
aji-137	161	19	rheumatoid	rheumatoid	NOUN
aji-137	161	20	arthritis	arthritis	NOUN
aji-137	161	21	,	,	PUNCT
aji-137	161	22	alopecia	alopecia	NOUN
aji-137	161	23	areata	areata	NOUN
aji-137	161	24	,	,	PUNCT
aji-137	161	25	and	and	CCONJ
aji-137	161	26	covid	covid	PROPN
aji-137	161	27	-19	-19	PROPN
aji-137	161	28	”	"	PUNCT
aji-137	162	1	[	[	X
aji-137	162	2	5	5	NUM
aji-137	162	3	]	]	PUNCT
aji-137	162	4	concluded	conclude	VERB
aji-137	162	5	by	by	ADP
aji-137	162	6	et	et	PROPN
aji-137	162	7	al	al	PROPN
aji-137	162	8	aman	aman	PROPN
aji-137	162	9	ahmad	ahmad	PROPN
aji-137	162	10	.	.	PUNCT
aji-137	163	1	2	2	X
aji-137	163	2	.	.	X
aji-137	163	3	mechanism	mechanism	NOUN
aji-137	163	4	of	of	ADP
aji-137	163	5	action	action	NOUN
aji-137	163	6	an	an	DET
aji-137	163	7	oral	oral	ADJ
aji-137	163	8	,	,	PUNCT
aji-137	163	9	selective	selective	ADJ
aji-137	163	10	,	,	PUNCT
aji-137	163	11	and	and	CCONJ
aji-137	163	12	reversible	reversible	ADJ
aji-137	163	13	jak	jak	PROPN
aji-137	163	14	inhibitor	inhibitor	NOUN
aji-137	163	15	is	be	AUX
aji-137	163	16	called	call	VERB
aji-137	163	17	baricitinib	baricitinib	NOUN
aji-137	163	18	.	.	PUNCT
aji-137	164	1	the	the	DET
aji-137	164	2	tyrosine	tyrosine	NOUN
aji-137	164	3	-	-	PUNCT
aji-137	164	4	protein	protein	NOUN
aji-137	164	5	kinase	kinase	NOUN
aji-137	164	6	family	family	NOUN
aji-137	164	7	of	of	ADP
aji-137	164	8	intracellular	intracellular	ADJ
aji-137	164	9	enzymes	enzyme	NOUN
aji-137	164	10	,	,	PUNCT
aji-137	164	11	jak	jak	PROPN
aji-137	164	12	,	,	PUNCT
aji-137	164	13	regulates	regulate	VERB
aji-137	164	14	signals	signal	NOUN
aji-137	164	15	from	from	ADP
aji-137	164	16	growth	growth	NOUN
aji-137	164	17	factor	factor	NOUN
aji-137	164	18	receptors	receptor	NOUN
aji-137	164	19	and	and	CCONJ
aji-137	164	20	cytokines	cytokine	NOUN
aji-137	164	21	that	that	PRON
aji-137	164	22	are	be	AUX
aji-137	164	23	important	important	ADJ
aji-137	164	24	for	for	ADP
aji-137	164	25	immune	immune	ADJ
aji-137	164	26	cell	cell	NOUN
aji-137	164	27	activity	activity	NOUN
aji-137	165	1	[	[	X
aji-137	165	2	5,15	5,15	NOUN
aji-137	165	3	]	]	PUNCT
aji-137	165	4	concluded	conclude	VERB
aji-137	165	5	by	by	ADP
aji-137	165	6	et	et	PROPN
aji-137	165	7	al	al	PROPN
aji-137	165	8	anam	anam	PROPN
aji-137	165	9	ahmad	ahmad	PROPN
aji-137	165	10	,	,	PUNCT
aji-137	165	11	amanda	amanda	PROPN
aji-137	165	12	mogul	mogul	PROPN
aji-137	165	13	four	four	NUM
aji-137	165	14	jak	jak	PROPN
aji-137	165	15	proteins	protein	NOUN
aji-137	165	16	—	—	PUNCT
aji-137	165	17	tyk2	tyk2	NOUN
aji-137	165	18	,	,	PUNCT
aji-137	165	19	jak1	jak1	PROPN
aji-137	165	20	,	,	PUNCT
aji-137	165	21	jak2	jak2	PROPN
aji-137	165	22	,	,	PUNCT
aji-137	165	23	and	and	CCONJ
aji-137	165	24	jak	jak	PROPN
aji-137	165	25	3	3	NUM
aji-137	165	26	—	—	PUNCT
aji-137	165	27	form	form	VERB
aji-137	165	28	distinct	distinct	ADJ
aji-137	165	29	pairings	pairing	NOUN
aji-137	165	30	in	in	ADP
aji-137	165	31	different	different	ADJ
aji-137	165	32	cell	cell	NOUN
aji-137	165	33	receptors	receptor	NOUN
aji-137	165	34	to	to	PART
aji-137	165	35	produce	produce	VERB
aji-137	165	36	homodimers	homodimer	NOUN
aji-137	165	37	or	or	CCONJ
aji-137	165	38	heterodimers	heterodimer	NOUN
aji-137	165	39	.	.	PUNCT
aji-137	166	1	these	these	DET
aji-137	166	2	jak	jak	PROPN
aji-137	166	3	dimers	dimer	NOUN
aji-137	166	4	stimulate	stimulate	VERB
aji-137	166	5	intracellular	intracellular	ADJ
aji-137	166	6	activity	activity	NOUN
aji-137	166	7	,	,	PUNCT
aji-137	166	8	including	include	VERB
aji-137	166	9	the	the	DET
aji-137	166	10	transcription	transcription	NOUN
aji-137	166	11	of	of	ADP
aji-137	166	12	inflammatory	inflammatory	ADJ
aji-137	166	13	mediator	mediator	NOUN
aji-137	166	14	genes	gene	NOUN
aji-137	166	15	,	,	PUNCT
aji-137	166	16	by	by	ADP
aji-137	166	17	phosphorylating	phosphorylate	VERB
aji-137	166	18	the	the	DET
aji-137	166	19	stat	stat	NOUN
aji-137	166	20	proteins	protein	NOUN
aji-137	166	21	.	.	PUNCT
aji-137	167	1	this	this	PRON
aji-137	167	2	ultimately	ultimately	ADV
aji-137	167	3	sets	set	VERB
aji-137	167	4	off	off	ADP
aji-137	167	5	an	an	DET
aji-137	167	6	autoimmune	autoimmune	ADJ
aji-137	167	7	reaction	reaction	NOUN
aji-137	168	1	[	[	X
aji-137	168	2	5,16	5,16	NUM
aji-137	168	3	]	]	PUNCT
aji-137	168	4	concluded	conclude	VERB
aji-137	168	5	by	by	ADP
aji-137	168	6	et	et	PROPN
aji-137	168	7	al	al	PROPN
aji-137	168	8	anam	anam	PROPN
aji-137	168	9	ahmad	ahmad	PROPN
aji-137	168	10	,	,	PUNCT
aji-137	168	11	musumeci	musumeci	PROPN
aji-137	168	12	,	,	PUNCT
aji-137	168	13	francesca	francesca	PROPN
aji-137	168	14	.	.	PUNCT
aji-137	169	1	there	there	PRON
aji-137	169	2	is	be	VERB
aji-137	169	3	an	an	DET
aji-137	169	4	increased	increase	VERB
aji-137	169	5	affinity	affinity	NOUN
aji-137	169	6	of	of	ADP
aji-137	169	7	baricitinib	baricitinib	NOUN
aji-137	169	8	for	for	ADP
aji-137	169	9	jak1	jak1	NOUN
aji-137	169	10	and	and	CCONJ
aji-137	169	11	jak2	jak2	PROPN
aji-137	169	12	.	.	PUNCT
aji-137	170	1	the	the	DET
aji-137	170	2	medication	medication	NOUN
aji-137	170	3	works	work	VERB
aji-137	170	4	by	by	ADP
aji-137	170	5	blocking	block	VERB
aji-137	170	6	these	these	DET
aji-137	170	7	jak	jak	PROPN
aji-137	170	8	proteins	protein	NOUN
aji-137	170	9	,	,	PUNCT
aji-137	170	10	which	which	PRON
aji-137	170	11	stop	stop	VERB
aji-137	170	12	stats	stat	NOUN
aji-137	170	13	from	from	ADP
aji-137	170	14	becoming	becoming	AUX
aji-137	170	15	phosphorylated	phosphorylate	VERB
aji-137	170	16	and	and	CCONJ
aji-137	170	17	activated	activate	VERB
aji-137	170	18	.	.	PUNCT
aji-137	171	1	furthermore	furthermore	ADV
aji-137	171	2	,	,	PUNCT
aji-137	171	3	baricitinib	baricitinib	NOUN
aji-137	171	4	modifies	modify	VERB
aji-137	171	5	the	the	DET
aji-137	171	6	signaling	signal	VERB
aji-137	171	7	pathway	pathway	NOUN
aji-137	171	8	of	of	ADP
aji-137	171	9	certain	certain	ADJ
aji-137	171	10	growth	growth	NOUN
aji-137	171	11	factors	factor	NOUN
aji-137	171	12	,	,	PUNCT
aji-137	171	13	interleukins	interleukin	NOUN
aji-137	171	14	,	,	PUNCT
aji-137	171	15	and	and	CCONJ
aji-137	171	16	interferons	interferon	NOUN
aji-137	171	17	.	.	PUNCT
aji-137	172	1	additionally	additionally	ADV
aji-137	172	2	,	,	PUNCT
aji-137	172	3	baricitinib	baricitinib	NOUN
aji-137	172	4	causes	cause	VERB
aji-137	172	5	cell	cell	NOUN
aji-137	172	6	death	death	NOUN
aji-137	172	7	and	and	CCONJ
aji-137	172	8	reduces	reduce	VERB
aji-137	172	9	the	the	DET
aji-137	172	10	growth	growth	NOUN
aji-137	172	11	of	of	ADP
aji-137	172	12	jak1	jak1	PROPN
aji-137	172	13	/	/	SYM
aji-137	172	14	jak2	jak2	PROPN
aji-137	172	15	expression	expression	NOUN
aji-137	172	16	in	in	ADP
aji-137	172	17	mutant	mutant	ADJ
aji-137	172	18	cells	cell	NOUN
aji-137	172	19	.	.	PUNCT
aji-137	173	1	within	within	ADP
aji-137	173	2	one	one	NUM
aji-137	173	3	week	week	NOUN
aji-137	173	4	of	of	ADP
aji-137	173	5	starting	start	VERB
aji-137	173	6	therapy	therapy	NOUN
aji-137	173	7	,	,	PUNCT
aji-137	173	8	baricitinib	baricitinib	NOUN
aji-137	173	9	dramatically	dramatically	ADV
aji-137	173	10	lowered	lower	VERB
aji-137	173	11	blood	blood	NOUN
aji-137	173	12	c	c	NOUN
aji-137	173	13	-	-	PUNCT
aji-137	173	14	reactive	reactive	ADJ
aji-137	173	15	protein	protein	NOUN
aji-137	173	16	levels	level	NOUN
aji-137	173	17	in	in	ADP
aji-137	173	18	rheumatoid	rheumatoid	NOUN
aji-137	173	19	arthritis	arthritis	NOUN
aji-137	173	20	patients	patient	NOUN
aji-137	173	21	.	.	PUNCT
aji-137	174	1	alopecia	alopecia	NOUN
aji-137	174	2	areata	areata	PROPN
aji-137	174	3	is	be	AUX
aji-137	174	4	thought	think	VERB
aji-137	174	5	to	to	PART
aji-137	174	6	be	be	AUX
aji-137	174	7	caused	cause	VERB
aji-137	174	8	by	by	ADP
aji-137	174	9	a	a	DET
aji-137	174	10	confluence	confluence	NOUN
aji-137	174	11	of	of	ADP
aji-137	174	12	immunological	immunological	ADJ
aji-137	174	13	dysregulation	dysregulation	NOUN
aji-137	174	14	and	and	CCONJ
aji-137	174	15	hereditary	hereditary	ADJ
aji-137	174	16	factors	factor	NOUN
aji-137	174	17	.	.	PUNCT
aji-137	175	1	important	important	ADJ
aji-137	175	2	cytokines	cytokine	NOUN
aji-137	175	3	that	that	PRON
aji-137	175	4	depend	depend	VERB
aji-137	175	5	on	on	ADP
aji-137	175	6	jaks	jak	NOUN
aji-137	175	7	for	for	ADP
aji-137	175	8	intracellular	intracellular	ADJ
aji-137	175	9	signaling	signal	VERB
aji-137	175	10	,	,	PUNCT
aji-137	175	11	like	like	ADP
aji-137	175	12	interleukin-15	interleukin-15	PROPN
aji-137	175	13	and	and	CCONJ
aji-137	175	14	interferon	interferon	ADJ
aji-137	175	15	-	-	PUNCT
aji-137	175	16	γ	γ	NOUN
aji-137	175	17	,	,	PUNCT
aji-137	175	18	are	be	AUX
aji-137	175	19	implicated	implicate	VERB
aji-137	175	20	in	in	ADP
aji-137	175	21	the	the	DET
aji-137	175	22	illness	illness	NOUN
aji-137	175	23	process	process	NOUN
aji-137	175	24	.	.	PUNCT
aji-137	176	1	baricitinib	baricitinib	NOUN
aji-137	176	2	has	have	AUX
aji-137	176	3	proven	prove	VERB
aji-137	176	4	to	to	PART
aji-137	176	5	be	be	AUX
aji-137	176	6	beneficial	beneficial	ADJ
aji-137	176	7	in	in	ADP
aji-137	176	8	helping	help	VERB
aji-137	176	9	people	people	NOUN
aji-137	176	10	with	with	ADP
aji-137	176	11	severe	severe	ADJ
aji-137	176	12	alopecia	alopecia	NOUN
aji-137	176	13	areata	areata	NOUN
aji-137	176	14	regrow	regrow	VERB
aji-137	176	15	their	their	PRON
aji-137	176	16	hair	hair	NOUN
aji-137	177	1	[	[	X
aji-137	177	2	5,17	5,17	X
aji-137	177	3	]	]	PUNCT
aji-137	177	4	concluded	conclude	VERB
aji-137	177	5	by	by	ADP
aji-137	177	6	et	et	PROPN
aji-137	177	7	al	al	PROPN
aji-137	177	8	anam	anam	PROPN
aji-137	177	9	ahmad	ahmad	PROPN
aji-137	177	10	.	.	PUNCT
aji-137	178	1	brett	brett	PROPN
aji-137	178	2	king	king	PROPN
aji-137	178	3	,	,	PUNCT
aji-137	178	4	m.d	m.d	PROPN
aji-137	178	5	.	.	PROPN
aji-137	178	6	,	,	PUNCT
aji-137	178	7	ph.d	ph.d	PROPN
aji-137	178	8	.	.	PROPN
aji-137	179	1	3	3	X
aji-137	179	2	.	.	NOUN
aji-137	179	3	pharmacokinetics	pharmacokinetic	NOUN
aji-137	179	4	absorption	absorption	NOUN
aji-137	179	5	:	:	PUNCT
aji-137	179	6	baricitinib	baricitinib	NOUN
aji-137	179	7	has	have	VERB
aji-137	179	8	a	a	DET
aji-137	179	9	97	97	NUM
aji-137	179	10	%	%	NOUN
aji-137	179	11	bioavailability	bioavailability	NOUN
aji-137	179	12	and	and	CCONJ
aji-137	179	13	is	be	AUX
aji-137	179	14	quickly	quickly	ADV
aji-137	179	15	absorbed	absorb	VERB
aji-137	179	16	from	from	ADP
aji-137	179	17	the	the	DET
aji-137	179	18	gastrointestinal	gastrointestinal	ADJ
aji-137	179	19	tract	tract	NOUN
aji-137	179	20	.	.	PUNCT
aji-137	180	1	baricitinib	baricitinib	NOUN
aji-137	180	2	takes	take	VERB
aji-137	180	3	an	an	DET
aji-137	180	4	average	average	NOUN
aji-137	180	5	of	of	ADP
aji-137	180	6	1.5	1.5	NUM
aji-137	180	7	hours	hour	NOUN
aji-137	180	8	to	to	PART
aji-137	180	9	reach	reach	VERB
aji-137	180	10	peak	peak	NOUN
aji-137	180	11	plasma	plasma	NOUN
aji-137	180	12	concentration	concentration	NOUN
aji-137	180	13	,	,	PUNCT
aji-137	180	14	although	although	SCONJ
aji-137	180	15	it	it	PRON
aji-137	180	16	can	can	AUX
aji-137	180	17	take	take	VERB
aji-137	180	18	anywhere	anywhere	ADV
aji-137	180	19	from	from	ADP
aji-137	180	20	0.5	0.5	NUM
aji-137	180	21	to	to	PART
aji-137	180	22	3	3	NUM
aji-137	180	23	hours	hour	NOUN
aji-137	180	24	.	.	PUNCT
aji-137	181	1	it	it	PRON
aji-137	181	2	has	have	AUX
aji-137	181	3	not	not	PART
aji-137	181	4	been	be	AUX
aji-137	181	5	demonstrated	demonstrate	VERB
aji-137	181	6	that	that	SCONJ
aji-137	181	7	administering	administer	VERB
aji-137	181	8	food	food	NOUN
aji-137	181	9	alters	alter	VERB
aji-137	181	10	the	the	DET
aji-137	181	11	peak	peak	NOUN
aji-137	181	12	plasma	plasma	NOUN
aji-137	181	13	concentration	concentration	NOUN
aji-137	181	14	.	.	PUNCT
aji-137	182	1	distribution	distribution	NOUN
aji-137	182	2	:	:	PUNCT
aji-137	182	3	approximately	approximately	ADV
aji-137	182	4	50	50	NUM
aji-137	182	5	%	%	NOUN
aji-137	182	6	of	of	ADP
aji-137	182	7	baricitinib	baricitinib	NOUN
aji-137	182	8	can	can	AUX
aji-137	182	9	bind	bind	VERB
aji-137	182	10	to	to	ADP
aji-137	182	11	plasma	plasma	NOUN
aji-137	182	12	proteins	protein	NOUN
aji-137	182	13	.	.	PUNCT
aji-137	183	1	baricitinib	baricitinib	NOUN
aji-137	183	2	's	's	PART
aji-137	183	3	apparent	apparent	ADJ
aji-137	183	4	volume	volume	NOUN
aji-137	183	5	of	of	ADP
aji-137	183	6	distribution	distribution	NOUN
aji-137	183	7	is	be	AUX
aji-137	183	8	76	76	NUM
aji-137	183	9	l	l	NOUN
aji-137	183	10	,	,	PUNCT
aji-137	183	11	which	which	PRON
aji-137	183	12	suggests	suggest	VERB
aji-137	183	13	that	that	SCONJ
aji-137	183	14	the	the	DET
aji-137	183	15	medication	medication	NOUN
aji-137	183	16	is	be	AUX
aji-137	183	17	widely	widely	ADV
aji-137	183	18	distributed	distribute	VERB
aji-137	183	19	throughout	throughout	ADP
aji-137	183	20	the	the	DET
aji-137	183	21	body	body	NOUN
aji-137	183	22	's	's	PART
aji-137	183	23	tissues	tissue	NOUN
aji-137	183	24	.	.	PUNCT
aji-137	184	1	metabolism	metabolism	NOUN
aji-137	184	2	:	:	PUNCT
aji-137	184	3	the	the	DET
aji-137	184	4	hepatic	hepatic	ADJ
aji-137	184	5	metabolism	metabolism	NOUN
aji-137	184	6	of	of	ADP
aji-137	184	7	approximately	approximately	ADV
aji-137	184	8	10	10	NUM
aji-137	184	9	%	%	NOUN
aji-137	184	10	of	of	ADP
aji-137	184	11	the	the	DET
aji-137	184	12	medication	medication	NOUN
aji-137	184	13	occurs	occur	VERB
aji-137	184	14	through	through	ADP
aji-137	184	15	oxidation	oxidation	NOUN
aji-137	184	16	by	by	ADP
aji-137	184	17	the	the	DET
aji-137	184	18	cyp3a4(cytochrome	cyp3a4(cytochrome	NOUN
aji-137	184	19	p450	p450	NUM
aji-137	184	20	3a4	3a4	NUM
aji-137	184	21	)	)	PUNCT
aji-137	184	22	enzyme	enzyme	NOUN
aji-137	184	23	and	and	CCONJ
aji-137	184	24	organic	organic	ADJ
aji-137	184	25	anion	anion	NOUN
aji-137	184	26	transporter-3	transporter-3	NUM
aji-137	184	27	(	(	PUNCT
aji-137	184	28	oat3	oat3	PROPN
aji-137	184	29	)	)	PUNCT
aji-137	184	30	.	.	PUNCT
aji-137	185	1	the	the	DET
aji-137	185	2	strong	strong	ADJ
aji-137	185	3	oat3	oat3	PROPN
aji-137	185	4	inhibitor	inhibitor	NOUN
aji-137	185	5	probenecid	probenecid	PROPN
aji-137	185	6	causes	cause	VERB
aji-137	185	7	a	a	DET
aji-137	185	8	two	two	NUM
aji-137	185	9	-	-	PUNCT
aji-137	185	10	fold	fold	ADJ
aji-137	185	11	rise	rise	NOUN
aji-137	185	12	in	in	ADP
aji-137	185	13	blood	blood	NOUN
aji-137	185	14	levels	level	NOUN
aji-137	185	15	of	of	ADP
aji-137	185	16	baricitinib	baricitinib	NOUN
aji-137	185	17	.	.	PUNCT
aji-137	186	1	consequently	consequently	ADV
aji-137	186	2	,	,	PUNCT
aji-137	186	3	patients	patient	NOUN
aji-137	186	4	taking	take	VERB
aji-137	186	5	probenecid	probenecid	PROPN
aji-137	186	6	at	at	ADP
aji-137	186	7	the	the	DET
aji-137	186	8	same	same	ADJ
aji-137	186	9	time	time	NOUN
aji-137	186	10	should	should	AUX
aji-137	186	11	cut	cut	VERB
aji-137	186	12	their	their	PRON
aji-137	186	13	baricitinib	baricitinib	NOUN
aji-137	186	14	dosage	dosage	NOUN
aji-137	186	15	in	in	ADP
aji-137	186	16	half	half	NOUN
aji-137	186	17	[	[	X
aji-137	186	18	5	5	NUM
aji-137	186	19	]	]	PUNCT
aji-137	186	20	concluded	conclude	VERB
aji-137	186	21	by	by	ADP
aji-137	186	22	et	et	PROPN
aji-137	186	23	al	al	PROPN
aji-137	186	24	anam	anam	PROPN
aji-137	186	25	ahmad	ahmad	PROPN
aji-137	186	26	.	.	PUNCT
aji-137	187	1	elimination	elimination	NOUN
aji-137	187	2	:	:	PUNCT
aji-137	187	3	in	in	ADP
aji-137	187	4	clinical	clinical	ADJ
aji-137	187	5	pharmacology	pharmacology	NOUN
aji-137	187	6	trials	trial	NOUN
aji-137	187	7	,	,	PUNCT
aji-137	187	8	the	the	DET
aji-137	187	9	gastrointestinal	gastrointestinal	ADJ
aji-137	187	10	tract	tract	NOUN
aji-137	187	11	eliminates	eliminate	VERB
aji-137	187	12	20	20	NUM
aji-137	187	13	%	%	NOUN
aji-137	187	14	of	of	ADP
aji-137	187	15	the	the	DET
aji-137	187	16	medication	medication	NOUN
aji-137	187	17	,	,	PUNCT
aji-137	187	18	and	and	CCONJ
aji-137	187	19	the	the	DET
aji-137	187	20	kidneys	kidney	NOUN
aji-137	187	21	clear	clear	ADJ
aji-137	187	22	about	about	ADV
aji-137	187	23	75	75	NUM
aji-137	187	24	%	%	NOUN
aji-137	187	25	of	of	ADP
aji-137	187	26	it	it	PRON
aji-137	187	27	.	.	PUNCT
aji-137	188	1	in	in	ADP
aji-137	188	2	patients	patient	NOUN
aji-137	188	3	with	with	ADP
aji-137	188	4	rheumatoid	rheumatoid	NOUN
aji-137	188	5	arthritis	arthritis	NOUN
aji-137	188	6	,	,	PUNCT
aji-137	188	7	baricitinib	baricitinib	NOUN
aji-137	188	8	has	have	VERB
aji-137	188	9	an	an	DET
aji-137	188	10	approximately	approximately	ADV
aji-137	188	11	12	12	NUM
aji-137	188	12	-	-	PUNCT
aji-137	188	13	hour	hour	NOUN
aji-137	188	14	elimination	elimination	NOUN
aji-137	188	15	half	half	ADJ
aji-137	188	16	-	-	PUNCT
aji-137	188	17	life	life	NOUN
aji-137	188	18	and	and	CCONJ
aji-137	188	19	a	a	DET
aji-137	188	20	renal	renal	ADJ
aji-137	188	21	clearance	clearance	NOUN
aji-137	188	22	of	of	ADP
aji-137	188	23	about	about	ADV
aji-137	188	24	12	12	NUM
aji-137	188	25	l	l	NOUN
aji-137	188	26	/	/	SYM
aji-137	188	27	h	h	NOUN
aji-137	189	1	[	[	X
aji-137	189	2	5,18	5,18	X
aji-137	189	3	]	]	X
aji-137	189	4	concluded	conclude	VERB
aji-137	189	5	by	by	ADP
aji-137	189	6	et	et	PROPN
aji-137	189	7	al	al	PROPN
aji-137	189	8	anam	anam	PROPN
aji-137	189	9	ahmad	ahmad	PROPN
aji-137	189	10	.	.	PUNCT
aji-137	190	1	jack	jack	PROPN
aji-137	190	2	g.	g.	PROPN
aji-137	190	3	shi	shi	PROPN
aji-137	190	4	phd	phd	PROPN
aji-137	190	5	.	.	PUNCT
aji-137	191	1	gupta	gupta	PROPN
aji-137	191	2	et	et	PROPN
aji-137	191	3	al	al	PROPN
aji-137	191	4	.	.	PROPN
aji-137	191	5	;	;	PUNCT
aji-137	191	6	asian	asian	PROPN
aji-137	191	7	j.	j.	PROPN
aji-137	191	8	immunol	immunol	PROPN
aji-137	191	9	.	.	PROPN
aji-137	191	10	,	,	PUNCT
aji-137	191	11	vol	vol	NOUN
aji-137	191	12	.	.	PROPN
aji-137	191	13	7	7	NUM
aji-137	191	14	,	,	PUNCT
aji-137	191	15	no	no	INTJ
aji-137	191	16	.	.	NOUN
aji-137	191	17	1	1	NUM
aji-137	191	18	,	,	PUNCT
aji-137	191	19	pp	pp	ADJ
aji-137	191	20	.	.	PUNCT
aji-137	192	1	123	123	NUM
aji-137	192	2	-	-	SYM
aji-137	192	3	130	130	NUM
aji-137	192	4	,	,	PUNCT
aji-137	192	5	2024	2024	NUM
aji-137	192	6	;	;	PUNCT
aji-137	192	7	article	article	NOUN
aji-137	192	8	no.aji.120135	no.aji.120135	VERB
aji-137	192	9	126	126	NUM
aji-137	192	10	4	4	NUM
aji-137	192	11	.	.	PUNCT
aji-137	193	1	administration	administration	NOUN
aji-137	193	2	4.1	4.1	NUM
aji-137	193	3	available	available	ADJ
aji-137	193	4	dosage	dosage	NOUN
aji-137	193	5	forms	form	NOUN
aji-137	193	6	and	and	CCONJ
aji-137	193	7	strengths	strength	NOUN
aji-137	193	8	oral	oral	ADJ
aji-137	193	9	administration	administration	NOUN
aji-137	193	10	of	of	ADP
aji-137	193	11	baricitinib	baricitinib	NOUN
aji-137	193	12	is	be	AUX
aji-137	193	13	possible	possible	ADJ
aji-137	193	14	in	in	ADP
aji-137	193	15	two	two	NUM
aji-137	193	16	dosage	dosage	NOUN
aji-137	193	17	forms	form	NOUN
aji-137	193	18	:	:	PUNCT
aji-137	193	19	2	2	NUM
aji-137	193	20	mg	mg	NOUN
aji-137	193	21	and	and	CCONJ
aji-137	193	22	4	4	NUM
aji-137	193	23	mg	mg	NOUN
aji-137	193	24	.	.	PUNCT
aji-137	194	1	for	for	ADP
aji-137	194	2	rheumatoid	rheumatoid	NOUN
aji-137	194	3	arthritis	arthritis	NOUN
aji-137	194	4	,	,	PUNCT
aji-137	194	5	a	a	DET
aji-137	194	6	dose	dose	NOUN
aji-137	194	7	of	of	ADP
aji-137	194	8	2	2	NUM
aji-137	194	9	mg	mg	NOUN
aji-137	194	10	taken	take	VERB
aji-137	194	11	once	once	ADV
aji-137	194	12	daily	daily	ADV
aji-137	194	13	by	by	ADP
aji-137	194	14	mouth	mouth	NOUN
aji-137	194	15	is	be	AUX
aji-137	194	16	advised	advise	VERB
aji-137	194	17	.	.	PUNCT
aji-137	195	1	clinical	clinical	ADJ
aji-137	195	2	trials	trial	NOUN
aji-137	195	3	evaluated	evaluate	VERB
aji-137	195	4	the	the	DET
aji-137	195	5	effects	effect	NOUN
aji-137	195	6	of	of	ADP
aji-137	195	7	2	2	NUM
aji-137	195	8	mg	mg	NOUN
aji-137	195	9	oral	oral	ADJ
aji-137	195	10	baricitinib	baricitinib	NOUN
aji-137	195	11	in	in	ADP
aji-137	195	12	conjunction	conjunction	NOUN
aji-137	195	13	with	with	ADP
aji-137	195	14	10–14	10–14	NUM
aji-137	195	15	days	day	NOUN
aji-137	195	16	of	of	ADP
aji-137	195	17	antiviral	antiviral	ADJ
aji-137	195	18	medication	medication	NOUN
aji-137	195	19	in	in	ADP
aji-137	195	20	the	the	DET
aji-137	195	21	setting	setting	NOUN
aji-137	195	22	of	of	ADP
aji-137	195	23	covid-19	covid-19	PROPN
aji-137	195	24	infection	infection	NOUN
aji-137	195	25	[	[	X
aji-137	195	26	19	19	NUM
aji-137	195	27	]	]	PUNCT
aji-137	195	28	concluded	conclude	VERB
aji-137	195	29	by	by	ADP
aji-137	195	30	et	et	PROPN
aji-137	195	31	al	al	PROPN
aji-137	195	32	feng	feng	PROPN
aji-137	195	33	huang	huang	PROPN
aji-137	195	34	.	.	PROPN
aji-137	195	35	4.2	4.2	NUM
aji-137	195	36	adult	adult	NOUN
aji-137	195	37	dosage	dosage	NOUN
aji-137	195	38	for	for	ADP
aji-137	195	39	rheumatoid	rheumatoid	NOUN
aji-137	195	40	arthritis	arthritis	NOUN
aji-137	195	41	,	,	PUNCT
aji-137	195	42	2	2	NUM
aji-137	195	43	mg	mg	NOUN
aji-137	195	44	of	of	ADP
aji-137	195	45	baricitinib	baricitinib	NOUN
aji-137	195	46	taken	take	VERB
aji-137	195	47	orally	orally	ADV
aji-137	195	48	once	once	ADV
aji-137	195	49	daily	daily	ADV
aji-137	195	50	,	,	PUNCT
aji-137	195	51	with	with	ADP
aji-137	195	52	or	or	CCONJ
aji-137	195	53	without	without	ADP
aji-137	195	54	food	food	NOUN
aji-137	195	55	,	,	PUNCT
aji-137	195	56	is	be	AUX
aji-137	195	57	the	the	DET
aji-137	195	58	suggested	suggest	VERB
aji-137	195	59	dosage	dosage	NOUN
aji-137	195	60	.	.	PUNCT
aji-137	196	1	the	the	DET
aji-137	196	2	medication	medication	NOUN
aji-137	196	3	can	can	AUX
aji-137	196	4	be	be	AUX
aji-137	196	5	taken	take	VERB
aji-137	196	6	either	either	CCONJ
aji-137	196	7	alone	alone	ADJ
aji-137	196	8	or	or	CCONJ
aji-137	196	9	in	in	ADP
aji-137	196	10	conjunction	conjunction	NOUN
aji-137	196	11	with	with	ADP
aji-137	196	12	methotrexate	methotrexate	NOUN
aji-137	196	13	or	or	CCONJ
aji-137	196	14	non	non	ADJ
aji-137	196	15	-	-	ADJ
aji-137	196	16	biologic	biologic	ADJ
aji-137	196	17	dmards	dmard	NOUN
aji-137	196	18	.	.	PUNCT
aji-137	197	1	covid-19	covid-19	PROPN
aji-137	197	2	:	:	PUNCT
aji-137	197	3	the	the	DET
aji-137	197	4	national	national	PROPN
aji-137	197	5	institutes	institutes	PROPN
aji-137	197	6	of	of	ADP
aji-137	197	7	health	health	NOUN
aji-137	197	8	advises	advise	VERB
aji-137	197	9	against	against	ADP
aji-137	197	10	using	use	VERB
aji-137	197	11	baricitinib	baricitinib	NOUN
aji-137	197	12	as	as	ADP
aji-137	197	13	a	a	DET
aji-137	197	14	secondary	secondary	ADJ
aji-137	197	15	immunomodulatory	immunomodulatory	ADJ
aji-137	197	16	medication	medication	NOUN
aji-137	197	17	and	and	CCONJ
aji-137	197	18	in	in	ADP
aji-137	197	19	favor	favor	NOUN
aji-137	197	20	of	of	ADP
aji-137	197	21	dexamethasone	dexamethasone	NOUN
aji-137	197	22	in	in	ADP
aji-137	197	23	covid-19	covid-19	PROPN
aji-137	197	24	patients	patient	NOUN
aji-137	197	25	who	who	PRON
aji-137	197	26	are	be	AUX
aji-137	197	27	exhibiting	exhibiting	AUX
aji-137	197	28	rapidly	rapidly	ADV
aji-137	197	29	increasing	increase	VERB
aji-137	197	30	oxygen	oxygen	NOUN
aji-137	197	31	requirements	requirement	NOUN
aji-137	197	32	and	and	CCONJ
aji-137	197	33	systemic	systemic	ADJ
aji-137	197	34	inflammation	inflammation	NOUN
aji-137	197	35	.	.	PUNCT
aji-137	198	1	adults	adult	NOUN
aji-137	198	2	should	should	AUX
aji-137	198	3	take	take	VERB
aji-137	198	4	4	4	NUM
aji-137	198	5	mg	mg	ADP
aji-137	198	6	of	of	ADP
aji-137	198	7	baricitinib	baricitinib	NOUN
aji-137	198	8	once	once	ADV
aji-137	198	9	a	a	DET
aji-137	198	10	day	day	NOUN
aji-137	198	11	for	for	ADP
aji-137	198	12	a	a	DET
aji-137	198	13	period	period	NOUN
aji-137	198	14	of	of	ADP
aji-137	198	15	14	14	NUM
aji-137	198	16	days	day	NOUN
aji-137	198	17	,	,	PUNCT
aji-137	198	18	or	or	CCONJ
aji-137	198	19	until	until	SCONJ
aji-137	198	20	they	they	PRON
aji-137	198	21	are	be	AUX
aji-137	198	22	released	release	VERB
aji-137	198	23	from	from	ADP
aji-137	198	24	the	the	DET
aji-137	198	25	hospital	hospital	NOUN
aji-137	199	1	[	[	X
aji-137	199	2	20	20	NUM
aji-137	199	3	]	]	PUNCT
aji-137	199	4	concluded	conclude	VERB
aji-137	199	5	by	by	ADP
aji-137	199	6	et	et	PROPN
aji-137	199	7	al	al	PROPN
aji-137	199	8	s	s	PROPN
aji-137	199	9	honda	honda	NOUN
aji-137	199	10	,	,	PUNCT
aji-137	199	11	m	m	VERB
aji-137	199	12	harigai	harigai	PROPN
aji-137	199	13	.	.	PUNCT
aji-137	200	1	4.3	4.3	NUM
aji-137	200	2	adverse	adverse	ADJ
aji-137	200	3	effects	effect	NOUN
aji-137	200	4	baricitinib	baricitinib	NOUN
aji-137	200	5	is	be	AUX
aji-137	200	6	generally	generally	ADV
aji-137	200	7	regarded	regard	VERB
aji-137	200	8	as	as	ADP
aji-137	200	9	a	a	DET
aji-137	200	10	safe	safe	ADJ
aji-137	200	11	and	and	CCONJ
aji-137	200	12	well	well	ADV
aji-137	200	13	-	-	PUNCT
aji-137	200	14	tolerated	tolerate	VERB
aji-137	200	15	drug	drug	NOUN
aji-137	200	16	.	.	PUNCT
aji-137	201	1	however	however	ADV
aji-137	201	2	,	,	PUNCT
aji-137	201	3	its	its	PRON
aji-137	201	4	immunosuppressive	immunosuppressive	ADJ
aji-137	201	5	qualities	quality	NOUN
aji-137	201	6	raise	raise	VERB
aji-137	201	7	the	the	DET
aji-137	201	8	risk	risk	NOUN
aji-137	201	9	of	of	ADP
aji-137	201	10	serious	serious	ADJ
aji-137	201	11	infections	infection	NOUN
aji-137	201	12	.	.	PUNCT
aji-137	202	1	the	the	DET
aji-137	202	2	most	most	ADV
aji-137	202	3	common	common	ADJ
aji-137	202	4	adverse	adverse	ADJ
aji-137	202	5	events	event	NOUN
aji-137	202	6	recorded	record	VERB
aji-137	202	7	in	in	ADP
aji-137	202	8	alopecia	alopecia	NOUN
aji-137	202	9	areata	areata	ADJ
aji-137	202	10	patients	patient	NOUN
aji-137	202	11	throughout	throughout	ADP
aji-137	202	12	clinical	clinical	ADJ
aji-137	202	13	trials	trial	NOUN
aji-137	202	14	were	be	AUX
aji-137	202	15	upper	upper	ADJ
aji-137	202	16	respiratory	respiratory	ADJ
aji-137	202	17	tract	tract	NOUN
aji-137	202	18	infections	infection	NOUN
aji-137	202	19	,	,	PUNCT
aji-137	202	20	acne	acne	NOUN
aji-137	202	21	vulgaris	vulgaris	NOUN
aji-137	202	22	,	,	PUNCT
aji-137	202	23	headaches	headache	NOUN
aji-137	202	24	,	,	PUNCT
aji-137	202	25	urinary	urinary	ADJ
aji-137	202	26	tract	tract	NOUN
aji-137	202	27	infections	infection	NOUN
aji-137	202	28	,	,	PUNCT
aji-137	202	29	and	and	CCONJ
aji-137	202	30	folliculitis	folliculitis	PROPN
aji-137	202	31	[	[	X
aji-137	202	32	21,22	21,22	NOUN
aji-137	202	33	]	]	PUNCT
aji-137	202	34	concluded	conclude	VERB
aji-137	202	35	by	by	ADP
aji-137	202	36	et	et	PROPN
aji-137	202	37	al	al	PROPN
aji-137	202	38	egídio	egídio	PROPN
aji-137	202	39	freitas	freitas	PROPN
aji-137	202	40	,	,	PUNCT
aji-137	202	41	t	t	PROPN
aji-137	202	42	bieber	bieber	PROPN
aji-137	202	43	,	,	PUNCT
aji-137	202	44	n	n	PRON
aji-137	202	45	katoh	katoh	NOUN
aji-137	202	46	.	.	PUNCT
aji-137	203	1	herpes	herpe	NOUN
aji-137	203	2	zoster	zoster	NOUN
aji-137	203	3	infections	infection	NOUN
aji-137	203	4	are	be	AUX
aji-137	203	5	also	also	ADV
aji-137	203	6	on	on	ADP
aji-137	203	7	the	the	DET
aji-137	203	8	rise	rise	NOUN
aji-137	203	9	.	.	PUNCT
aji-137	204	1	baricitinib	baricitinib	NOUN
aji-137	204	2	has	have	AUX
aji-137	204	3	been	be	AUX
aji-137	204	4	linked	link	VERB
aji-137	204	5	to	to	ADP
aji-137	204	6	bone	bone	NOUN
aji-137	204	7	marrow	marrow	NOUN
aji-137	204	8	suppression	suppression	NOUN
aji-137	204	9	and	and	CCONJ
aji-137	204	10	hematological	hematological	ADJ
aji-137	204	11	abnormalities	abnormality	NOUN
aji-137	204	12	such	such	ADJ
aji-137	204	13	as	as	ADP
aji-137	204	14	anemia	anemia	NOUN
aji-137	204	15	,	,	PUNCT
aji-137	204	16	neutropenia	neutropenia	NOUN
aji-137	204	17	,	,	PUNCT
aji-137	204	18	and	and	CCONJ
aji-137	204	19	lymphopenia	lymphopenia	NOUN
aji-137	204	20	and	and	CCONJ
aji-137	204	21	should	should	AUX
aji-137	204	22	be	be	AUX
aji-137	204	23	monitored	monitor	VERB
aji-137	204	24	regularly	regularly	ADV
aji-137	204	25	in	in	ADP
aji-137	204	26	the	the	DET
aji-137	204	27	lab	lab	NOUN
aji-137	204	28	.	.	PUNCT
aji-137	205	1	another	another	DET
aji-137	205	2	side	side	ADJ
aji-137	205	3	effect	effect	NOUN
aji-137	205	4	commonly	commonly	ADV
aji-137	205	5	seen	see	VERB
aji-137	205	6	after	after	ADP
aji-137	205	7	12	12	NUM
aji-137	205	8	weeks	week	NOUN
aji-137	205	9	of	of	ADP
aji-137	205	10	baricitinib	baricitinib	NOUN
aji-137	205	11	treatment	treatment	NOUN
aji-137	205	12	is	be	AUX
aji-137	205	13	an	an	DET
aji-137	205	14	increase	increase	NOUN
aji-137	205	15	in	in	ADP
aji-137	205	16	mean	mean	ADJ
aji-137	205	17	cholesterol	cholesterol	NOUN
aji-137	205	18	,	,	PUNCT
aji-137	205	19	low	low	ADJ
aji-137	205	20	-	-	PUNCT
aji-137	205	21	density	density	NOUN
aji-137	205	22	lipoprotein	lipoprotein	ADJ
aji-137	205	23	(	(	PUNCT
aji-137	205	24	ldl	ldl	NOUN
aji-137	205	25	)	)	PUNCT
aji-137	205	26	,	,	PUNCT
aji-137	205	27	and	and	CCONJ
aji-137	205	28	high	high	ADJ
aji-137	205	29	-	-	PUNCT
aji-137	205	30	density	density	NOUN
aji-137	205	31	lipoprotein	lipoprotein	ADJ
aji-137	205	32	(	(	PUNCT
aji-137	205	33	hdl	hdl	NOUN
aji-137	205	34	)	)	PUNCT
aji-137	205	35	levels	level	NOUN
aji-137	205	36	without	without	ADP
aji-137	205	37	an	an	DET
aji-137	205	38	increase	increase	NOUN
aji-137	205	39	in	in	ADP
aji-137	205	40	the	the	DET
aji-137	205	41	ldl	ldl	NOUN
aji-137	205	42	to	to	ADP
aji-137	205	43	hdl	hdl	PROPN
aji-137	205	44	ratio	ratio	NOUN
aji-137	205	45	.	.	PUNCT
aji-137	206	1	furthermore	furthermore	ADV
aji-137	206	2	,	,	PUNCT
aji-137	206	3	some	some	DET
aji-137	206	4	individuals	individual	NOUN
aji-137	206	5	may	may	AUX
aji-137	206	6	have	have	VERB
aji-137	206	7	a	a	DET
aji-137	206	8	rise	rise	NOUN
aji-137	206	9	in	in	ADP
aji-137	206	10	creatine	creatine	NOUN
aji-137	206	11	phosphokinase	phosphokinase	NOUN
aji-137	206	12	levels	level	NOUN
aji-137	206	13	[	[	X
aji-137	206	14	23,24	23,24	NOUN
aji-137	206	15	]	]	PUNCT
aji-137	206	16	concluded	conclude	VERB
aji-137	206	17	by	by	ADP
aji-137	206	18	et	et	X
aji-137	206	19	al	al	PROPN
aji-137	206	20	d	d	PROPN
aji-137	206	21	van	van	PROPN
aji-137	206	22	der	der	NOUN
aji-137	206	23	heijde	heijde	NOUN
aji-137	206	24	,	,	PUNCT
aji-137	206	25	27	27	NUM
aji-137	206	26	pc	pc	NOUN
aji-137	206	27	taylor	taylor	NOUN
aji-137	206	28	.	.	PUNCT
aji-137	207	1	4.4	4.4	NUM
aji-137	207	2	baricitinib	baricitinib	NOUN
aji-137	207	3	for	for	ADP
aji-137	207	4	the	the	DET
aji-137	207	5	treatment	treatment	NOUN
aji-137	207	6	of	of	ADP
aji-137	207	7	rheumatoid	rheumatoid	NOUN
aji-137	207	8	arthritis	arthritis	NOUN
aji-137	207	9	since	since	SCONJ
aji-137	207	10	the	the	DET
aji-137	207	11	mid-1990s	mid-1990	NOUN
aji-137	207	12	,	,	PUNCT
aji-137	207	13	the	the	DET
aji-137	207	14	treatment	treatment	NOUN
aji-137	207	15	approach	approach	NOUN
aji-137	207	16	to	to	PART
aji-137	207	17	rheumatoid	rheumatoid	VERB
aji-137	207	18	arthritis	arthritis	NOUN
aji-137	207	19	has	have	AUX
aji-137	207	20	undergone	undergo	VERB
aji-137	207	21	significant	significant	ADJ
aji-137	207	22	modifications	modification	NOUN
aji-137	207	23	in	in	ADP
aji-137	207	24	the	the	DET
aji-137	207	25	area	area	NOUN
aji-137	207	26	of	of	ADP
aji-137	207	27	rheumatology	rheumatology	NOUN
aji-137	207	28	.	.	PUNCT
aji-137	208	1	with	with	ADP
aji-137	208	2	the	the	DET
aji-137	208	3	increased	increase	VERB
aji-137	208	4	use	use	NOUN
aji-137	208	5	of	of	ADP
aji-137	208	6	traditional	traditional	ADJ
aji-137	208	7	synthetic	synthetic	ADJ
aji-137	208	8	dmards	dmard	NOUN
aji-137	208	9	,	,	PUNCT
aji-137	208	10	the	the	DET
aji-137	208	11	advent	advent	NOUN
aji-137	208	12	of	of	ADP
aji-137	208	13	biologic	biologic	NOUN
aji-137	208	14	treatments	treatment	NOUN
aji-137	208	15	,	,	PUNCT
aji-137	208	16	and	and	CCONJ
aji-137	208	17	,	,	PUNCT
aji-137	208	18	most	most	ADV
aji-137	208	19	recently	recently	ADV
aji-137	208	20	,	,	PUNCT
aji-137	208	21	the	the	DET
aji-137	208	22	development	development	NOUN
aji-137	208	23	of	of	ADP
aji-137	208	24	novel	novel	ADJ
aji-137	208	25	small	small	ADJ
aji-137	208	26	compounds	compound	NOUN
aji-137	208	27	that	that	PRON
aji-137	208	28	target	target	VERB
aji-137	208	29	the	the	DET
aji-137	208	30	jak	jak	PROPN
aji-137	208	31	pathway	pathway	NOUN
aji-137	208	32	,	,	PUNCT
aji-137	208	33	treatment	treatment	NOUN
aji-137	208	34	paradigms	paradigm	NOUN
aji-137	208	35	have	have	AUX
aji-137	208	36	changed	change	VERB
aji-137	208	37	.	.	PUNCT
aji-137	209	1	a	a	DET
aji-137	209	2	strong	strong	ADJ
aji-137	209	3	and	and	CCONJ
aji-137	209	4	specific	specific	ADJ
aji-137	209	5	jak1	jak1	NOUN
aji-137	209	6	and	and	CCONJ
aji-137	209	7	jak2	jak2	PROPN
aji-137	209	8	inhibitor	inhibitor	NOUN
aji-137	209	9	is	be	AUX
aji-137	209	10	baricitinib	baricitinib	NOUN
aji-137	209	11	.	.	PUNCT
aji-137	210	1	it	it	PRON
aji-137	210	2	has	have	AUX
aji-137	210	3	been	be	AUX
aji-137	210	4	proposed	propose	VERB
aji-137	210	5	that	that	SCONJ
aji-137	210	6	various	various	ADJ
aji-137	210	7	medicines	medicine	NOUN
aji-137	210	8	may	may	AUX
aji-137	210	9	exhibit	exhibit	VERB
aji-137	210	10	differential	differential	ADJ
aji-137	210	11	clinical	clinical	ADJ
aji-137	210	12	effects	effect	NOUN
aji-137	210	13	based	base	VERB
aji-137	210	14	on	on	ADP
aji-137	210	15	their	their	PRON
aji-137	210	16	profiles	profile	NOUN
aji-137	210	17	of	of	ADP
aji-137	210	18	jak	jak	PROPN
aji-137	210	19	inhibition	inhibition	NOUN
aji-137	210	20	[	[	X
aji-137	210	21	25,26	25,26	X
aji-137	210	22	]	]	PUNCT
aji-137	210	23	concluded	conclude	VERB
aji-137	210	24	by	by	ADP
aji-137	210	25	et	et	PROPN
aji-137	210	26	al	al	PROPN
aji-137	210	27	mark	mark	PROPN
aji-137	210	28	c.	c.	PROPN
aji-137	210	29	genovese	genovese	PROPN
aji-137	210	30	,	,	PUNCT
aji-137	210	31	m.d	m.d	PROPN
aji-137	210	32	.	.	PROPN
aji-137	210	33	,	,	PUNCT
aji-137	210	34	joel	joel	PROPN
aji-137	210	35	kremer	kremer	PROPN
aji-137	210	36	,	,	PUNCT
aji-137	210	37	m.d	m.d	PROPN
aji-137	210	38	.	.	PROPN
aji-137	210	39	,	,	PUNCT
aji-137	210	40	omid	omid	PROPN
aji-137	210	41	zamani	zamani	PROPN
aji-137	210	42	,	,	PUNCT
aji-137	210	43	m.d	m.d	PROPN
aji-137	210	44	.	.	PROPN
aji-137	210	45	,	,	PUNCT
aji-137	210	46	jj	jj	PROPN
aji-137	210	47	o'shea	o'shea	PROPN
aji-137	210	48	,	,	PUNCT
aji-137	210	49	j	j	PROPN
aji-137	210	50	israel	israel	PROPN
aji-137	210	51	,	,	PUNCT
aji-137	210	52	h	h	PROPN
aji-137	210	53	hakobyan	hakobyan	PROPN
aji-137	210	54	.	.	PUNCT
aji-137	211	1	adults	adult	NOUN
aji-137	211	2	with	with	ADP
aji-137	211	3	mild	mild	ADJ
aji-137	211	4	to	to	ADP
aji-137	211	5	severe	severe	ADJ
aji-137	211	6	active	active	ADJ
aji-137	211	7	ra	ra	PROPN
aji-137	211	8	are	be	AUX
aji-137	211	9	advised	advise	VERB
aji-137	211	10	to	to	PART
aji-137	211	11	take	take	VERB
aji-137	211	12	baricitinib	baricitinib	NOUN
aji-137	211	13	once	once	ADV
aji-137	211	14	a	a	DET
aji-137	211	15	day	day	NOUN
aji-137	211	16	.	.	PUNCT
aji-137	212	1	it	it	PRON
aji-137	212	2	is	be	AUX
aji-137	212	3	usually	usually	ADV
aji-137	212	4	administered	administer	VERB
aji-137	212	5	as	as	ADP
aji-137	212	6	a	a	DET
aji-137	212	7	second	second	ADJ
aji-137	212	8	-	-	PUNCT
aji-137	212	9	choice	choice	NOUN
aji-137	212	10	medication	medication	NOUN
aji-137	212	11	after	after	SCONJ
aji-137	212	12	patients	patient	NOUN
aji-137	212	13	have	have	AUX
aji-137	212	14	tried	try	VERB
aji-137	212	15	using	use	VERB
aji-137	212	16	tnf	tnf	PROPN
aji-137	212	17	inhibitors	inhibitor	NOUN
aji-137	212	18	but	but	CCONJ
aji-137	212	19	did	do	AUX
aji-137	212	20	not	not	PART
aji-137	212	21	experience	experience	VERB
aji-137	212	22	meaningful	meaningful	ADJ
aji-137	212	23	relief	relief	NOUN
aji-137	212	24	or	or	CCONJ
aji-137	212	25	could	could	AUX
aji-137	212	26	not	not	PART
aji-137	212	27	handle	handle	VERB
aji-137	212	28	the	the	DET
aji-137	212	29	medication	medication	NOUN
aji-137	212	30	owing	owe	VERB
aji-137	212	31	to	to	ADP
aji-137	212	32	adverse	adverse	ADJ
aji-137	212	33	effects	effect	NOUN
aji-137	212	34	because	because	SCONJ
aji-137	212	35	of	of	ADP
aji-137	212	36	several	several	ADJ
aji-137	212	37	potentially	potentially	ADV
aji-137	212	38	dangerous	dangerous	ADJ
aji-137	212	39	side	side	NOUN
aji-137	212	40	effects.both	effects.both	PROPN
aji-137	212	41	brands	brand	NOUN
aji-137	212	42	warn	warn	VERB
aji-137	212	43	of	of	ADP
aji-137	212	44	potential	potential	ADJ
aji-137	212	45	significant	significant	ADJ
aji-137	212	46	adverse	adverse	ADJ
aji-137	212	47	effects	effect	NOUN
aji-137	212	48	.	.	PUNCT
aji-137	213	1	both	both	PRON
aji-137	213	2	caution	caution	VERB
aji-137	213	3	against	against	ADP
aji-137	213	4	administering	administer	VERB
aji-137	213	5	the	the	DET
aji-137	213	6	medicine	medicine	NOUN
aji-137	213	7	if	if	SCONJ
aji-137	213	8	there	there	PRON
aji-137	213	9	is	be	VERB
aji-137	213	10	a	a	DET
aji-137	213	11	known	know	VERB
aji-137	213	12	severe	severe	ADJ
aji-137	213	13	illness	illness	NOUN
aji-137	213	14	,	,	PUNCT
aji-137	213	15	such	such	ADJ
aji-137	213	16	as	as	ADP
aji-137	213	17	tuberculosis	tuberculosis	NOUN
aji-137	213	18	(	(	PUNCT
aji-137	213	19	tb	tb	NOUN
aji-137	213	20	)	)	PUNCT
aji-137	213	21	,	,	PUNCT
aji-137	213	22	and	and	CCONJ
aji-137	213	23	recommend	recommend	VERB
aji-137	213	24	tb	tb	ADP
aji-137	213	25	screening	screen	VERB
aji-137	213	26	prior	prior	ADV
aji-137	213	27	to	to	ADP
aji-137	213	28	therapy	therapy	NOUN
aji-137	213	29	.	.	PUNCT
aji-137	214	1	other	other	ADJ
aji-137	214	2	adverse	adverse	ADJ
aji-137	214	3	effects	effect	NOUN
aji-137	214	4	may	may	AUX
aji-137	214	5	include	include	VERB
aji-137	214	6	kidney	kidney	NOUN
aji-137	214	7	,	,	PUNCT
aji-137	214	8	cardiovascular	cardiovascular	ADJ
aji-137	214	9	,	,	PUNCT
aji-137	214	10	and	and	CCONJ
aji-137	214	11	eye	eye	NOUN
aji-137	214	12	health	health	NOUN
aji-137	214	13	[	[	X
aji-137	214	14	27,28	27,28	NOUN
aji-137	214	15	]	]	PUNCT
aji-137	214	16	concluded	conclude	VERB
aji-137	214	17	by	by	ADP
aji-137	214	18	et	et	PROPN
aji-137	214	19	al	al	PROPN
aji-137	214	20	ivan	ivan	PROPN
aji-137	214	21	urits1	urits1	PROPN
aji-137	214	22	,	,	PUNCT
aji-137	214	23	jacob	jacob	PROPN
aji-137	214	24	israel2	israel2	PROPN
aji-137	214	25	.	.	PUNCT
aji-137	215	1	since	since	SCONJ
aji-137	215	2	the	the	DET
aji-137	215	3	mid-1990s	mid-1990	NOUN
aji-137	215	4	,	,	PUNCT
aji-137	215	5	the	the	DET
aji-137	215	6	treatment	treatment	NOUN
aji-137	215	7	approach	approach	NOUN
aji-137	215	8	for	for	ADP
aji-137	215	9	rheumatoid	rheumatoid	NOUN
aji-137	215	10	arthritis	arthritis	NOUN
aji-137	215	11	has	have	AUX
aji-137	215	12	changed	change	VERB
aji-137	215	13	dramatically	dramatically	ADV
aji-137	215	14	.	.	PUNCT
aji-137	216	1	treatment	treatment	NOUN
aji-137	216	2	paradigms	paradigm	NOUN
aji-137	216	3	have	have	AUX
aji-137	216	4	shifted	shift	VERB
aji-137	216	5	with	with	ADP
aji-137	216	6	the	the	DET
aji-137	216	7	increased	increase	VERB
aji-137	216	8	use	use	NOUN
aji-137	216	9	of	of	ADP
aji-137	216	10	traditional	traditional	ADJ
aji-137	216	11	synthetic	synthetic	ADJ
aji-137	216	12	dmards	dmard	NOUN
aji-137	216	13	,	,	PUNCT
aji-137	216	14	the	the	DET
aji-137	216	15	advent	advent	NOUN
aji-137	216	16	of	of	ADP
aji-137	216	17	biologic	biologic	NOUN
aji-137	216	18	medicines	medicine	NOUN
aji-137	216	19	,	,	PUNCT
aji-137	216	20	and	and	CCONJ
aji-137	216	21	,	,	PUNCT
aji-137	216	22	most	most	ADV
aji-137	216	23	recently	recently	ADV
aji-137	216	24	,	,	PUNCT
aji-137	216	25	novel	novel	ADJ
aji-137	216	26	small	small	ADJ
aji-137	216	27	compounds	compound	NOUN
aji-137	216	28	targeting	target	VERB
aji-137	216	29	the	the	DET
aji-137	216	30	jak	jak	PROPN
aji-137	216	31	pathway	pathway	NOUN
aji-137	216	32	.	.	PUNCT
aji-137	217	1	baricitinib	baricitinib	NOUN
aji-137	217	2	is	be	AUX
aji-137	217	3	a	a	DET
aji-137	217	4	very	very	ADV
aji-137	217	5	effective	effective	ADJ
aji-137	217	6	and	and	CCONJ
aji-137	217	7	specific	specific	ADJ
aji-137	217	8	inhibitor	inhibitor	NOUN
aji-137	217	9	of	of	ADP
aji-137	217	10	jak1	jak1	PROPN
aji-137	217	11	and	and	CCONJ
aji-137	217	12	jak2	jak2	PROPN
aji-137	217	13	.	.	PUNCT
aji-137	218	1	it	it	PRON
aji-137	218	2	has	have	AUX
aji-137	218	3	been	be	AUX
aji-137	218	4	proposed	propose	VERB
aji-137	218	5	that	that	SCONJ
aji-137	218	6	medicines	medicine	NOUN
aji-137	218	7	with	with	ADP
aji-137	218	8	varied	varied	ADJ
aji-137	218	9	jak	jak	PROPN
aji-137	218	10	inhibition	inhibition	NOUN
aji-137	218	11	profiles	profile	NOUN
aji-137	218	12	may	may	AUX
aji-137	218	13	have	have	VERB
aji-137	218	14	unique	unique	ADJ
aji-137	218	15	clinical	clinical	ADJ
aji-137	218	16	outcomes	outcome	NOUN
aji-137	218	17	.	.	PUNCT
aji-137	219	1	the	the	DET
aji-137	219	2	purpose	purpose	NOUN
aji-137	219	3	of	of	ADP
aji-137	219	4	this	this	DET
aji-137	219	5	evaluation	evaluation	NOUN
aji-137	219	6	was	be	AUX
aji-137	219	7	to	to	PART
aji-137	219	8	evaluate	evaluate	VERB
aji-137	219	9	the	the	DET
aji-137	219	10	safety	safety	NOUN
aji-137	219	11	and	and	CCONJ
aji-137	219	12	effectiveness	effectiveness	NOUN
aji-137	219	13	of	of	ADP
aji-137	219	14	baricitinib	baricitinib	NOUN
aji-137	219	15	in	in	ADP
aji-137	219	16	patients	patient	NOUN
aji-137	219	17	with	with	ADP
aji-137	219	18	active	active	ADJ
aji-137	219	19	rheumatoid	rheumatoid	NOUN
aji-137	219	20	arthritis	arthritis	NOUN
aji-137	219	21	who	who	PRON
aji-137	219	22	were	be	AUX
aji-137	219	23	using	use	VERB
aji-137	219	24	conventional	conventional	ADJ
aji-137	219	25	synthetic	synthetic	ADJ
aji-137	219	26	dmards	dmard	NOUN
aji-137	219	27	but	but	CCONJ
aji-137	219	28	had	have	AUX
aji-137	219	29	not	not	PART
aji-137	219	30	responded	respond	VERB
aji-137	219	31	adequately	adequately	ADV
aji-137	219	32	to	to	ADP
aji-137	219	33	earlier	early	ADJ
aji-137	219	34	biologic	biologic	ADJ
aji-137	219	35	dmard	dmard	NOUN
aji-137	219	36	therapy	therapy	NOUN
aji-137	219	37	.	.	PUNCT
aji-137	220	1	in	in	ADP
aji-137	220	2	this	this	DET
aji-137	220	3	patient	patient	ADJ
aji-137	220	4	cohort	cohort	NOUN
aji-137	220	5	,	,	PUNCT
aji-137	220	6	once	once	SCONJ
aji-137	220	7	gupta	gupta	PROPN
aji-137	220	8	et	et	PROPN
aji-137	220	9	al	al	PROPN
aji-137	220	10	.	.	PROPN
aji-137	220	11	;	;	PUNCT
aji-137	220	12	asian	asian	PROPN
aji-137	220	13	j.	j.	PROPN
aji-137	220	14	immunol	immunol	PROPN
aji-137	220	15	.	.	PROPN
aji-137	220	16	,	,	PUNCT
aji-137	220	17	vol	vol	NOUN
aji-137	220	18	.	.	PROPN
aji-137	220	19	7	7	NUM
aji-137	220	20	,	,	PUNCT
aji-137	220	21	no	no	INTJ
aji-137	220	22	.	.	NOUN
aji-137	220	23	1	1	NUM
aji-137	220	24	,	,	PUNCT
aji-137	220	25	pp	pp	ADJ
aji-137	220	26	.	.	PUNCT
aji-137	221	1	123	123	NUM
aji-137	221	2	-	-	SYM
aji-137	221	3	130	130	NUM
aji-137	221	4	,	,	PUNCT
aji-137	221	5	2024	2024	NUM
aji-137	221	6	;	;	PUNCT
aji-137	221	7	article	article	NOUN
aji-137	221	8	no.aji.120135	no.aji.120135	VERB
aji-137	221	9	127	127	NUM
aji-137	221	10	daily	daily	ADJ
aji-137	221	11	oral	oral	ADJ
aji-137	221	12	baricitinib	baricitinib	NOUN
aji-137	221	13	resulted	result	VERB
aji-137	221	14	in	in	ADP
aji-137	221	15	substantial	substantial	ADJ
aji-137	221	16	clinical	clinical	ADJ
aji-137	221	17	improvements	improvement	NOUN
aji-137	221	18	at	at	ADP
aji-137	221	19	12	12	NUM
aji-137	221	20	weeks	week	NOUN
aji-137	221	21	when	when	SCONJ
aji-137	221	22	compared	compare	VERB
aji-137	221	23	to	to	ADP
aji-137	221	24	placebo	placebo	NOUN
aji-137	221	25	.	.	PUNCT
aji-137	222	1	the	the	DET
aji-137	222	2	therapeutic	therapeutic	ADJ
aji-137	222	3	advantages	advantage	NOUN
aji-137	222	4	were	be	AUX
aji-137	222	5	greater	great	ADJ
aji-137	222	6	with	with	ADP
aji-137	222	7	the	the	DET
aji-137	222	8	4	4	NUM
aji-137	222	9	mg	mg	NOUN
aji-137	222	10	dosage	dosage	NOUN
aji-137	222	11	than	than	ADP
aji-137	222	12	with	with	ADP
aji-137	222	13	the	the	DET
aji-137	222	14	2	2	NUM
aji-137	222	15	mg	mg	NOUN
aji-137	222	16	dose	dose	NOUN
aji-137	222	17	.	.	PUNCT
aji-137	223	1	adverse	adverse	ADJ
aji-137	223	2	events	event	NOUN
aji-137	223	3	,	,	PUNCT
aji-137	223	4	such	such	ADJ
aji-137	223	5	as	as	ADP
aji-137	223	6	non	non	ADJ
aji-137	223	7	-	-	ADJ
aji-137	223	8	serious	serious	ADJ
aji-137	223	9	infections	infection	NOUN
aji-137	223	10	,	,	PUNCT
aji-137	223	11	were	be	AUX
aji-137	223	12	more	more	ADV
aji-137	223	13	common	common	ADJ
aji-137	223	14	in	in	ADP
aji-137	223	15	the	the	DET
aji-137	223	16	baricitinib	baricitinib	NOUN
aji-137	223	17	group	group	NOUN
aji-137	223	18	than	than	ADP
aji-137	223	19	in	in	ADP
aji-137	223	20	the	the	DET
aji-137	223	21	placebo	placebo	NOUN
aji-137	223	22	group	group	NOUN
aji-137	223	23	.	.	PUNCT
aji-137	224	1	baricitinib	baricitinib	NOUN
aji-137	224	2	was	be	AUX
aji-137	224	3	associated	associate	VERB
aji-137	224	4	with	with	ADP
aji-137	224	5	lower	low	ADJ
aji-137	224	6	neutrophil	neutrophil	ADJ
aji-137	224	7	counts	count	NOUN
aji-137	224	8	,	,	PUNCT
aji-137	224	9	higher	high	ADJ
aji-137	224	10	creatinine	creatinine	NOUN
aji-137	224	11	levels	level	NOUN
aji-137	224	12	,	,	PUNCT
aji-137	224	13	and	and	CCONJ
aji-137	224	14	higher	high	ADJ
aji-137	224	15	low	low	ADJ
aji-137	224	16	-	-	PUNCT
aji-137	224	17	density	density	NOUN
aji-137	224	18	lipoprotein	lipoprotein	ADJ
aji-137	224	19	cholesterol	cholesterol	NOUN
aji-137	224	20	levels	level	NOUN
aji-137	224	21	.	.	PUNCT
aji-137	225	1	these	these	DET
aji-137	225	2	adjustments	adjustment	NOUN
aji-137	225	3	were	be	AUX
aji-137	225	4	primarily	primarily	ADV
aji-137	225	5	modest	modest	ADJ
aji-137	225	6	and	and	CCONJ
aji-137	225	7	did	do	AUX
aji-137	225	8	not	not	PART
aji-137	225	9	result	result	VERB
aji-137	225	10	in	in	ADP
aji-137	225	11	their	their	PRON
aji-137	225	12	removal	removal	NOUN
aji-137	225	13	from	from	ADP
aji-137	225	14	the	the	DET
aji-137	225	15	research	research	NOUN
aji-137	225	16	[	[	X
aji-137	225	17	25	25	NUM
aji-137	225	18	]	]	PUNCT
aji-137	225	19	concluded	conclude	VERB
aji-137	225	20	by	by	ADP
aji-137	225	21	et	et	PROPN
aji-137	225	22	al	al	PROPN
aji-137	225	23	mark	mark	PROPN
aji-137	225	24	c.	c.	PROPN
aji-137	225	25	genovese	genovese	PROPN
aji-137	225	26	,	,	PUNCT
aji-137	225	27	m.d	m.d	PROPN
aji-137	225	28	.	.	PROPN
aji-137	225	29	,	,	PUNCT
aji-137	225	30	joel	joel	PROPN
aji-137	225	31	kremer	kremer	PROPN
aji-137	225	32	,	,	PUNCT
aji-137	225	33	m.d	m.d	PROPN
aji-137	225	34	.	.	PROPN
aji-137	225	35	,	,	PUNCT
aji-137	225	36	omid	omid	PROPN
aji-137	225	37	zamani	zamani	PROPN
aji-137	225	38	,	,	PUNCT
aji-137	225	39	m.d	m.d	PROPN
aji-137	225	40	.	.	PROPN
aji-137	225	41	4.5	4.5	NUM
aji-137	225	42	efficacy	efficacy	NOUN
aji-137	225	43	of	of	ADP
aji-137	225	44	baricitinib	baricitinib	NOUN
aji-137	225	45	in	in	ADP
aji-137	225	46	phase	phase	NOUN
aji-137	225	47	ii	ii	NOUN
aji-137	225	48	studies	study	NOUN
aji-137	225	49	in	in	ADP
aji-137	225	50	the	the	DET
aji-137	225	51	jada(journal	jada(journal	PROPN
aji-137	225	52	of	of	ADP
aji-137	225	53	the	the	DET
aji-137	225	54	american	american	PROPN
aji-137	225	55	dental	dental	PROPN
aji-137	225	56	association	association	PROPN
aji-137	225	57	)	)	PUNCT
aji-137	225	58	research	research	NOUN
aji-137	225	59	(	(	PUNCT
aji-137	225	60	phase	phase	NOUN
aji-137	225	61	2	2	NUM
aji-137	225	62	)	)	PUNCT
aji-137	225	63	,	,	PUNCT
aji-137	225	64	301	301	NUM
aji-137	225	65	patients	patient	NOUN
aji-137	225	66	with	with	ADP
aji-137	225	67	active	active	ADJ
aji-137	225	68	ra(rheumatoid	ra(rheumatoid	PROPN
aji-137	225	69	arthritis	arthritis	NOUN
aji-137	225	70	)	)	PUNCT
aji-137	225	71	receiving	receive	VERB
aji-137	225	72	steady	steady	ADJ
aji-137	225	73	-	-	PUNCT
aji-137	225	74	state	state	NOUN
aji-137	225	75	mtx	mtx	NOUN
aji-137	225	76	and	and	CCONJ
aji-137	225	77	mtx	mtx	PROPN
aji-137	225	78	-	-	PROPN
aji-137	225	79	ir	ir	PROPN
aji-137	225	80	were	be	AUX
aji-137	225	81	included	include	VERB
aji-137	225	82	.	.	PUNCT
aji-137	226	1	at	at	ADP
aji-137	226	2	week	week	NOUN
aji-137	226	3	12	12	NUM
aji-137	226	4	,	,	PUNCT
aji-137	226	5	76	76	NUM
aji-137	226	6	%	%	NOUN
aji-137	226	7	of	of	ADP
aji-137	226	8	patients	patient	NOUN
aji-137	226	9	in	in	ADP
aji-137	226	10	the	the	DET
aji-137	226	11	combined	combine	VERB
aji-137	226	12	baricitinib	baricitinib	NOUN
aji-137	226	13	4	4	NUM
aji-137	226	14	and	and	CCONJ
aji-137	226	15	8	8	NUM
aji-137	226	16	mg	mg	PROPN
aji-137	226	17	group	group	NOUN
aji-137	226	18	had	have	VERB
aji-137	226	19	an	an	DET
aji-137	226	20	acr20(american	acr20(american	ADJ
aji-137	226	21	college	college	NOUN
aji-137	226	22	of	of	ADP
aji-137	226	23	rheumatology	rheumatology	NOUN
aji-137	226	24	20	20	NUM
aji-137	226	25	)	)	PUNCT
aji-137	227	1	[	[	X
aji-137	227	2	29	29	NUM
aji-137	227	3	]	]	PUNCT
aji-137	227	4	concluded	conclude	VERB
aji-137	227	5	by	by	ADP
aji-137	227	6	et	et	PROPN
aji-137	227	7	al	al	PROPN
aji-137	227	8	david	david	PROPN
aji-137	227	9	t.	t.	PROPN
aji-137	227	10	felson	felson	PROPN
aji-137	227	11	md	md	PROPN
aji-137	227	12	,	,	PUNCT
aji-137	227	13	mph	mph	PROPN
aji-137	227	14	,	,	PUNCT
aji-137	227	15	response	response	NOUN
aji-137	227	16	,	,	PUNCT
aji-137	227	17	compared	compare	VERB
aji-137	227	18	to	to	ADP
aji-137	227	19	41	41	NUM
aji-137	227	20	%	%	NOUN
aji-137	227	21	in	in	ADP
aji-137	227	22	the	the	DET
aji-137	227	23	placebo	placebo	NOUN
aji-137	227	24	group	group	NOUN
aji-137	227	25	[	[	X
aji-137	227	26	30	30	NUM
aji-137	227	27	]	]	PUNCT
aji-137	227	28	concluded	conclude	VERB
aji-137	227	29	by	by	ADP
aji-137	227	30	et	et	PROPN
aji-137	227	31	al	al	PROPN
aji-137	227	32	david	david	PROPN
aji-137	227	33	t.	t.	PROPN
aji-137	227	34	felson	felson	PROPN
aji-137	227	35	md	md	PROPN
aji-137	227	36	,	,	PUNCT
aji-137	227	37	mph	mph	PROPN
aji-137	227	38	.	.	PUNCT
aji-137	228	1	the	the	DET
aji-137	228	2	placebo	placebo	NOUN
aji-137	228	3	and	and	CCONJ
aji-137	228	4	4	4	NUM
aji-137	228	5	mg	mg	NOUN
aji-137	228	6	groups	group	NOUN
aji-137	228	7	showed	show	VERB
aji-137	228	8	significant	significant	ADJ
aji-137	228	9	differences	difference	NOUN
aji-137	228	10	in	in	ADP
aji-137	228	11	secondary	secondary	ADJ
aji-137	228	12	endpoints	endpoint	NOUN
aji-137	228	13	,	,	PUNCT
aji-137	228	14	including	include	VERB
aji-137	228	15	minimal	minimal	ADJ
aji-137	228	16	disease	disease	NOUN
aji-137	228	17	activity	activity	NOUN
aji-137	228	18	and	and	CCONJ
aji-137	228	19	remission	remission	NOUN
aji-137	228	20	.	.	PUNCT
aji-137	229	1	the	the	DET
aji-137	229	2	jada(journal	jada(journal	PROPN
aji-137	229	3	of	of	ADP
aji-137	229	4	the	the	DET
aji-137	229	5	american	american	PROPN
aji-137	229	6	dental	dental	PROPN
aji-137	229	7	association	association	PROPN
aji-137	229	8	)	)	PUNCT
aji-137	229	9	research	research	NOUN
aji-137	229	10	(	(	PUNCT
aji-137	229	11	phase	phase	NOUN
aji-137	229	12	2	2	NUM
aji-137	229	13	)	)	PUNCT
aji-137	229	14	included	include	VERB
aji-137	229	15	145	145	NUM
aji-137	229	16	japanese	japanese	ADJ
aji-137	229	17	patients	patient	NOUN
aji-137	229	18	with	with	ADP
aji-137	229	19	active	active	ADJ
aji-137	229	20	ra	ra	PROPN
aji-137	229	21	and	and	CCONJ
aji-137	229	22	mtxir(methotrexate	mtxir(methotrexate	PROPN
aji-137	229	23	)	)	PUNCT
aji-137	229	24	receiving	receive	VERB
aji-137	229	25	steady	steady	ADJ
aji-137	229	26	background	background	NOUN
aji-137	229	27	mtx	mtx	NOUN
aji-137	229	28	.	.	PUNCT
aji-137	230	1	at	at	ADP
aji-137	230	2	week	week	NOUN
aji-137	230	3	12	12	NUM
aji-137	230	4	,	,	PUNCT
aji-137	230	5	the	the	DET
aji-137	230	6	combined	combine	VERB
aji-137	230	7	baricitinib	baricitinib	NOUN
aji-137	230	8	4	4	NUM
aji-137	230	9	mg	mg	NOUN
aji-137	230	10	and	and	CCONJ
aji-137	230	11	8	8	NUM
aji-137	230	12	mg	mg	PROPN
aji-137	230	13	group	group	NOUN
aji-137	230	14	had	have	VERB
aji-137	230	15	a	a	DET
aji-137	230	16	significantly	significantly	ADV
aji-137	230	17	greater	great	ADJ
aji-137	230	18	acr20	acr20	NOUN
aji-137	230	19	response	response	NOUN
aji-137	230	20	rate	rate	NOUN
aji-137	230	21	(	(	PUNCT
aji-137	230	22	77	77	NUM
aji-137	230	23	%	%	NOUN
aji-137	230	24	)	)	PUNCT
aji-137	230	25	than	than	ADP
aji-137	230	26	the	the	DET
aji-137	230	27	placebo	placebo	NOUN
aji-137	230	28	group	group	NOUN
aji-137	230	29	(	(	PUNCT
aji-137	230	30	31	31	NUM
aji-137	230	31	%	%	NOUN
aji-137	230	32	)	)	PUNCT
aji-137	230	33	,	,	PUNCT
aji-137	230	34	according	accord	VERB
aji-137	230	35	to	to	ADP
aji-137	230	36	a	a	DET
aji-137	230	37	primary	primary	ADJ
aji-137	230	38	efficacy	efficacy	NOUN
aji-137	230	39	study	study	NOUN
aji-137	230	40	[	[	X
aji-137	230	41	31	31	NUM
aji-137	230	42	]	]	PUNCT
aji-137	230	43	concluded	conclude	VERB
aji-137	230	44	by	by	ADP
aji-137	230	45	et	et	PROPN
aji-137	230	46	al	al	PROPN
aji-137	230	47	yoshiya	yoshiya	PROPN
aji-137	230	48	tanaka	tanaka	PROPN
aji-137	230	49	.	.	PUNCT
aji-137	231	1	at	at	ADP
aji-137	231	2	week	week	NOUN
aji-137	231	3	12	12	NUM
aji-137	231	4	,	,	PUNCT
aji-137	231	5	the	the	DET
aji-137	231	6	2	2	NUM
aji-137	231	7	,	,	PUNCT
aji-137	231	8	4	4	NUM
aji-137	231	9	,	,	PUNCT
aji-137	231	10	and	and	CCONJ
aji-137	231	11	8	8	NUM
aji-137	231	12	mg	mg	NOUN
aji-137	231	13	groups	group	NOUN
aji-137	231	14	improved	improve	VERB
aji-137	231	15	similarly	similarly	ADV
aji-137	231	16	across	across	ADP
aji-137	231	17	efficacy	efficacy	NOUN
aji-137	231	18	measures	measure	NOUN
aji-137	231	19	.	.	PUNCT
aji-137	232	1	however	however	ADV
aji-137	232	2	,	,	PUNCT
aji-137	232	3	the	the	DET
aji-137	232	4	4	4	NUM
aji-137	232	5	and	and	CCONJ
aji-137	232	6	8	8	NUM
aji-137	232	7	mg	mg	NOUN
aji-137	232	8	groups	group	NOUN
aji-137	232	9	showed	show	VERB
aji-137	232	10	earlier	early	ADV
aji-137	232	11	onset	onset	NOUN
aji-137	232	12	than	than	ADP
aji-137	232	13	the	the	DET
aji-137	232	14	1	1	NUM
aji-137	232	15	and	and	CCONJ
aji-137	232	16	2	2	NUM
aji-137	232	17	mg	mg	NOUN
aji-137	232	18	groups	group	NOUN
aji-137	232	19	as	as	ADV
aji-137	232	20	early	early	ADV
aji-137	232	21	as	as	ADP
aji-137	232	22	week	week	NOUN
aji-137	232	23	2	2	NUM
aji-137	232	24	[	[	X
aji-137	232	25	1	1	NUM
aji-137	232	26	]	]	PUNCT
aji-137	232	27	concluded	conclude	VERB
aji-137	232	28	by	by	ADP
aji-137	232	29	et	et	PROPN
aji-137	232	30	al	al	PROPN
aji-137	232	31	satoshi	satoshi	PROPN
aji-137	232	32	kubo	kubo	PROPN
aji-137	232	33	.	.	PUNCT
aji-137	233	1	4.6	4.6	NUM
aji-137	233	2	efficacy	efficacy	NOUN
aji-137	233	3	of	of	ADP
aji-137	233	4	baricitinib	baricitinib	NOUN
aji-137	233	5	in	in	ADP
aji-137	233	6	phase	phase	NOUN
aji-137	233	7	iii	iii	NUM
aji-137	233	8	studies	study	NOUN
aji-137	233	9	six	six	NUM
aji-137	233	10	phase	phase	NOUN
aji-137	233	11	3	3	NUM
aji-137	233	12	trials	trial	NOUN
aji-137	233	13	on	on	ADP
aji-137	233	14	baricitinib	baricitinib	NOUN
aji-137	233	15	for	for	ADP
aji-137	233	16	ra	ra	PROPN
aji-137	233	17	are	be	AUX
aji-137	233	18	underway	underway	ADJ
aji-137	233	19	or	or	CCONJ
aji-137	233	20	completed	complete	VERB
aji-137	233	21	to	to	PART
aji-137	233	22	establish	establish	VERB
aji-137	233	23	its	its	PRON
aji-137	233	24	efficacy	efficacy	NOUN
aji-137	233	25	,	,	PUNCT
aji-137	233	26	evaluate	evaluate	VERB
aji-137	233	27	adverse	adverse	ADJ
aji-137	233	28	effects	effect	NOUN
aji-137	233	29	,	,	PUNCT
aji-137	233	30	and	and	CCONJ
aji-137	233	31	compare	compare	VERB
aji-137	233	32	it	it	PRON
aji-137	233	33	to	to	ADP
aji-137	233	34	other	other	ADJ
aji-137	233	35	dmards	dmard	NOUN
aji-137	233	36	or	or	CCONJ
aji-137	233	37	placebos	placebo	NOUN
aji-137	233	38	.	.	PUNCT
aji-137	234	1	in	in	ADP
aji-137	234	2	these	these	DET
aji-137	234	3	investigations	investigation	NOUN
aji-137	234	4	,	,	PUNCT
aji-137	234	5	patients	patient	NOUN
aji-137	234	6	in	in	ADP
aji-137	234	7	both	both	CCONJ
aji-137	234	8	the	the	DET
aji-137	234	9	baricitinib	baricitinib	NOUN
aji-137	234	10	and	and	CCONJ
aji-137	234	11	control	control	NOUN
aji-137	234	12	groups	group	NOUN
aji-137	234	13	received	receive	VERB
aji-137	234	14	corticosteroids	corticosteroid	NOUN
aji-137	234	15	at	at	ADP
aji-137	234	16	baseline	baseline	NOUN
aji-137	234	17	.	.	PUNCT
aji-137	235	1	baricitinib	baricitinib	NOUN
aji-137	235	2	should	should	AUX
aji-137	235	3	be	be	AUX
aji-137	235	4	compared	compare	VERB
aji-137	235	5	to	to	PART
aji-137	235	6	mtx	mtx	VERB
aji-137	235	7	with	with	ADP
aji-137	235	8	corticosteroids	corticosteroid	NOUN
aji-137	235	9	,	,	PUNCT
aji-137	235	10	as	as	ADP
aji-137	235	11	early	early	ADJ
aji-137	235	12	ra	ra	PROPN
aji-137	235	13	patients	patient	NOUN
aji-137	235	14	typically	typically	ADV
aji-137	235	15	get	get	VERB
aji-137	235	16	both	both	DET
aji-137	235	17	medications	medication	NOUN
aji-137	235	18	.	.	PUNCT
aji-137	236	1	however	however	ADV
aji-137	236	2	,	,	PUNCT
aji-137	236	3	no	no	DET
aji-137	236	4	trials	trial	NOUN
aji-137	236	5	have	have	AUX
aji-137	236	6	compared	compare	VERB
aji-137	236	7	baricitinib	baricitinib	NOUN
aji-137	236	8	to	to	PART
aji-137	236	9	mtx	mtx	VERB
aji-137	236	10	with	with	ADP
aji-137	236	11	corticosteroids	corticosteroid	NOUN
aji-137	236	12	[	[	X
aji-137	236	13	1	1	X
aji-137	236	14	]	]	PUNCT
aji-137	236	15	concluded	conclude	VERB
aji-137	236	16	by	by	ADP
aji-137	236	17	et	et	PROPN
aji-137	236	18	al	al	PROPN
aji-137	236	19	satoshi	satoshi	PROPN
aji-137	236	20	kubo	kubo	PROPN
aji-137	236	21	.	.	PUNCT
aji-137	237	1	the	the	DET
aji-137	237	2	ra	ra	PROPN
aji-137	237	3	-	-	PUNCT
aji-137	237	4	beacon	beacon	NOUN
aji-137	237	5	trial	trial	NOUN
aji-137	237	6	(	(	PUNCT
aji-137	237	7	jade(jak1	jade(jak1	PROPN
aji-137	237	8	atopic	atopic	NOUN
aji-137	237	9	dermatitis	dermatitis	PROPN
aji-137	237	10	efficacy	efficacy	NOUN
aji-137	237	11	and	and	CCONJ
aji-137	237	12	safety	safety	NOUN
aji-137	237	13	)	)	PUNCT
aji-137	237	14	comprised	comprise	VERB
aji-137	237	15	527	527	NUM
aji-137	237	16	individuals	individual	NOUN
aji-137	237	17	with	with	ADP
aji-137	237	18	active	active	ADJ
aji-137	237	19	ra	ra	PROPN
aji-137	237	20	and	and	CCONJ
aji-137	237	21	tnf	tnf	PROPN
aji-137	237	22	-	-	PUNCT
aji-137	237	23	ir(tumor	ir(tumor	PROPN
aji-137	237	24	necrosis	necrosis	NOUN
aji-137	237	25	factor	factor	NOUN
aji-137	237	26	)	)	PUNCT
aji-137	237	27	.	.	PUNCT
aji-137	238	1	at	at	ADP
aji-137	238	2	week	week	NOUN
aji-137	238	3	12	12	NUM
aji-137	238	4	,	,	PUNCT
aji-137	238	5	55	55	NUM
aji-137	238	6	%	%	NOUN
aji-137	238	7	of	of	ADP
aji-137	238	8	patients	patient	NOUN
aji-137	238	9	who	who	PRON
aji-137	238	10	received	receive	VERB
aji-137	238	11	the	the	DET
aji-137	238	12	4	4	NUM
aji-137	238	13	mg	mg	NOUN
aji-137	238	14	dosage	dosage	NOUN
aji-137	238	15	of	of	ADP
aji-137	238	16	baricitinib	baricitinib	NOUN
aji-137	238	17	had	have	VERB
aji-137	238	18	an	an	DET
aji-137	238	19	acr20	acr20	NOUN
aji-137	238	20	response	response	NOUN
aji-137	238	21	,	,	PUNCT
aji-137	238	22	compared	compare	VERB
aji-137	238	23	to	to	ADP
aji-137	238	24	27	27	NUM
aji-137	238	25	%	%	NOUN
aji-137	238	26	who	who	PRON
aji-137	238	27	received	receive	VERB
aji-137	238	28	the	the	DET
aji-137	238	29	placebo	placebo	NOUN
aji-137	238	30	[	[	X
aji-137	238	31	32	32	NUM
aji-137	238	32	]	]	PUNCT
aji-137	238	33	concluded	conclude	VERB
aji-137	238	34	by	by	ADP
aji-137	238	35	et	et	PROPN
aji-137	238	36	al	al	PROPN
aji-137	238	37	charles	charles	PROPN
aji-137	238	38	ludivico	ludivico	PROPN
aji-137	238	39	,	,	PUNCT
aji-137	238	40	m.d	m.d	PROPN
aji-137	238	41	.	.	PROPN
aji-137	239	1	compared	compare	VERB
aji-137	239	2	to	to	ADP
aji-137	239	3	the	the	DET
aji-137	239	4	placebo	placebo	NOUN
aji-137	239	5	,	,	PUNCT
aji-137	239	6	there	there	PRON
aji-137	239	7	were	be	VERB
aji-137	239	8	substantial	substantial	ADJ
aji-137	239	9	improvements	improvement	NOUN
aji-137	239	10	in	in	ADP
aji-137	239	11	the	the	DET
aji-137	239	12	sdai(simple	sdai(simple	PROPN
aji-137	239	13	disease	disease	NOUN
aji-137	239	14	activity	activity	NOUN
aji-137	239	15	index	index	NOUN
aji-137	239	16	)	)	PUNCT
aji-137	239	17	≤3.3	≤3.3	NOUN
aji-137	239	18	ratio	ratio	NOUN
aji-137	239	19	.	.	PUNCT
aji-137	240	1	downloaded	download	VERB
aji-137	240	2	by	by	ADP
aji-137	240	3	[	[	X
aji-137	240	4	weill	weill	PROPN
aji-137	240	5	cornell	cornell	PROPN
aji-137	240	6	medical	medical	PROPN
aji-137	240	7	college	college	PROPN
aji-137	240	8	]	]	PUNCT
aji-137	240	9	at	at	ADP
aji-137	240	10	06:35	06:35	NUM
aji-137	240	11	on	on	ADP
aji-137	240	12	july	july	PROPN
aji-137	240	13	20	20	NUM
aji-137	240	14	,	,	PUNCT
aji-137	240	15	2016	2016	NUM
aji-137	240	16	.	.	PUNCT
aji-137	241	1	week	week	NOUN
aji-137	241	2	24	24	NUM
aji-137	241	3	for	for	ADP
aji-137	241	4	the	the	DET
aji-137	241	5	baricitinib	baricitinib	NOUN
aji-137	241	6	4	4	NUM
aji-137	241	7	mg	mg	PROPN
aji-137	241	8	group	group	NOUN
aji-137	241	9	.	.	PUNCT
aji-137	242	1	all	all	DET
aji-137	242	2	subgroup	subgroup	NOUN
aji-137	242	3	analyses	analysis	NOUN
aji-137	242	4	showed	show	VERB
aji-137	242	5	a	a	DET
aji-137	242	6	favorable	favorable	ADJ
aji-137	242	7	treatment	treatment	NOUN
aji-137	242	8	impact	impact	NOUN
aji-137	242	9	,	,	PUNCT
aji-137	242	10	regardless	regardless	ADV
aji-137	242	11	of	of	ADP
aji-137	242	12	prior	prior	ADJ
aji-137	242	13	bdmard	bdmard	NOUN
aji-137	242	14	usage	usage	NOUN
aji-137	242	15	(	(	PUNCT
aji-137	242	16	number	number	NOUN
aji-137	242	17	or	or	CCONJ
aji-137	242	18	kind	kind	NOUN
aji-137	242	19	)	)	PUNCT
aji-137	243	1	[	[	X
aji-137	243	2	33	33	NUM
aji-137	243	3	]	]	PUNCT
aji-137	243	4	concluded	conclude	VERB
aji-137	243	5	by	by	ADP
aji-137	243	6	et	et	PROPN
aji-137	243	7	al	al	PROPN
aji-137	243	8	dario	dario	PROPN
aji-137	243	9	ummarino	ummarino	PROPN
aji-137	243	10	.	.	PUNCT
aji-137	244	1	4.7	4.7	NUM
aji-137	244	2	safety	safety	NOUN
aji-137	244	3	and	and	CCONJ
aji-137	244	4	tolerability	tolerability	NOUN
aji-137	244	5	of	of	ADP
aji-137	244	6	baricitinib	baricitinib	NOUN
aji-137	244	7	in	in	ADP
aji-137	244	8	the	the	DET
aji-137	244	9	ra	ra	PROPN
aji-137	244	10	-	-	PUNCT
aji-137	244	11	beacon	beacon	NOUN
aji-137	244	12	study	study	NOUN
aji-137	244	13	[	[	X
aji-137	244	14	32	32	NUM
aji-137	244	15	]	]	PUNCT
aji-137	244	16	,	,	PUNCT
aji-137	244	17	concluded	conclude	VERB
aji-137	244	18	by	by	ADP
aji-137	244	19	etal	etal	PROPN
aji-137	244	20	charles	charles	PROPN
aji-137	244	21	ludivico	ludivico	PROPN
aji-137	244	22	,	,	PUNCT
aji-137	244	23	m.d	m.d	PROPN
aji-137	244	24	.	.	PROPN
aji-137	244	25	527	527	NUM
aji-137	244	26	adult	adult	NOUN
aji-137	244	27	patients	patient	NOUN
aji-137	244	28	with	with	ADP
aji-137	244	29	moderately	moderately	ADV
aji-137	244	30	to	to	PART
aji-137	244	31	severely	severely	ADV
aji-137	244	32	active	active	ADJ
aji-137	244	33	ra	ra	NOUN
aji-137	244	34	who	who	PRON
aji-137	244	35	had	have	AUX
aji-137	244	36	not	not	PART
aji-137	244	37	responded	respond	VERB
aji-137	244	38	to	to	ADP
aji-137	244	39	or	or	CCONJ
aji-137	244	40	were	be	AUX
aji-137	244	41	intolerant	intolerant	ADJ
aji-137	244	42	to	to	ADP
aji-137	244	43	at	at	ADV
aji-137	244	44	least	least	ADV
aji-137	244	45	one	one	NUM
aji-137	244	46	biologic	biologic	NOUN
aji-137	244	47	tnf	tnf	PROPN
aji-137	244	48	-	-	PUNCT
aji-137	244	49	α	α	NOUN
aji-137	244	50	inhibitor	inhibitor	NOUN
aji-137	244	51	and	and	CCONJ
aji-137	244	52	were	be	AUX
aji-137	244	53	taking	take	VERB
aji-137	244	54	background	background	NOUN
aji-137	244	55	csdmard	csdmard	PROPN
aji-137	244	56	therapy	therapy	NOUN
aji-137	244	57	experienced	experience	VERB
aji-137	244	58	more	more	ADJ
aji-137	244	59	treatment	treatment	NOUN
aji-137	244	60	-	-	PUNCT
aji-137	244	61	emergent	emergent	ADJ
aji-137	244	62	adverse	adverse	ADJ
aji-137	244	63	events	event	NOUN
aji-137	244	64	(	(	PUNCT
aji-137	244	65	teaes	teaes	ADV
aji-137	244	66	)	)	PUNCT
aji-137	244	67	than	than	ADP
aji-137	244	68	those	those	PRON
aji-137	244	69	taking	take	VERB
aji-137	244	70	placebo	placebo	NOUN
aji-137	244	71	.	.	PUNCT
aji-137	245	1	patients	patient	NOUN
aji-137	245	2	receiving	receive	VERB
aji-137	245	3	the	the	DET
aji-137	245	4	2	2	NUM
aji-137	245	5	mg	mg	NOUN
aji-137	245	6	and	and	CCONJ
aji-137	245	7	4	4	NUM
aji-137	245	8	mg	mg	NOUN
aji-137	245	9	doses	dose	NOUN
aji-137	245	10	of	of	ADP
aji-137	245	11	baricitinib	baricitinib	NOUN
aji-137	245	12	experienced	experience	VERB
aji-137	245	13	more	more	ADJ
aji-137	245	14	adverse	adverse	ADJ
aji-137	245	15	events	event	NOUN
aji-137	245	16	(	(	PUNCT
aji-137	245	17	71	71	NUM
aji-137	245	18	%	%	NOUN
aji-137	245	19	)	)	PUNCT
aji-137	245	20	and	and	CCONJ
aji-137	245	21	77	77	NUM
aji-137	245	22	%	%	NOUN
aji-137	245	23	,	,	PUNCT
aji-137	245	24	respectively	respectively	ADV
aji-137	245	25	,	,	PUNCT
aji-137	245	26	compared	compare	VERB
aji-137	245	27	to	to	ADP
aji-137	245	28	those	those	PRON
aji-137	245	29	receiving	receive	VERB
aji-137	245	30	the	the	DET
aji-137	245	31	placebo	placebo	NOUN
aji-137	245	32	(	(	PUNCT
aji-137	245	33	64	64	NUM
aji-137	245	34	%	%	NOUN
aji-137	245	35	)	)	PUNCT
aji-137	245	36	,	,	PUNCT
aji-137	245	37	including	include	VERB
aji-137	245	38	infections	infection	NOUN
aji-137	245	39	(	(	PUNCT
aji-137	245	40	44	44	NUM
aji-137	245	41	%	%	NOUN
aji-137	245	42	and	and	CCONJ
aji-137	245	43	40	40	NUM
aji-137	245	44	%	%	NOUN
aji-137	245	45	,	,	PUNCT
aji-137	245	46	vs.	vs.	X
aji-137	245	47	31	31	NUM
aji-137	245	48	%	%	NOUN
aji-137	245	49	)	)	PUNCT
aji-137	245	50	.	.	PUNCT
aji-137	246	1	mild	mild	ADJ
aji-137	246	2	upper	upper	ADJ
aji-137	246	3	respiratory	respiratory	ADJ
aji-137	246	4	tract	tract	NOUN
aji-137	246	5	infections	infection	NOUN
aji-137	246	6	were	be	AUX
aji-137	246	7	found	find	VERB
aji-137	246	8	to	to	PART
aji-137	246	9	significantly	significantly	ADV
aji-137	246	10	lead	lead	VERB
aji-137	246	11	to	to	ADP
aji-137	246	12	imbalances	imbalance	NOUN
aji-137	246	13	.	.	PUNCT
aji-137	247	1	the	the	DET
aji-137	247	2	baricitinib	baricitinib	NOUN
aji-137	247	3	group	group	NOUN
aji-137	247	4	saw	see	VERB
aji-137	247	5	briefer	briefer	NOUN
aji-137	247	6	,	,	PUNCT
aji-137	247	7	transitory	transitory	ADJ
aji-137	247	8	disruptions	disruption	NOUN
aji-137	247	9	of	of	ADP
aji-137	247	10	the	the	DET
aji-137	247	11	study	study	NOUN
aji-137	247	12	medicine	medicine	NOUN
aji-137	247	13	.	.	PUNCT
aji-137	248	1	sae	sae	PROPN
aji-137	248	2	rates	rate	NOUN
aji-137	248	3	were	be	AUX
aji-137	248	4	4	4	NUM
aji-137	248	5	%	%	NOUN
aji-137	248	6	,	,	PUNCT
aji-137	248	7	10	10	NUM
aji-137	248	8	%	%	NOUN
aji-137	248	9	,	,	PUNCT
aji-137	248	10	and	and	CCONJ
aji-137	248	11	7	7	NUM
aji-137	248	12	%	%	NOUN
aji-137	248	13	for	for	ADP
aji-137	248	14	the	the	DET
aji-137	248	15	three	three	NUM
aji-137	248	16	groups	group	NOUN
aji-137	248	17	,	,	PUNCT
aji-137	248	18	respectively	respectively	ADV
aji-137	248	19	.	.	PUNCT
aji-137	249	1	the	the	DET
aji-137	249	2	proportion	proportion	NOUN
aji-137	249	3	of	of	ADP
aji-137	249	4	patients	patient	NOUN
aji-137	249	5	experiencing	experience	VERB
aji-137	249	6	an	an	DET
aji-137	249	7	sae	sae	PROPN
aji-137	249	8	was	be	AUX
aji-137	249	9	consistent	consistent	ADJ
aji-137	249	10	across	across	ADP
aji-137	249	11	treatment	treatment	NOUN
aji-137	249	12	groups	group	NOUN
aji-137	249	13	.	.	PUNCT
aji-137	250	1	there	there	PRON
aji-137	250	2	were	be	VERB
aji-137	250	3	only	only	ADV
aji-137	250	4	two	two	NUM
aji-137	250	5	nonmelanoma	nonmelanoma	ADJ
aji-137	250	6	skin	skin	NOUN
aji-137	250	7	tumors	tumor	NOUN
aji-137	250	8	in	in	ADP
aji-137	250	9	the	the	DET
aji-137	250	10	baricitinib	baricitinib	NOUN
aji-137	250	11	4	4	NUM
aji-137	250	12	mg	mg	PROPN
aji-137	250	13	group	group	NOUN
aji-137	250	14	,	,	PUNCT
aji-137	250	15	with	with	ADP
aji-137	250	16	no	no	DET
aji-137	250	17	reports	report	NOUN
aji-137	250	18	of	of	ADP
aji-137	250	19	solid	solid	ADJ
aji-137	250	20	organ	organ	NOUN
aji-137	250	21	,	,	PUNCT
aji-137	250	22	hematologic	hematologic	NOUN
aji-137	250	23	,	,	PUNCT
aji-137	250	24	or	or	CCONJ
aji-137	250	25	other	other	ADJ
aji-137	250	26	malignancies	malignancy	NOUN
aji-137	250	27	.	.	PUNCT
aji-137	251	1	the	the	DET
aji-137	251	2	trial	trial	NOUN
aji-137	251	3	found	find	VERB
aji-137	251	4	two	two	NUM
aji-137	251	5	treatment	treatment	NOUN
aji-137	251	6	-	-	PUNCT
aji-137	251	7	emergent	emergent	NOUN
aji-137	251	8	serious	serious	ADJ
aji-137	251	9	adverse	adverse	ADJ
aji-137	251	10	cardiovascular	cardiovascular	ADJ
aji-137	251	11	events	event	NOUN
aji-137	251	12	(	(	PUNCT
aji-137	251	13	mace	mace	NOUN
aji-137	251	14	):	):	PUNCT
aji-137	251	15	one	one	NUM
aji-137	251	16	myocardial	myocardial	ADJ
aji-137	251	17	infarction	infarction	NOUN
aji-137	251	18	(	(	PUNCT
aji-137	251	19	baricitinib	baricitinib	NOUN
aji-137	251	20	4	4	NUM
aji-137	251	21	mg	mg	NUM
aji-137	251	22	)	)	PUNCT
aji-137	251	23	and	and	CCONJ
aji-137	251	24	one	one	NUM
aji-137	251	25	basilar	basilar	ADJ
aji-137	251	26	artery	artery	NOUN
aji-137	251	27	thrombosis	thrombosis	NOUN
aji-137	251	28	(	(	PUNCT
aji-137	251	29	baricitinib	baricitinib	NOUN
aji-137	251	30	4	4	NUM
aji-137	251	31	mg	mg	NUM
aji-137	251	32	)	)	PUNCT
aji-137	251	33	,	,	PUNCT
aji-137	251	34	which	which	PRON
aji-137	251	35	also	also	ADV
aji-137	251	36	resulted	result	VERB
aji-137	251	37	in	in	ADP
aji-137	251	38	one	one	NUM
aji-137	251	39	death	death	NOUN
aji-137	251	40	.	.	PUNCT
aji-137	252	1	no	no	DET
aji-137	252	2	patients	patient	NOUN
aji-137	252	3	had	have	VERB
aji-137	252	4	a	a	DET
aji-137	252	5	gastrointestinal	gastrointestinal	ADJ
aji-137	252	6	perforation.serum	perforation.serum	NOUN
aji-137	252	7	creatinine	creatinine	NOUN
aji-137	252	8	and	and	CCONJ
aji-137	252	9	ldl	ldl	VERB
aji-137	252	10	cholesterol	cholesterol	NOUN
aji-137	252	11	levels	level	NOUN
aji-137	252	12	increased	increase	VERB
aji-137	252	13	,	,	PUNCT
aji-137	252	14	and	and	CCONJ
aji-137	252	15	neutrophil	neutrophil	ADJ
aji-137	252	16	counts	count	NOUN
aji-137	252	17	somewhat	somewhat	ADV
aji-137	252	18	decreased	decrease	VERB
aji-137	252	19	when	when	SCONJ
aji-137	252	20	baricitinib	baricitinib	NOUN
aji-137	252	21	was	be	AUX
aji-137	252	22	administered	administer	VERB
aji-137	252	23	.	.	PUNCT
aji-137	253	1	in	in	ADP
aji-137	253	2	the	the	DET
aji-137	253	3	baricitinib	baricitinib	NOUN
aji-137	253	4	groups	group	NOUN
aji-137	253	5	,	,	PUNCT
aji-137	253	6	very	very	ADV
aji-137	253	7	few	few	ADJ
aji-137	253	8	patients	patient	NOUN
aji-137	253	9	experienced	experience	VERB
aji-137	253	10	a	a	DET
aji-137	253	11	treatment	treatment	NOUN
aji-137	253	12	-	-	PUNCT
aji-137	253	13	emergent	emergent	NOUN
aji-137	253	14	laboratory	laboratory	NOUN
aji-137	253	15	abnormality	abnormality	NOUN
aji-137	253	16	that	that	PRON
aji-137	253	17	led	lead	VERB
aji-137	253	18	to	to	ADP
aji-137	253	19	a	a	DET
aji-137	253	20	permanent	permanent	ADJ
aji-137	253	21	gupta	gupta	NOUN
aji-137	253	22	et	et	NOUN
aji-137	253	23	al	al	PROPN
aji-137	253	24	.	.	PROPN
aji-137	253	25	;	;	PUNCT
aji-137	254	1	asian	asian	PROPN
aji-137	254	2	j.	j.	PROPN
aji-137	254	3	immunol	immunol	PROPN
aji-137	254	4	.	.	PROPN
aji-137	254	5	,	,	PUNCT
aji-137	254	6	vol	vol	NOUN
aji-137	254	7	.	.	PROPN
aji-137	254	8	7	7	NUM
aji-137	254	9	,	,	PUNCT
aji-137	254	10	no	no	INTJ
aji-137	254	11	.	.	NOUN
aji-137	254	12	1	1	NUM
aji-137	254	13	,	,	PUNCT
aji-137	254	14	pp	pp	ADJ
aji-137	254	15	.	.	PUNCT
aji-137	255	1	123	123	NUM
aji-137	255	2	-	-	SYM
aji-137	255	3	130	130	NUM
aji-137	255	4	,	,	PUNCT
aji-137	255	5	2024	2024	NUM
aji-137	255	6	;	;	PUNCT
aji-137	255	7	article	article	NOUN
aji-137	255	8	no.aji.120135	no.aji.120135	VERB
aji-137	255	9	128	128	NUM
aji-137	255	10	discontinuation	discontinuation	NOUN
aji-137	255	11	of	of	ADP
aji-137	255	12	the	the	DET
aji-137	255	13	study	study	NOUN
aji-137	255	14	medicine	medicine	NOUN
aji-137	255	15	[	[	X
aji-137	255	16	1	1	X
aji-137	255	17	]	]	PUNCT
aji-137	255	18	concluded	conclude	VERB
aji-137	255	19	by	by	ADP
aji-137	255	20	et	et	PROPN
aji-137	255	21	al	al	PROPN
aji-137	255	22	satoshi	satoshi	PROPN
aji-137	255	23	kubo	kubo	PROPN
aji-137	255	24	.	.	PROPN
aji-137	256	1	5	5	X
aji-137	256	2	.	.	X
aji-137	256	3	conclusion	conclusion	NOUN
aji-137	256	4	in	in	ADP
aji-137	256	5	the	the	DET
aji-137	256	6	review	review	NOUN
aji-137	256	7	,	,	PUNCT
aji-137	256	8	we	we	PRON
aji-137	256	9	have	have	AUX
aji-137	256	10	described	describe	VERB
aji-137	256	11	the	the	DET
aji-137	256	12	potential	potential	NOUN
aji-137	256	13	of	of	ADP
aji-137	256	14	the	the	DET
aji-137	256	15	jak	jak	PROPN
aji-137	256	16	inhibitor	inhibitor	NOUN
aji-137	256	17	baricitinib	baricitinib	NOUN
aji-137	256	18	.	.	PUNCT
aji-137	257	1	baricitinib	baricitinib	NOUN
aji-137	257	2	has	have	AUX
aji-137	257	3	demonstrated	demonstrate	VERB
aji-137	257	4	a	a	DET
aji-137	257	5	greater	great	ADJ
aji-137	257	6	selectivity	selectivity	NOUN
aji-137	257	7	for	for	ADP
aji-137	257	8	jak1	jak1	NOUN
aji-137	257	9	and	and	CCONJ
aji-137	257	10	jak2	jak2	PROPN
aji-137	257	11	than	than	ADP
aji-137	257	12	for	for	ADP
aji-137	257	13	the	the	DET
aji-137	257	14	other	other	ADJ
aji-137	257	15	tyrosine	tyrosine	NOUN
aji-137	257	16	kinases	kinase	NOUN
aji-137	257	17	,	,	PUNCT
aji-137	257	18	jak3	jak3	NOUN
aji-137	257	19	and	and	CCONJ
aji-137	257	20	tyk2	tyk2	PROPN
aji-137	257	21	,	,	PUNCT
aji-137	257	22	in	in	ADP
aji-137	257	23	basic	basic	ADJ
aji-137	257	24	research	research	NOUN
aji-137	257	25	investigations	investigation	NOUN
aji-137	257	26	,	,	PUNCT
aji-137	257	27	suggesting	suggest	VERB
aji-137	257	28	that	that	SCONJ
aji-137	257	29	it	it	PRON
aji-137	257	30	may	may	AUX
aji-137	257	31	be	be	AUX
aji-137	257	32	useful	useful	ADJ
aji-137	257	33	as	as	ADP
aji-137	257	34	a	a	DET
aji-137	257	35	molecular	molecular	ADJ
aji-137	257	36	target	target	NOUN
aji-137	257	37	medication	medication	NOUN
aji-137	257	38	.	.	PUNCT
aji-137	258	1	the	the	DET
aji-137	258	2	use	use	NOUN
aji-137	258	3	of	of	ADP
aji-137	258	4	baricitinib	baricitinib	NOUN
aji-137	258	5	in	in	ADP
aji-137	258	6	ra	ra	PROPN
aji-137	258	7	is	be	AUX
aji-137	258	8	supported	support	VERB
aji-137	258	9	by	by	ADP
aji-137	258	10	strong	strong	ADJ
aji-137	258	11	evidence	evidence	NOUN
aji-137	258	12	,	,	PUNCT
aji-137	258	13	particularly	particularly	ADV
aji-137	258	14	when	when	SCONJ
aji-137	258	15	combined	combine	VERB
aji-137	258	16	with	with	ADP
aji-137	258	17	the	the	DET
aji-137	258	18	existing	exist	VERB
aji-137	258	19	dmard	dmard	ADJ
aji-137	258	20	treatment	treatment	NOUN
aji-137	258	21	.	.	PUNCT
aji-137	259	1	disclaimer	disclaimer	NOUN
aji-137	259	2	(	(	PUNCT
aji-137	259	3	artificial	artificial	ADJ
aji-137	259	4	intelligence	intelligence	NOUN
aji-137	259	5	)	)	PUNCT
aji-137	259	6	author(s	author(s	NOUN
aji-137	259	7	)	)	PUNCT
aji-137	259	8	hereby	hereby	ADV
aji-137	259	9	declare	declare	VERB
aji-137	259	10	that	that	SCONJ
aji-137	259	11	no	no	DET
aji-137	259	12	generative	generative	NOUN
aji-137	259	13	ai	ai	VERB
aji-137	259	14	technologies	technology	NOUN
aji-137	259	15	such	such	ADJ
aji-137	259	16	as	as	ADP
aji-137	259	17	large	large	ADJ
aji-137	259	18	language	language	NOUN
aji-137	259	19	models	model	NOUN
aji-137	259	20	(	(	PUNCT
aji-137	259	21	chatgpt	chatgpt	NOUN
aji-137	259	22	,	,	PUNCT
aji-137	259	23	copilot	copilot	NOUN
aji-137	259	24	,	,	PUNCT
aji-137	259	25	etc	etc	X
aji-137	259	26	)	)	PUNCT
aji-137	259	27	and	and	CCONJ
aji-137	259	28	text	text	NOUN
aji-137	259	29	-	-	PUNCT
aji-137	259	30	to	to	ADP
aji-137	259	31	-	-	PUNCT
aji-137	259	32	image	image	NOUN
aji-137	259	33	generators	generator	NOUN
aji-137	259	34	have	have	AUX
aji-137	259	35	been	be	AUX
aji-137	259	36	used	use	VERB
aji-137	259	37	during	during	ADP
aji-137	259	38	writing	writing	NOUN
aji-137	259	39	or	or	CCONJ
aji-137	259	40	editing	editing	NOUN
aji-137	259	41	of	of	ADP
aji-137	259	42	manuscripts	manuscript	NOUN
aji-137	259	43	.	.	PUNCT
aji-137	260	1	competing	compete	VERB
aji-137	260	2	interests	interest	NOUN
aji-137	260	3	authors	author	NOUN
aji-137	260	4	have	have	AUX
aji-137	260	5	declared	declare	VERB
aji-137	260	6	that	that	SCONJ
aji-137	260	7	no	no	DET
aji-137	260	8	competing	compete	VERB
aji-137	260	9	interests	interest	NOUN
aji-137	260	10	exist	exist	VERB
aji-137	260	11	.	.	PUNCT
aji-137	261	1	references	reference	NOUN
aji-137	261	2	1	1	NUM
aji-137	261	3	.	.	PUNCT
aji-137	262	1	kubo	kubo	PROPN
aji-137	262	2	s	s	PROPN
aji-137	262	3	,	,	PUNCT
aji-137	262	4	nakayamada	nakayamada	PROPN
aji-137	262	5	s	s	PROPN
aji-137	262	6	,	,	PUNCT
aji-137	262	7	tanaka	tanaka	PROPN
aji-137	262	8	y.	y.	PROPN
aji-137	262	9	baricitinib	baricitinib	NOUN
aji-137	262	10	for	for	ADP
aji-137	262	11	the	the	DET
aji-137	262	12	treatment	treatment	NOUN
aji-137	262	13	of	of	ADP
aji-137	262	14	rheumatoid	rheumatoid	NOUN
aji-137	262	15	arthritis	arthritis	NOUN
aji-137	262	16	.	.	PUNCT
aji-137	263	1	expert	expert	NOUN
aji-137	263	2	review	review	NOUN
aji-137	263	3	of	of	ADP
aji-137	263	4	clinical	clinical	ADJ
aji-137	263	5	immunology	immunology	NOUN
aji-137	263	6	.	.	PUNCT
aji-137	264	1	2016;12(9):911	2016;12(9):911	NUM
aji-137	264	2	-	-	SYM
aji-137	264	3	9	9	NUM
aji-137	264	4	.	.	NOUN
aji-137	264	5	2	2	NUM
aji-137	264	6	.	.	X
aji-137	264	7	emery	emery	PROPN
aji-137	264	8	p	p	PROPN
aji-137	264	9	,	,	PUNCT
aji-137	264	10	durez	durez	NOUN
aji-137	264	11	p	p	NOUN
aji-137	264	12	,	,	PUNCT
aji-137	264	13	hueber	hueber	PROPN
aji-137	264	14	aj	aj	PROPN
aji-137	264	15	,	,	PUNCT
aji-137	264	16	de	de	PROPN
aji-137	264	17	la	la	PROPN
aji-137	264	18	torre	torre	PROPN
aji-137	265	1	i	i	PRON
aji-137	265	2	,	,	PUNCT
aji-137	265	3	larsson	larsson	PROPN
aji-137	265	4	e	e	PROPN
aji-137	265	5	,	,	PUNCT
aji-137	265	6	holzkämper	holzkämper	PROPN
aji-137	265	7	t	t	PROPN
aji-137	265	8	,	,	PUNCT
aji-137	265	9	tanaka	tanaka	PROPN
aji-137	265	10	y.	y.	PROPN
aji-137	265	11	baricitinib	baricitinib	NOUN
aji-137	265	12	inhibits	inhibit	VERB
aji-137	265	13	structural	structural	ADJ
aji-137	265	14	joint	joint	ADJ
aji-137	265	15	damage	damage	NOUN
aji-137	265	16	progression	progression	NOUN
aji-137	265	17	in	in	ADP
aji-137	265	18	patients	patient	NOUN
aji-137	265	19	with	with	ADP
aji-137	265	20	rheumatoid	rheumatoid	NOUN
aji-137	265	21	arthritis	arthritis	NOUN
aji-137	265	22	—	—	PUNCT
aji-137	265	23	a	a	DET
aji-137	265	24	comprehensive	comprehensive	ADJ
aji-137	265	25	review	review	NOUN
aji-137	265	26	.	.	PUNCT
aji-137	266	1	arthritis	arthritis	NOUN
aji-137	266	2	research	research	NOUN
aji-137	266	3	and	and	CCONJ
aji-137	266	4	therapy	therapy	NOUN
aji-137	266	5	.	.	PUNCT
aji-137	267	1	2021;23:1	2021;23:1	NUM
aji-137	267	2	-	-	SYM
aji-137	267	3	3	3	NUM
aji-137	267	4	.	.	NOUN
aji-137	267	5	3	3	NUM
aji-137	267	6	.	.	X
aji-137	268	1	aletaha	aletaha	PROPN
aji-137	268	2	d	d	PROPN
aji-137	268	3	,	,	PUNCT
aji-137	268	4	smolen	smolen	ADJ
aji-137	268	5	js	js	ADJ
aji-137	268	6	.	.	PUNCT
aji-137	268	7	diagnosis	diagnosis	NOUN
aji-137	268	8	and	and	CCONJ
aji-137	268	9	management	management	NOUN
aji-137	268	10	of	of	ADP
aji-137	268	11	rheumatoid	rheumatoid	NOUN
aji-137	268	12	arthritis	arthritis	NOUN
aji-137	268	13	:	:	PUNCT
aji-137	268	14	a	a	DET
aji-137	268	15	review	review	NOUN
aji-137	268	16	.	.	PUNCT
aji-137	269	1	jama	jama	PROPN
aji-137	269	2	.	.	PUNCT
aji-137	270	1	2018;320(13):1360	2018;320(13):1360	NUM
aji-137	270	2	-	-	SYM
aji-137	270	3	72	72	NUM
aji-137	270	4	.	.	NOUN
aji-137	271	1	4	4	NUM
aji-137	271	2	.	.	NOUN
aji-137	271	3	harre	harre	PROPN
aji-137	271	4	u	u	PROPN
aji-137	271	5	,	,	PUNCT
aji-137	271	6	schett	schett	PROPN
aji-137	271	7	g.	g.	PROPN
aji-137	271	8	cellular	cellular	PROPN
aji-137	271	9	and	and	CCONJ
aji-137	271	10	molecular	molecular	ADJ
aji-137	271	11	pathways	pathway	NOUN
aji-137	271	12	of	of	ADP
aji-137	271	13	structural	structural	ADJ
aji-137	271	14	damage	damage	NOUN
aji-137	271	15	in	in	ADP
aji-137	271	16	rheumatoid	rheumatoid	NOUN
aji-137	271	17	arthritis	arthritis	NOUN
aji-137	271	18	.	.	PUNCT
aji-137	272	1	inseminars	inseminar	NOUN
aji-137	272	2	in	in	ADP
aji-137	272	3	immunopathology	immunopathology	NOUN
aji-137	272	4	.	.	PUNCT
aji-137	273	1	berlin	berlin	PROPN
aji-137	273	2	/	/	SYM
aji-137	273	3	heidelberg	heidelberg	PROPN
aji-137	273	4	:	:	PUNCT
aji-137	273	5	springer	springer	PROPN
aji-137	273	6	berlin	berlin	PROPN
aji-137	273	7	heidelberg	heidelberg	PROPN
aji-137	273	8	.	.	PUNCT
aji-137	274	1	2017;39(4):355	2017;39(4):355	NUM
aji-137	274	2	-	-	PUNCT
aji-137	274	3	363	363	NUM
aji-137	274	4	.	.	PUNCT
aji-137	275	1	5	5	NUM
aji-137	275	2	.	.	X
aji-137	276	1	ahmad	ahmad	PROPN
aji-137	276	2	a	a	PRON
aji-137	276	3	,	,	PUNCT
aji-137	276	4	zaheer	zaheer	PROPN
aji-137	276	5	m	m	PROPN
aji-137	276	6	,	,	PUNCT
aji-137	276	7	balis	balis	PROPN
aji-137	276	8	fj	fj	PROPN
aji-137	276	9	.	.	PUNCT
aji-137	276	10	baricitinib	baricitinib	PROPN
aji-137	276	11	.	.	PUNCT
aji-137	277	1	in	in	ADP
aji-137	277	2	stat	stat	NOUN
aji-137	277	3	pearls	pearl	NOUN
aji-137	277	4	.	.	PUNCT
aji-137	278	1	statpearls	statpearls	PROPN
aji-137	278	2	publishing	publishing	NOUN
aji-137	278	3	;	;	PUNCT
aji-137	278	4	2022	2022	NUM
aji-137	278	5	.	.	PUNCT
aji-137	279	1	6	6	NUM
aji-137	279	2	.	.	X
aji-137	279	3	genovese	genovese	PROPN
aji-137	279	4	mc	mc	PROPN
aji-137	279	5	,	,	PUNCT
aji-137	279	6	smolen	smolen	PROPN
aji-137	279	7	js	js	PROPN
aji-137	279	8	,	,	PUNCT
aji-137	279	9	takeuchi	takeuchi	PROPN
aji-137	279	10	t	t	PROPN
aji-137	279	11	,	,	PUNCT
aji-137	279	12	burmester	burmester	NOUN
aji-137	279	13	g	g	PROPN
aji-137	279	14	,	,	PUNCT
aji-137	279	15	brinker	brinker	PROPN
aji-137	279	16	d	d	PROPN
aji-137	279	17	,	,	PUNCT
aji-137	279	18	rooney	rooney	PROPN
aji-137	279	19	tp	tp	PROPN
aji-137	279	20	,	,	PUNCT
aji-137	279	21	zhong	zhong	PROPN
aji-137	279	22	j	j	PROPN
aji-137	279	23	,	,	PUNCT
aji-137	279	24	daojun	daojun	PROPN
aji-137	279	25	m	m	PROPN
aji-137	279	26	,	,	PUNCT
aji-137	279	27	saifan	saifan	PROPN
aji-137	279	28	c	c	NOUN
aji-137	279	29	,	,	PUNCT
aji-137	279	30	cardoso	cardoso	PROPN
aji-137	279	31	a	a	PRON
aji-137	279	32	,	,	PUNCT
aji-137	279	33	issa	issa	ADJ
aji-137	279	34	m.	m.	NOUN
aji-137	279	35	safety	safety	NOUN
aji-137	279	36	profile	profile	NOUN
aji-137	279	37	of	of	ADP
aji-137	279	38	baricitinib	baricitinib	NOUN
aji-137	279	39	for	for	ADP
aji-137	279	40	the	the	DET
aji-137	279	41	treatment	treatment	NOUN
aji-137	279	42	of	of	ADP
aji-137	279	43	rheumatoid	rheumatoid	NOUN
aji-137	279	44	arthritis	arthritis	NOUN
aji-137	279	45	over	over	ADP
aji-137	279	46	a	a	DET
aji-137	279	47	median	median	NOUN
aji-137	279	48	of	of	ADP
aji-137	279	49	3	3	NUM
aji-137	279	50	years	year	NOUN
aji-137	279	51	of	of	ADP
aji-137	279	52	treatment	treatment	NOUN
aji-137	279	53	:	:	PUNCT
aji-137	279	54	an	an	DET
aji-137	279	55	updated	update	VERB
aji-137	279	56	integrated	integrate	VERB
aji-137	279	57	safety	safety	NOUN
aji-137	279	58	analysis	analysis	NOUN
aji-137	279	59	.	.	PUNCT
aji-137	280	1	the	the	DET
aji-137	280	2	lancet	lancet	PROPN
aji-137	280	3	rheumatology	rheumatology	NOUN
aji-137	280	4	.	.	PUNCT
aji-137	281	1	2020;2(6):e347	2020;2(6):e347	NUM
aji-137	281	2	-	-	PUNCT
aji-137	281	3	57	57	NUM
aji-137	281	4	.	.	PUNCT
aji-137	282	1	7	7	X
aji-137	282	2	.	.	X
aji-137	282	3	smolen	smolen	PROPN
aji-137	282	4	js	js	PROPN
aji-137	282	5	,	,	PUNCT
aji-137	282	6	aletaha	aletaha	NOUN
aji-137	282	7	d	d	PROPN
aji-137	282	8	,	,	PUNCT
aji-137	282	9	bijlsma	bijlsma	PROPN
aji-137	282	10	jw	jw	PROPN
aji-137	282	11	,	,	PUNCT
aji-137	282	12	breedveld	breedveld	PROPN
aji-137	282	13	fc	fc	PROPN
aji-137	282	14	,	,	PUNCT
aji-137	282	15	boumpas	boumpas	NOUN
aji-137	282	16	d	d	NOUN
aji-137	282	17	,	,	PUNCT
aji-137	282	18	burmester	burmester	NOUN
aji-137	282	19	g	g	PROPN
aji-137	282	20	,	,	PUNCT
aji-137	282	21	combe	combe	NOUN
aji-137	282	22	b	b	PROPN
aji-137	282	23	,	,	PUNCT
aji-137	282	24	cutolo	cutolo	PROPN
aji-137	282	25	m	m	PROPN
aji-137	282	26	,	,	PUNCT
aji-137	282	27	de	de	X
aji-137	282	28	wit	wit	NOUN
aji-137	282	29	m	m	PROPN
aji-137	282	30	,	,	PUNCT
aji-137	282	31	dougados	dougado	VERB
aji-137	282	32	m	m	PROPN
aji-137	282	33	,	,	PUNCT
aji-137	282	34	emery	emery	PROPN
aji-137	282	35	p.	p.	NOUN
aji-137	282	36	treating	treat	VERB
aji-137	282	37	rheumatoid	rheumatoid	NOUN
aji-137	282	38	arthritis	arthritis	NOUN
aji-137	282	39	to	to	PART
aji-137	282	40	target	target	VERB
aji-137	282	41	:	:	PUNCT
aji-137	282	42	recommendations	recommendation	NOUN
aji-137	282	43	of	of	ADP
aji-137	282	44	an	an	DET
aji-137	282	45	international	international	ADJ
aji-137	282	46	task	task	NOUN
aji-137	282	47	force	force	NOUN
aji-137	282	48	.	.	PUNCT
aji-137	283	1	annals	annal	NOUN
aji-137	283	2	of	of	ADP
aji-137	283	3	the	the	DET
aji-137	283	4	rheumatic	rheumatic	ADJ
aji-137	283	5	diseases	disease	NOUN
aji-137	283	6	.	.	PUNCT
aji-137	284	1	2010;69(4):631	2010;69(4):631	NUM
aji-137	284	2	-	-	SYM
aji-137	284	3	7	7	NUM
aji-137	284	4	.	.	NOUN
aji-137	284	5	8	8	NUM
aji-137	284	6	.	.	PUNCT
aji-137	285	1	smolen	smolen	PROPN
aji-137	285	2	js	js	PROPN
aji-137	285	3	,	,	PUNCT
aji-137	285	4	breedveld	breedveld	VERB
aji-137	285	5	fc	fc	PROPN
aji-137	285	6	,	,	PUNCT
aji-137	285	7	burmester	burmester	NOUN
aji-137	285	8	gr	gr	NOUN
aji-137	285	9	,	,	PUNCT
aji-137	285	10	bykerk	bykerk	NOUN
aji-137	285	11	v	v	NOUN
aji-137	285	12	,	,	PUNCT
aji-137	285	13	dougados	dougado	VERB
aji-137	285	14	m	m	PROPN
aji-137	285	15	,	,	PUNCT
aji-137	285	16	emery	emery	PROPN
aji-137	285	17	p	p	PROPN
aji-137	285	18	,	,	PUNCT
aji-137	285	19	kvien	kvien	PROPN
aji-137	285	20	tk	tk	PROPN
aji-137	285	21	,	,	PUNCT
aji-137	285	22	navarro	navarro	PROPN
aji-137	285	23	-	-	PUNCT
aji-137	285	24	compán	compán	PROPN
aji-137	285	25	mv	mv	PROPN
aji-137	285	26	,	,	PUNCT
aji-137	285	27	oliver	oliver	PROPN
aji-137	285	28	s	s	PROPN
aji-137	285	29	,	,	PUNCT
aji-137	285	30	schoels	schoels	PROPN
aji-137	285	31	m	m	PROPN
aji-137	285	32	,	,	PUNCT
aji-137	285	33	scholte	scholte	ADJ
aji-137	285	34	-	-	PUNCT
aji-137	285	35	voshaar	voshaar	NOUN
aji-137	285	36	m.	m.	NOUN
aji-137	285	37	treating	treat	VERB
aji-137	285	38	rheumatoid	rheumatoid	NOUN
aji-137	285	39	arthritis	arthritis	NOUN
aji-137	285	40	to	to	PART
aji-137	285	41	target	target	VERB
aji-137	285	42	:	:	PUNCT
aji-137	285	43	2014	2014	NUM
aji-137	285	44	update	update	NOUN
aji-137	285	45	of	of	ADP
aji-137	285	46	the	the	DET
aji-137	285	47	recommendations	recommendation	NOUN
aji-137	285	48	of	of	ADP
aji-137	285	49	an	an	DET
aji-137	285	50	international	international	ADJ
aji-137	285	51	task	task	NOUN
aji-137	285	52	force	force	NOUN
aji-137	285	53	.	.	PUNCT
aji-137	286	1	annals	annal	NOUN
aji-137	286	2	of	of	ADP
aji-137	286	3	the	the	DET
aji-137	286	4	rheumatic	rheumatic	ADJ
aji-137	286	5	diseases	disease	NOUN
aji-137	286	6	.	.	PUNCT
aji-137	287	1	2016;75(1):3	2016;75(1):3	NUM
aji-137	287	2	-	-	SYM
aji-137	287	3	15	15	NUM
aji-137	287	4	.	.	NOUN
aji-137	288	1	9	9	NUM
aji-137	288	2	.	.	X
aji-137	288	3	taylor	taylor	PROPN
aji-137	288	4	pc	pc	PROPN
aji-137	288	5	,	,	PUNCT
aji-137	288	6	weinblatt	weinblatt	PROPN
aji-137	288	7	me	i	PRON
aji-137	288	8	,	,	PUNCT
aji-137	288	9	burmester	burmester	NOUN
aji-137	288	10	gr	gr	PROPN
aji-137	288	11	,	,	PUNCT
aji-137	288	12	rooney	rooney	PROPN
aji-137	288	13	tp	tp	NOUN
aji-137	288	14	,	,	PUNCT
aji-137	288	15	witt	witt	PROPN
aji-137	288	16	s	s	PROPN
aji-137	288	17	,	,	PUNCT
aji-137	288	18	walls	wall	NOUN
aji-137	288	19	cd	cd	PROPN
aji-137	288	20	,	,	PUNCT
aji-137	288	21	issa	issa	PROPN
aji-137	288	22	m	m	PROPN
aji-137	288	23	,	,	PUNCT
aji-137	288	24	salinas	salinas	PROPN
aji-137	288	25	ca	ca	PROPN
aji-137	288	26	,	,	PUNCT
aji-137	288	27	saifan	saifan	NOUN
aji-137	288	28	c	c	PROPN
aji-137	288	29	,	,	PUNCT
aji-137	288	30	zhang	zhang	PROPN
aji-137	288	31	x	x	PROPN
aji-137	288	32	,	,	PUNCT
aji-137	288	33	cardoso	cardoso	PROPN
aji-137	288	34	a.	a.	PROPN
aji-137	288	35	cardiovascular	cardiovascular	PROPN
aji-137	288	36	safety	safety	NOUN
aji-137	288	37	during	during	ADP
aji-137	288	38	treatment	treatment	NOUN
aji-137	288	39	with	with	ADP
aji-137	288	40	baricitinib	baricitinib	NOUN
aji-137	288	41	in	in	ADP
aji-137	288	42	rheumatoid	rheumatoid	NOUN
aji-137	288	43	arthritis	arthritis	NOUN
aji-137	288	44	.	.	PUNCT
aji-137	289	1	arthritis	arthritis	NOUN
aji-137	289	2	and	and	CCONJ
aji-137	289	3	rheumatology	rheumatology	NOUN
aji-137	289	4	.	.	PUNCT
aji-137	290	1	2019;71(7	2019;71(7	NUM
aji-137	290	2	):	):	PUNCT
aji-137	290	3	1042	1042	NUM
aji-137	290	4	-	-	SYM
aji-137	290	5	55	55	NUM
aji-137	290	6	.	.	PUNCT
aji-137	291	1	10	10	NUM
aji-137	291	2	.	.	PUNCT
aji-137	292	1	smolen	smolen	VERB
aji-137	292	2	js	js	PROPN
aji-137	292	3	,	,	PUNCT
aji-137	292	4	landewé	landewé	NOUN
aji-137	292	5	r	r	NOUN
aji-137	292	6	,	,	PUNCT
aji-137	292	7	breedveld	breedveld	X
aji-137	292	8	fc	fc	PROPN
aji-137	292	9	,	,	PUNCT
aji-137	292	10	buch	buch	PROPN
aji-137	292	11	m	m	PROPN
aji-137	292	12	,	,	PUNCT
aji-137	292	13	burmester	burmester	PROPN
aji-137	292	14	g	g	PROPN
aji-137	292	15	,	,	PUNCT
aji-137	292	16	dougados	dougado	VERB
aji-137	292	17	m	m	PROPN
aji-137	292	18	,	,	PUNCT
aji-137	292	19	emery	emery	PROPN
aji-137	292	20	p	p	NOUN
aji-137	292	21	,	,	PUNCT
aji-137	292	22	gaujoux	gaujoux	ADJ
aji-137	292	23	-	-	PUNCT
aji-137	292	24	viala	viala	NOUN
aji-137	292	25	c	c	NOUN
aji-137	292	26	,	,	PUNCT
aji-137	292	27	gossec	gossec	PROPN
aji-137	292	28	l	l	NOUN
aji-137	292	29	,	,	PUNCT
aji-137	292	30	nam	nam	PROPN
aji-137	292	31	j	j	PROPN
aji-137	292	32	,	,	PUNCT
aji-137	292	33	ramiro	ramiro	PROPN
aji-137	292	34	s.	s.	PROPN
aji-137	292	35	eular	eular	ADJ
aji-137	292	36	recommendations	recommendation	NOUN
aji-137	292	37	for	for	ADP
aji-137	292	38	the	the	DET
aji-137	292	39	management	management	NOUN
aji-137	292	40	of	of	ADP
aji-137	292	41	rheumatoid	rheumatoid	VERB
aji-137	292	42	arthritis	arthritis	NOUN
aji-137	292	43	with	with	ADP
aji-137	292	44	synthetic	synthetic	ADJ
aji-137	292	45	and	and	CCONJ
aji-137	292	46	biological	biological	ADJ
aji-137	292	47	disease	disease	NOUN
aji-137	292	48	-	-	PUNCT
aji-137	292	49	modifying	modify	VERB
aji-137	292	50	antirheumatic	antirheumatic	ADJ
aji-137	292	51	drugs	drug	NOUN
aji-137	292	52	:	:	PUNCT
aji-137	292	53	2013	2013	NUM
aji-137	292	54	update	update	NOUN
aji-137	292	55	.	.	PUNCT
aji-137	293	1	annals	annal	NOUN
aji-137	293	2	of	of	ADP
aji-137	293	3	the	the	DET
aji-137	293	4	rheumatic	rheumatic	ADJ
aji-137	293	5	diseases	disease	NOUN
aji-137	293	6	.	.	PUNCT
aji-137	294	1	2014;73(3):492	2014;73(3):492	NUM
aji-137	294	2	-	-	PUNCT
aji-137	294	3	509	509	NUM
aji-137	294	4	.	.	PUNCT
aji-137	294	5	11	11	NUM
aji-137	294	6	.	.	PUNCT
aji-137	295	1	singh	singh	PROPN
aji-137	295	2	ja	ja	PROPN
aji-137	295	3	,	,	PUNCT
aji-137	295	4	saag	saag	PROPN
aji-137	295	5	kg	kg	PROPN
aji-137	295	6	,	,	PUNCT
aji-137	295	7	bridges	bridge	NOUN
aji-137	295	8	jr	jr	PROPN
aji-137	295	9	sl	sl	PROPN
aji-137	295	10	,	,	PUNCT
aji-137	295	11	akl	akl	PROPN
aji-137	295	12	ea	ea	PROPN
aji-137	295	13	,	,	PUNCT
aji-137	295	14	bannuru	bannuru	PROPN
aji-137	295	15	rr	rr	PROPN
aji-137	295	16	,	,	PUNCT
aji-137	295	17	sullivan	sullivan	PROPN
aji-137	295	18	mc	mc	PROPN
aji-137	295	19	,	,	PUNCT
aji-137	295	20	vaysbrot	vaysbrot	PROPN
aji-137	295	21	e	e	PROPN
aji-137	295	22	,	,	PUNCT
aji-137	295	23	mcnaughton	mcnaughton	PROPN
aji-137	295	24	c	c	PROPN
aji-137	295	25	,	,	PUNCT
aji-137	295	26	osani	osani	PROPN
aji-137	295	27	m	m	PROPN
aji-137	295	28	,	,	PUNCT
aji-137	295	29	shmerling	shmerle	VERB
aji-137	295	30	rh	rh	PROPN
aji-137	295	31	,	,	PUNCT
aji-137	295	32	curtis	curtis	PROPN
aji-137	295	33	jr	jr	PROPN
aji-137	295	34	.	.	PROPN
aji-137	295	35	2015	2015	NUM
aji-137	295	36	american	american	PROPN
aji-137	295	37	college	college	PROPN
aji-137	295	38	of	of	ADP
aji-137	295	39	rheumatology	rheumatology	NOUN
aji-137	295	40	guideline	guideline	NOUN
aji-137	295	41	for	for	ADP
aji-137	295	42	the	the	DET
aji-137	295	43	treatment	treatment	NOUN
aji-137	295	44	of	of	ADP
aji-137	295	45	rheumatoid	rheumatoid	NOUN
aji-137	295	46	arthritis	arthritis	NOUN
aji-137	295	47	.	.	PUNCT
aji-137	296	1	arthritis	arthritis	NOUN
aji-137	296	2	and	and	CCONJ
aji-137	296	3	rheumatology	rheumatology	NOUN
aji-137	296	4	.	.	PUNCT
aji-137	297	1	2016;68(1):1	2016;68(1):1	NUM
aji-137	297	2	-	-	SYM
aji-137	297	3	26	26	NUM
aji-137	297	4	.	.	PUNCT
aji-137	298	1	12	12	NUM
aji-137	298	2	.	.	PUNCT
aji-137	299	1	smolen	smolen	VERB
aji-137	299	2	js	js	PROPN
aji-137	299	3	,	,	PUNCT
aji-137	299	4	aletaha	aletaha	NOUN
aji-137	299	5	d.	d.	PROPN
aji-137	299	6	rheumatoid	rheumatoid	VERB
aji-137	299	7	arthritis	arthritis	NOUN
aji-137	299	8	therapy	therapy	NOUN
aji-137	299	9	reappraisal	reappraisal	NOUN
aji-137	299	10	:	:	PUNCT
aji-137	300	1	strategies	strategy	NOUN
aji-137	300	2	,	,	PUNCT
aji-137	300	3	opportunities	opportunity	NOUN
aji-137	300	4	and	and	CCONJ
aji-137	300	5	challenges	challenge	NOUN
aji-137	300	6	.	.	PUNCT
aji-137	301	1	nature	nature	NOUN
aji-137	301	2	reviews	review	VERB
aji-137	301	3	rheumatology	rheumatology	NOUN
aji-137	301	4	.	.	PUNCT
aji-137	302	1	2015;11	2015;11	NUM
aji-137	302	2	(	(	PUNCT
aji-137	302	3	5):276	5):276	NUM
aji-137	302	4	89	89	NUM
aji-137	302	5	.	.	PUNCT
aji-137	303	1	13	13	NUM
aji-137	303	2	.	.	X
aji-137	304	1	genovese	genovese	PROPN
aji-137	304	2	mc	mc	PROPN
aji-137	304	3	,	,	PUNCT
aji-137	304	4	kremer	kremer	PROPN
aji-137	304	5	j	j	PROPN
aji-137	304	6	,	,	PUNCT
aji-137	304	7	zamani	zamani	PROPN
aji-137	304	8	o	o	PROPN
aji-137	304	9	,	,	PUNCT
aji-137	304	10	ludivico	ludivico	PROPN
aji-137	304	11	c	c	X
aji-137	304	12	,	,	PUNCT
aji-137	304	13	krogulec	krogulec	PROPN
aji-137	304	14	m	m	PROPN
aji-137	304	15	,	,	PUNCT
aji-137	304	16	xie	xie	PROPN
aji-137	304	17	l	l	PROPN
aji-137	304	18	,	,	PUNCT
aji-137	304	19	beattie	beattie	PROPN
aji-137	304	20	sd	sd	PROPN
aji-137	304	21	,	,	PUNCT
aji-137	304	22	koch	koch	PROPN
aji-137	304	23	ae	ae	PROPN
aji-137	304	24	,	,	PUNCT
aji-137	304	25	cardillo	cardillo	VERB
aji-137	304	26	te	te	PROPN
aji-137	304	27	,	,	PUNCT
aji-137	304	28	rooney	rooney	PROPN
aji-137	304	29	tp	tp	PROPN
aji-137	304	30	,	,	PUNCT
aji-137	304	31	macias	macias	PROPN
aji-137	304	32	wl	wl	PROPN
aji-137	304	33	.	.	PROPN
aji-137	304	34	baricitinib	baricitinib	NOUN
aji-137	304	35	in	in	ADP
aji-137	304	36	patients	patient	NOUN
aji-137	304	37	with	with	ADP
aji-137	304	38	refractory	refractory	NOUN
aji-137	304	39	rheumatoid	rheumatoid	NOUN
aji-137	304	40	arthritis	arthritis	NOUN
aji-137	304	41	.	.	PUNCT
aji-137	305	1	new	new	PROPN
aji-137	305	2	england	england	PROPN
aji-137	305	3	journal	journal	PROPN
aji-137	305	4	of	of	ADP
aji-137	305	5	medicine	medicine	NOUN
aji-137	305	6	.	.	PUNCT
aji-137	306	1	2016;374(13):1243	2016;374(13):1243	NUM
aji-137	306	2	-	-	SYM
aji-137	306	3	52	52	NUM
aji-137	306	4	.	.	PUNCT
aji-137	307	1	14	14	NUM
aji-137	307	2	.	.	PUNCT
aji-137	308	1	genovese	genovese	PROPN
aji-137	308	2	mc	mc	PROPN
aji-137	308	3	,	,	PUNCT
aji-137	308	4	kremer	kremer	PROPN
aji-137	308	5	jm	jm	PROPN
aji-137	308	6	,	,	PUNCT
aji-137	308	7	kartman	kartman	PROPN
aji-137	308	8	ce	ce	PROPN
aji-137	308	9	,	,	PUNCT
aji-137	308	10	schlichting	schlichte	VERB
aji-137	308	11	de	de	ADP
aji-137	308	12	,	,	PUNCT
aji-137	308	13	xie	xie	PROPN
aji-137	308	14	l	l	PROPN
aji-137	308	15	,	,	PUNCT
aji-137	308	16	carmack	carmack	PROPN
aji-137	308	17	t	t	PROPN
aji-137	308	18	,	,	PUNCT
aji-137	308	19	pantojas	pantojas	ADV
aji-137	308	20	c	c	X
aji-137	308	21	,	,	PUNCT
aji-137	308	22	sanchez	sanchez	PROPN
aji-137	308	23	burson	burson	PROPN
aji-137	308	24	j	j	PROPN
aji-137	308	25	,	,	PUNCT
aji-137	308	26	tony	tony	PROPN
aji-137	308	27	hp	hp	PROPN
aji-137	308	28	,	,	PUNCT
aji-137	308	29	gupta	gupta	PROPN
aji-137	308	30	et	et	NOUN
aji-137	308	31	al	al	PROPN
aji-137	308	32	.	.	PROPN
aji-137	308	33	;	;	PUNCT
aji-137	308	34	asian	asian	PROPN
aji-137	308	35	j.	j.	PROPN
aji-137	308	36	immunol	immunol	PROPN
aji-137	308	37	.	.	PROPN
aji-137	308	38	,	,	PUNCT
aji-137	308	39	vol	vol	NOUN
aji-137	308	40	.	.	PROPN
aji-137	308	41	7	7	NUM
aji-137	308	42	,	,	PUNCT
aji-137	308	43	no	no	INTJ
aji-137	308	44	.	.	NOUN
aji-137	308	45	1	1	NUM
aji-137	308	46	,	,	PUNCT
aji-137	308	47	pp	pp	ADJ
aji-137	308	48	.	.	PUNCT
aji-137	309	1	123	123	NUM
aji-137	309	2	-	-	SYM
aji-137	309	3	130	130	NUM
aji-137	309	4	,	,	PUNCT
aji-137	309	5	2024	2024	NUM
aji-137	309	6	;	;	PUNCT
aji-137	310	1	article	article	NOUN
aji-137	310	2	no.aji.120135	no.aji.120135	PROPN
aji-137	310	3	129	129	NUM
aji-137	310	4	macias	macias	PROPN
aji-137	310	5	wl	wl	PROPN
aji-137	310	6	,	,	PUNCT
aji-137	310	7	rooney	rooney	PROPN
aji-137	310	8	tp	tp	PROPN
aji-137	310	9	.	.	PUNCT
aji-137	310	10	response	response	NOUN
aji-137	310	11	to	to	ADP
aji-137	310	12	baricitinib	baricitinib	NOUN
aji-137	310	13	based	base	VERB
aji-137	310	14	on	on	ADP
aji-137	310	15	prior	prior	ADJ
aji-137	310	16	biologic	biologic	NOUN
aji-137	310	17	use	use	NOUN
aji-137	310	18	in	in	ADP
aji-137	310	19	patients	patient	NOUN
aji-137	310	20	with	with	ADP
aji-137	310	21	refractory	refractory	NOUN
aji-137	310	22	rheumatoid	rheumatoid	NOUN
aji-137	310	23	arthritis	arthritis	NOUN
aji-137	310	24	.	.	PUNCT
aji-137	311	1	rheumatology	rheumatology	NOUN
aji-137	311	2	.	.	PUNCT
aji-137	312	1	2018;57(5):900	2018;57(5):900	NUM
aji-137	312	2	-	-	SYM
aji-137	312	3	8	8	NUM
aji-137	312	4	.	.	NOUN
aji-137	312	5	15	15	NUM
aji-137	312	6	.	.	PUNCT
aji-137	313	1	mogul	mogul	NOUN
aji-137	313	2	a	a	PRON
aji-137	313	3	,	,	PUNCT
aji-137	313	4	corsi	corsi	ADJ
aji-137	313	5	k	k	PROPN
aji-137	313	6	,	,	PUNCT
aji-137	313	7	mcauliffe	mcauliffe	PROPN
aji-137	313	8	l.	l.	PROPN
aji-137	313	9	baricitinib	baricitinib	PROPN
aji-137	313	10	:	:	PUNCT
aji-137	313	11	the	the	DET
aji-137	313	12	second	second	ADJ
aji-137	313	13	fda	fda	PROPN
aji-137	313	14	-	-	PUNCT
aji-137	313	15	approved	approve	VERB
aji-137	313	16	jak	jak	PROPN
aji-137	313	17	inhibitor	inhibitor	NOUN
aji-137	313	18	for	for	ADP
aji-137	313	19	the	the	DET
aji-137	313	20	treatment	treatment	NOUN
aji-137	313	21	of	of	ADP
aji-137	313	22	rheumatoid	rheumatoid	NOUN
aji-137	313	23	arthritis	arthritis	NOUN
aji-137	313	24	.	.	PUNCT
aji-137	314	1	annals	annal	NOUN
aji-137	314	2	of	of	ADP
aji-137	314	3	pharmacotherapy	pharmacotherapy	NOUN
aji-137	314	4	.	.	PUNCT
aji-137	315	1	2019;53(9):947	2019;53(9):947	NUM
aji-137	315	2	-	-	SYM
aji-137	315	3	53	53	NUM
aji-137	315	4	.	.	PUNCT
aji-137	316	1	16	16	NUM
aji-137	316	2	.	.	PUNCT
aji-137	317	1	musumeci	musumeci	PROPN
aji-137	317	2	f	f	PROPN
aji-137	317	3	,	,	PUNCT
aji-137	317	4	greco	greco	PROPN
aji-137	317	5	c	c	PROPN
aji-137	317	6	,	,	PUNCT
aji-137	317	7	giacchello	giacchello	VERB
aji-137	317	8	i	i	PRON
aji-137	317	9	,	,	PUNCT
aji-137	317	10	fallacara	fallacara	PROPN
aji-137	317	11	al	al	PROPN
aji-137	317	12	,	,	PUNCT
aji-137	317	13	ibrahim	ibrahim	PROPN
aji-137	317	14	mm	mm	PROPN
aji-137	317	15	,	,	PUNCT
aji-137	317	16	grossi	grossi	PROPN
aji-137	317	17	g	g	PROPN
aji-137	317	18	,	,	PUNCT
aji-137	317	19	brullo	brullo	NOUN
aji-137	317	20	c	c	NOUN
aji-137	317	21	,	,	PUNCT
aji-137	317	22	schenone	schenone	PROPN
aji-137	317	23	s.	s.	PROPN
aji-137	317	24	an	an	DET
aji-137	317	25	update	update	NOUN
aji-137	317	26	on	on	ADP
aji-137	317	27	jak	jak	PROPN
aji-137	317	28	inhibitors	inhibitor	NOUN
aji-137	317	29	.	.	PUNCT
aji-137	318	1	current	current	ADJ
aji-137	318	2	medicinal	medicinal	ADJ
aji-137	318	3	chemistry	chemistry	NOUN
aji-137	318	4	.	.	PUNCT
aji-137	319	1	2019	2019	NUM
aji-137	319	2	;	;	PUNCT
aji-137	319	3	26(10):1806	26(10):1806	NUM
aji-137	319	4	-	-	SYM
aji-137	319	5	32	32	NUM
aji-137	319	6	.	.	PUNCT
aji-137	320	1	17	17	NUM
aji-137	320	2	.	.	PUNCT
aji-137	321	1	king	king	PROPN
aji-137	321	2	b	b	PROPN
aji-137	321	3	,	,	PUNCT
aji-137	321	4	ohyama	ohyama	PROPN
aji-137	321	5	m	m	PROPN
aji-137	321	6	,	,	PUNCT
aji-137	321	7	kwon	kwon	VERB
aji-137	321	8	o	o	NOUN
aji-137	321	9	,	,	PUNCT
aji-137	321	10	zlotogorski	zlotogorski	PROPN
aji-137	321	11	a	a	PROPN
aji-137	321	12	,	,	PUNCT
aji-137	321	13	ko	ko	PROPN
aji-137	321	14	j	j	PROPN
aji-137	321	15	,	,	PUNCT
aji-137	321	16	mesinkovska	mesinkovska	PROPN
aji-137	321	17	na	na	NOUN
aji-137	321	18	,	,	PUNCT
aji-137	321	19	hordinsky	hordinsky	PROPN
aji-137	321	20	m	m	PROPN
aji-137	321	21	,	,	PUNCT
aji-137	321	22	dutronc	dutronc	VERB
aji-137	321	23	y	y	PROPN
aji-137	321	24	,	,	PUNCT
aji-137	321	25	wu	wu	PROPN
aji-137	321	26	ws	ws	PROPN
aji-137	321	27	,	,	PUNCT
aji-137	321	28	mccollam	mccollam	PROPN
aji-137	321	29	j	j	PROPN
aji-137	321	30	,	,	PUNCT
aji-137	321	31	chiasserini	chiasserini	PROPN
aji-137	321	32	c.	c.	NOUN
aji-137	321	33	two	two	NUM
aji-137	321	34	phase	phase	NOUN
aji-137	321	35	3	3	NUM
aji-137	321	36	trials	trial	NOUN
aji-137	321	37	of	of	ADP
aji-137	321	38	baricitinib	baricitinib	NOUN
aji-137	321	39	for	for	ADP
aji-137	321	40	alopecia	alopecia	NOUN
aji-137	321	41	areata	areata	NOUN
aji-137	321	42	.	.	PUNCT
aji-137	322	1	new	new	PROPN
aji-137	322	2	england	england	PROPN
aji-137	322	3	journal	journal	PROPN
aji-137	322	4	of	of	ADP
aji-137	322	5	medicine	medicine	NOUN
aji-137	322	6	.	.	PUNCT
aji-137	323	1	2022;386(18):1687	2022;386(18):1687	X
aji-137	323	2	-	-	SYM
aji-137	323	3	99	99	NUM
aji-137	323	4	.	.	PUNCT
aji-137	323	5	18	18	NUM
aji-137	323	6	.	.	PUNCT
aji-137	324	1	shi	shi	PROPN
aji-137	324	2	jg	jg	PROPN
aji-137	324	3	,	,	PUNCT
aji-137	324	4	chen	chen	PROPN
aji-137	324	5	x	x	PROPN
aji-137	324	6	,	,	PUNCT
aji-137	324	7	lee	lee	PROPN
aji-137	324	8	f	f	PROPN
aji-137	324	9	,	,	PUNCT
aji-137	324	10	emm	emm	PROPN
aji-137	324	11	t	t	PROPN
aji-137	324	12	,	,	PUNCT
aji-137	324	13	scherle	scherle	PROPN
aji-137	324	14	pa	pa	PROPN
aji-137	324	15	,	,	PUNCT
aji-137	324	16	lo	lo	PROPN
aji-137	324	17	y	y	PROPN
aji-137	324	18	,	,	PUNCT
aji-137	324	19	punwani	punwani	PROPN
aji-137	324	20	n	n	CCONJ
aji-137	324	21	,	,	PUNCT
aji-137	324	22	williams	williams	PROPN
aji-137	324	23	wv	wv	PROPN
aji-137	324	24	,	,	PUNCT
aji-137	324	25	yeleswaram	yeleswaram	PROPN
aji-137	324	26	s.	s.	PROPN
aji-137	324	27	the	the	DET
aji-137	324	28	pharmacokinetics	pharmacokinetic	NOUN
aji-137	324	29	,	,	PUNCT
aji-137	324	30	pharmacodynamics	pharmacodynamic	NOUN
aji-137	324	31	,	,	PUNCT
aji-137	324	32	and	and	CCONJ
aji-137	324	33	safety	safety	NOUN
aji-137	324	34	of	of	ADP
aji-137	324	35	baricitinib	baricitinib	NOUN
aji-137	324	36	,	,	PUNCT
aji-137	324	37	an	an	DET
aji-137	324	38	oral	oral	ADJ
aji-137	324	39	jak	jak	PROPN
aji-137	324	40	1/2	1/2	NUM
aji-137	324	41	inhibitor	inhibitor	NOUN
aji-137	324	42	,	,	PUNCT
aji-137	324	43	in	in	ADP
aji-137	324	44	healthy	healthy	ADJ
aji-137	324	45	volunteers	volunteer	NOUN
aji-137	324	46	.	.	PUNCT
aji-137	325	1	the	the	DET
aji-137	325	2	journal	journal	NOUN
aji-137	325	3	of	of	ADP
aji-137	325	4	clinical	clinical	ADJ
aji-137	325	5	pharmacology	pharmacology	NOUN
aji-137	325	6	.	.	PUNCT
aji-137	326	1	2014;54(12):1354	2014;54(12):1354	NUM
aji-137	326	2	-	-	SYM
aji-137	326	3	61	61	NUM
aji-137	326	4	.	.	PUNCT
aji-137	327	1	19	19	NUM
aji-137	327	2	.	.	PUNCT
aji-137	328	1	huang	huang	PROPN
aji-137	328	2	f	f	PROPN
aji-137	328	3	,	,	PUNCT
aji-137	328	4	luo	luo	PROPN
aji-137	328	5	zc	zc	PROPN
aji-137	328	6	.	.	PROPN
aji-137	328	7	risk	risk	NOUN
aji-137	328	8	of	of	ADP
aji-137	328	9	adverse	adverse	ADJ
aji-137	328	10	drug	drug	NOUN
aji-137	328	11	events	event	NOUN
aji-137	328	12	observed	observe	VERB
aji-137	328	13	with	with	ADP
aji-137	328	14	baricitinib	baricitinib	NOUN
aji-137	328	15	2	2	NUM
aji-137	328	16	mg	mg	NOUN
aji-137	328	17	versus	versus	ADP
aji-137	328	18	baricitinib	baricitinib	NOUN
aji-137	328	19	4	4	NUM
aji-137	328	20	mg	mg	ADP
aji-137	328	21	once	once	ADV
aji-137	328	22	daily	daily	ADV
aji-137	328	23	for	for	ADP
aji-137	328	24	the	the	DET
aji-137	328	25	treatment	treatment	NOUN
aji-137	328	26	of	of	ADP
aji-137	328	27	rheumatoid	rheumatoid	NOUN
aji-137	328	28	arthritis	arthritis	NOUN
aji-137	328	29	:	:	PUNCT
aji-137	328	30	a	a	DET
aji-137	328	31	systematic	systematic	ADJ
aji-137	328	32	review	review	NOUN
aji-137	328	33	and	and	CCONJ
aji-137	328	34	meta	meta	NOUN
aji-137	328	35	-	-	PUNCT
aji-137	328	36	analysis	analysis	NOUN
aji-137	328	37	of	of	ADP
aji-137	328	38	randomized	randomized	ADJ
aji-137	328	39	controlled	control	VERB
aji-137	328	40	trials	trial	NOUN
aji-137	328	41	.	.	PUNCT
aji-137	329	1	biodrugs	biodrug	NOUN
aji-137	329	2	.	.	PUNCT
aji-137	330	1	2018;32(5):415	2018;32(5):415	NUM
aji-137	330	2	-	-	PUNCT
aji-137	330	3	23	23	NUM
aji-137	330	4	.	.	PUNCT
aji-137	330	5	20	20	NUM
aji-137	330	6	.	.	PUNCT
aji-137	331	1	honda	honda	PROPN
aji-137	331	2	s	s	PROPN
aji-137	331	3	,	,	PUNCT
aji-137	331	4	harigai	harigai	PROPN
aji-137	331	5	m.	m.	VERB
aji-137	331	6	the	the	DET
aji-137	331	7	safety	safety	NOUN
aji-137	331	8	of	of	ADP
aji-137	331	9	baricitinib	baricitinib	NOUN
aji-137	331	10	in	in	ADP
aji-137	331	11	patients	patient	NOUN
aji-137	331	12	with	with	ADP
aji-137	331	13	rheumatoid	rheumatoid	NOUN
aji-137	331	14	arthritis	arthritis	NOUN
aji-137	331	15	.	.	PUNCT
aji-137	332	1	expert	expert	ADJ
aji-137	332	2	opinion	opinion	NOUN
aji-137	332	3	on	on	ADP
aji-137	332	4	drug	drug	NOUN
aji-137	332	5	safety	safety	NOUN
aji-137	332	6	.	.	PUNCT
aji-137	333	1	2020;19(5):545	2020;19(5):545	NUM
aji-137	333	2	-	-	SYM
aji-137	333	3	51	51	NUM
aji-137	333	4	.	.	PUNCT
aji-137	333	5	21	21	NUM
aji-137	333	6	.	.	PUNCT
aji-137	334	1	freitas	freitas	PROPN
aji-137	334	2	e	e	NOUN
aji-137	334	3	,	,	PUNCT
aji-137	334	4	guttman	guttman	ADJ
aji-137	334	5	-	-	PUNCT
aji-137	334	6	yassky	yassky	ADJ
aji-137	334	7	e	e	NOUN
aji-137	334	8	,	,	PUNCT
aji-137	334	9	torres	torre	VERB
aji-137	334	10	t.	t.	NOUN
aji-137	334	11	baricitinib	baricitinib	NOUN
aji-137	334	12	for	for	ADP
aji-137	334	13	the	the	DET
aji-137	334	14	treatment	treatment	NOUN
aji-137	334	15	of	of	ADP
aji-137	334	16	alopecia	alopecia	NOUN
aji-137	334	17	areata	areata	ADJ
aji-137	334	18	.	.	PUNCT
aji-137	335	1	drugs	drug	NOUN
aji-137	335	2	.	.	PUNCT
aji-137	336	1	2023;83(9):761	2023;83(9):761	NUM
aji-137	336	2	-	-	SYM
aji-137	336	3	770	770	NUM
aji-137	336	4	.	.	NOUN
aji-137	337	1	22	22	NUM
aji-137	337	2	.	.	PUNCT
aji-137	338	1	bieber	bieber	PROPN
aji-137	338	2	t	t	PROPN
aji-137	338	3	,	,	PUNCT
aji-137	338	4	katoh	katoh	NOUN
aji-137	338	5	n	n	CCONJ
aji-137	338	6	,	,	PUNCT
aji-137	338	7	simpson	simpson	PROPN
aji-137	338	8	el	el	PROPN
aji-137	338	9	,	,	PUNCT
aji-137	338	10	de	de	X
aji-137	338	11	bruinweller	bruinweller	PROPN
aji-137	338	12	m	m	PROPN
aji-137	338	13	,	,	PUNCT
aji-137	338	14	thaçi	thaçi	PROPN
aji-137	338	15	d	d	PROPN
aji-137	338	16	,	,	PUNCT
aji-137	338	17	torrelo	torrelo	VERB
aji-137	338	18	a	a	PRON
aji-137	338	19	,	,	PUNCT
aji-137	338	20	sontag	sontag	NOUN
aji-137	338	21	a	a	NOUN
aji-137	338	22	,	,	PUNCT
aji-137	338	23	grond	grond	PROPN
aji-137	338	24	s	s	PROPN
aji-137	338	25	,	,	PUNCT
aji-137	338	26	issa	issa	PROPN
aji-137	338	27	m	m	PROPN
aji-137	338	28	,	,	PUNCT
aji-137	338	29	lu	lu	PROPN
aji-137	338	30	x	x	NOUN
aji-137	338	31	,	,	PUNCT
aji-137	338	32	cardillo	cardillo	ADJ
aji-137	338	33	t.	t.	NOUN
aji-137	338	34	safety	safety	NOUN
aji-137	338	35	of	of	ADP
aji-137	338	36	baricitinib	baricitinib	NOUN
aji-137	338	37	for	for	ADP
aji-137	338	38	the	the	DET
aji-137	338	39	treatment	treatment	NOUN
aji-137	338	40	of	of	ADP
aji-137	338	41	atopic	atopic	NOUN
aji-137	338	42	dermatitis	dermatitis	NOUN
aji-137	338	43	over	over	ADP
aji-137	338	44	a	a	DET
aji-137	338	45	median	median	NOUN
aji-137	338	46	of	of	ADP
aji-137	338	47	1.6	1.6	NUM
aji-137	338	48	years	year	NOUN
aji-137	338	49	and	and	CCONJ
aji-137	338	50	up	up	ADP
aji-137	338	51	to	to	PART
aji-137	338	52	3.9	3.9	NUM
aji-137	338	53	years	year	NOUN
aji-137	338	54	of	of	ADP
aji-137	338	55	treatment	treatment	NOUN
aji-137	338	56	:	:	PUNCT
aji-137	338	57	an	an	DET
aji-137	338	58	updated	update	VERB
aji-137	338	59	integrated	integrated	ADJ
aji-137	338	60	analysis	analysis	NOUN
aji-137	338	61	of	of	ADP
aji-137	338	62	eight	eight	NUM
aji-137	338	63	clinical	clinical	ADJ
aji-137	338	64	trials	trial	NOUN
aji-137	338	65	.	.	PUNCT
aji-137	339	1	journal	journal	NOUN
aji-137	339	2	of	of	ADP
aji-137	339	3	dermatological	dermatological	ADJ
aji-137	339	4	treatment	treatment	NOUN
aji-137	339	5	.	.	PUNCT
aji-137	340	1	2023;34(1):2161812.*/	2023;34(1):2161812.*/	NUM
aji-137	340	2	23	23	NUM
aji-137	340	3	.	.	PUNCT
aji-137	341	1	taylor	taylor	PROPN
aji-137	341	2	pc	pc	PROPN
aji-137	341	3	,	,	PUNCT
aji-137	341	4	keystone	keystone	PROPN
aji-137	341	5	ec	ec	PROPN
aji-137	341	6	,	,	PUNCT
aji-137	341	7	van	van	PROPN
aji-137	341	8	der	der	NOUN
aji-137	341	9	heijde	heijde	NOUN
aji-137	341	10	d	d	PROPN
aji-137	341	11	,	,	PUNCT
aji-137	341	12	weinblatt	weinblatt	PROPN
aji-137	341	13	me	me	PROPN
aji-137	341	14	,	,	PUNCT
aji-137	341	15	del	del	X
aji-137	341	16	carmen	carmen	PROPN
aji-137	341	17	morales	morales	PROPN
aji-137	341	18	l	l	PROPN
aji-137	341	19	,	,	PUNCT
aji-137	341	20	reyes	reyes	PROPN
aji-137	341	21	gonzaga	gonzaga	PROPN
aji-137	341	22	j	j	PROPN
aji-137	341	23	,	,	PUNCT
aji-137	341	24	yakushin	yakushin	PROPN
aji-137	341	25	s	s	PROPN
aji-137	341	26	,	,	PUNCT
aji-137	341	27	ishii	ishii	PROPN
aji-137	341	28	t	t	PROPN
aji-137	341	29	,	,	PUNCT
aji-137	341	30	emoto	emoto	PROPN
aji-137	341	31	k	k	PROPN
aji-137	341	32	,	,	PUNCT
aji-137	341	33	beattie	beattie	PROPN
aji-137	341	34	s	s	PROPN
aji-137	341	35	,	,	PUNCT
aji-137	341	36	arora	arora	PROPN
aji-137	341	37	v.	v.	ADP
aji-137	341	38	baricitinib	baricitinib	NOUN
aji-137	341	39	versus	versus	ADP
aji-137	341	40	placebo	placebo	NOUN
aji-137	341	41	or	or	CCONJ
aji-137	341	42	adalimumab	adalimumab	NOUN
aji-137	341	43	in	in	ADP
aji-137	341	44	rheumatoid	rheumatoid	NOUN
aji-137	341	45	arthritis	arthritis	NOUN
aji-137	341	46	.	.	PUNCT
aji-137	342	1	new	new	PROPN
aji-137	342	2	england	england	PROPN
aji-137	342	3	journal	journal	PROPN
aji-137	342	4	of	of	ADP
aji-137	342	5	medicine	medicine	NOUN
aji-137	342	6	.	.	PUNCT
aji-137	343	1	2017;376(7):652	2017;376(7):652	NUM
aji-137	343	2	-	-	SYM
aji-137	343	3	62	62	NUM
aji-137	343	4	.	.	PUNCT
aji-137	344	1	24	24	NUM
aji-137	344	2	.	.	PUNCT
aji-137	345	1	taylor	taylor	PROPN
aji-137	345	2	pc	pc	PROPN
aji-137	345	3	,	,	PUNCT
aji-137	345	4	kremer	kremer	PROPN
aji-137	345	5	jm	jm	PROPN
aji-137	345	6	,	,	PUNCT
aji-137	345	7	emery	emery	PROPN
aji-137	345	8	p	p	PROPN
aji-137	345	9	,	,	PUNCT
aji-137	345	10	zuckerman	zuckerman	PROPN
aji-137	345	11	sh	sh	PROPN
aji-137	345	12	,	,	PUNCT
aji-137	345	13	ruotolo	ruotolo	ADV
aji-137	345	14	g	g	PROPN
aji-137	345	15	,	,	PUNCT
aji-137	345	16	zhong	zhong	PROPN
aji-137	345	17	j	j	PROPN
aji-137	345	18	,	,	PUNCT
aji-137	345	19	chen	chen	PROPN
aji-137	345	20	l	l	PROPN
aji-137	345	21	,	,	PUNCT
aji-137	345	22	witt	witt	PROPN
aji-137	345	23	s	s	PROPN
aji-137	345	24	,	,	PUNCT
aji-137	345	25	saifan	saifan	NOUN
aji-137	345	26	c	c	NOUN
aji-137	345	27	,	,	PUNCT
aji-137	345	28	kurzawa	kurzawa	PROPN
aji-137	345	29	m	m	PROPN
aji-137	345	30	,	,	PUNCT
aji-137	345	31	otvos	otvos	PROPN
aji-137	345	32	jd	jd	PROPN
aji-137	345	33	.	.	PUNCT
aji-137	345	34	lipid	lipid	PROPN
aji-137	345	35	profile	profile	NOUN
aji-137	345	36	and	and	CCONJ
aji-137	345	37	effect	effect	NOUN
aji-137	345	38	of	of	ADP
aji-137	345	39	statin	statin	ADJ
aji-137	345	40	treatment	treatment	NOUN
aji-137	345	41	in	in	ADP
aji-137	345	42	pooled	pooled	ADJ
aji-137	345	43	phase	phase	NOUN
aji-137	345	44	ii	ii	NOUN
aji-137	345	45	and	and	CCONJ
aji-137	345	46	phase	phase	NOUN
aji-137	345	47	iii	iii	NUM
aji-137	345	48	baricitinib	baricitinib	NOUN
aji-137	345	49	studies	study	NOUN
aji-137	345	50	.	.	PUNCT
aji-137	346	1	annals	annal	NOUN
aji-137	346	2	of	of	ADP
aji-137	346	3	the	the	DET
aji-137	346	4	rheumatic	rheumatic	ADJ
aji-137	346	5	diseases	disease	NOUN
aji-137	346	6	.	.	PUNCT
aji-137	347	1	2018;77(7):988	2018;77(7):988	NUM
aji-137	347	2	-	-	SYM
aji-137	347	3	95	95	NUM
aji-137	347	4	.	.	PUNCT
aji-137	348	1	25	25	NUM
aji-137	348	2	.	.	PUNCT
aji-137	349	1	genovese	genovese	PROPN
aji-137	349	2	mc	mc	PROPN
aji-137	349	3	,	,	PUNCT
aji-137	349	4	kremer	kremer	PROPN
aji-137	349	5	j	j	PROPN
aji-137	349	6	,	,	PUNCT
aji-137	349	7	zamani	zamani	PROPN
aji-137	349	8	o	o	PROPN
aji-137	349	9	,	,	PUNCT
aji-137	349	10	ludivico	ludivico	PROPN
aji-137	349	11	c	c	X
aji-137	349	12	,	,	PUNCT
aji-137	349	13	krogulec	krogulec	PROPN
aji-137	349	14	m	m	PROPN
aji-137	349	15	,	,	PUNCT
aji-137	349	16	xie	xie	PROPN
aji-137	349	17	l	l	PROPN
aji-137	349	18	,	,	PUNCT
aji-137	349	19	beattie	beattie	PROPN
aji-137	349	20	sd	sd	PROPN
aji-137	349	21	,	,	PUNCT
aji-137	349	22	koch	koch	PROPN
aji-137	349	23	ae	ae	PROPN
aji-137	349	24	,	,	PUNCT
aji-137	349	25	cardillo	cardillo	VERB
aji-137	349	26	te	te	PROPN
aji-137	349	27	,	,	PUNCT
aji-137	349	28	rooney	rooney	PROPN
aji-137	349	29	tp	tp	PROPN
aji-137	349	30	,	,	PUNCT
aji-137	349	31	macias	macias	PROPN
aji-137	349	32	wl	wl	PROPN
aji-137	349	33	.	.	PROPN
aji-137	349	34	baricitinib	baricitinib	NOUN
aji-137	349	35	in	in	ADP
aji-137	349	36	patients	patient	NOUN
aji-137	349	37	with	with	ADP
aji-137	349	38	refractory	refractory	NOUN
aji-137	349	39	rheumatoid	rheumatoid	NOUN
aji-137	349	40	arthritis	arthritis	NOUN
aji-137	349	41	.	.	PUNCT
aji-137	350	1	new	new	PROPN
aji-137	350	2	england	england	PROPN
aji-137	350	3	journal	journal	PROPN
aji-137	350	4	of	of	ADP
aji-137	350	5	medicine	medicine	NOUN
aji-137	350	6	.	.	PUNCT
aji-137	351	1	2016;374	2016;374	NUM
aji-137	351	2	(	(	PUNCT
aji-137	351	3	13):124352	13):124352	NUM
aji-137	351	4	.	.	NOUN
aji-137	351	5	26	26	NUM
aji-137	351	6	.	.	PUNCT
aji-137	352	1	o’shea	o’shea	PROPN
aji-137	352	2	jj	jj	PROPN
aji-137	352	3	,	,	PUNCT
aji-137	352	4	kanno	kanno	PROPN
aji-137	352	5	y	y	PROPN
aji-137	352	6	,	,	PUNCT
aji-137	352	7	chan	chan	PROPN
aji-137	352	8	ac	ac	PROPN
aji-137	352	9	.	.	PUNCT
aji-137	353	1	in	in	ADP
aji-137	353	2	search	search	NOUN
aji-137	353	3	of	of	ADP
aji-137	353	4	magic	magic	ADJ
aji-137	353	5	bullets	bullet	NOUN
aji-137	353	6	:	:	PUNCT
aji-137	353	7	the	the	DET
aji-137	353	8	golden	golden	ADJ
aji-137	353	9	age	age	NOUN
aji-137	353	10	of	of	ADP
aji-137	353	11	immunotherapeutics	immunotherapeutic	NOUN
aji-137	353	12	.	.	PUNCT
aji-137	354	1	cell	cell	NOUN
aji-137	354	2	.	.	PUNCT
aji-137	355	1	2014;157(1	2014;157(1	NUM
aji-137	355	2	):	):	PUNCT
aji-137	355	3	227	227	NUM
aji-137	355	4	-	-	SYM
aji-137	355	5	40	40	NUM
aji-137	355	6	.	.	PUNCT
aji-137	356	1	27	27	NUM
aji-137	356	2	.	.	PUNCT
aji-137	357	1	urits	urit	VERB
aji-137	357	2	i	i	PRON
aji-137	357	3	,	,	PUNCT
aji-137	357	4	israel	israel	PROPN
aji-137	357	5	j	j	PROPN
aji-137	357	6	,	,	PUNCT
aji-137	357	7	hakobyan	hakobyan	PROPN
aji-137	357	8	h	h	NOUN
aji-137	357	9	,	,	PUNCT
aji-137	357	10	yusin	yusin	NOUN
aji-137	357	11	g	g	PROPN
aji-137	357	12	,	,	PUNCT
aji-137	357	13	lassiter	lassiter	PROPN
aji-137	357	14	g	g	PROPN
aji-137	357	15	,	,	PUNCT
aji-137	357	16	fackler	fackler	NOUN
aji-137	357	17	n	n	NOUN
aji-137	357	18	,	,	PUNCT
aji-137	357	19	berger	berger	PROPN
aji-137	357	20	aa	aa	PROPN
aji-137	357	21	,	,	PUNCT
aji-137	357	22	kassem	kassem	PROPN
aji-137	357	23	h	h	PROPN
aji-137	357	24	,	,	PUNCT
aji-137	357	25	kaye	kaye	PROPN
aji-137	357	26	a	a	PRON
aji-137	357	27	,	,	PUNCT
aji-137	357	28	viswanath	viswanath	NOUN
aji-137	357	29	o.	o.	NOUN
aji-137	357	30	baricitinib	baricitinib	NOUN
aji-137	357	31	for	for	ADP
aji-137	357	32	the	the	DET
aji-137	357	33	treatment	treatment	NOUN
aji-137	357	34	of	of	ADP
aji-137	357	35	rheumatoid	rheumatoid	NOUN
aji-137	357	36	arthritis	arthritis	NOUN
aji-137	357	37	.	.	PUNCT
aji-137	358	1	reumatologia	reumatologia	PROPN
aji-137	358	2	/	/	SYM
aji-137	358	3	rheumatology	rheumatology	NOUN
aji-137	358	4	.	.	PUNCT
aji-137	359	1	2020;58(6	2020;58(6	NUM
aji-137	359	2	):	):	PUNCT
aji-137	359	3	407	407	NUM
aji-137	359	4	-	-	SYM
aji-137	359	5	15	15	NUM
aji-137	359	6	.	.	NOUN
aji-137	360	1	28	28	NUM
aji-137	360	2	.	.	PUNCT
aji-137	361	1	urits	urit	VERB
aji-137	361	2	i	i	PRON
aji-137	361	3	,	,	PUNCT
aji-137	361	4	israel	israel	PROPN
aji-137	361	5	j	j	PROPN
aji-137	361	6	,	,	PUNCT
aji-137	361	7	hakobyan	hakobyan	PROPN
aji-137	361	8	h	h	NOUN
aji-137	361	9	,	,	PUNCT
aji-137	361	10	yusin	yusin	NOUN
aji-137	361	11	g	g	PROPN
aji-137	361	12	,	,	PUNCT
aji-137	361	13	lassiter	lassiter	PROPN
aji-137	361	14	g	g	PROPN
aji-137	361	15	,	,	PUNCT
aji-137	361	16	fackler	fackler	NOUN
aji-137	361	17	n	n	NOUN
aji-137	361	18	,	,	PUNCT
aji-137	361	19	berger	berger	PROPN
aji-137	361	20	aa	aa	PROPN
aji-137	361	21	,	,	PUNCT
aji-137	361	22	kassem	kassem	PROPN
aji-137	361	23	h	h	PROPN
aji-137	361	24	,	,	PUNCT
aji-137	361	25	kaye	kaye	PROPN
aji-137	361	26	a	a	PRON
aji-137	361	27	,	,	PUNCT
aji-137	361	28	viswanath	viswanath	NOUN
aji-137	361	29	o.	o.	NOUN
aji-137	361	30	baricitinib	baricitinib	NOUN
aji-137	361	31	for	for	ADP
aji-137	361	32	the	the	DET
aji-137	361	33	treatment	treatment	NOUN
aji-137	361	34	of	of	ADP
aji-137	361	35	rheumatoid	rheumatoid	NOUN
aji-137	361	36	arthritis	arthritis	NOUN
aji-137	361	37	.	.	PUNCT
aji-137	362	1	reumatologia/	reumatologia/	NUM
aji-137	362	2	rheumatology	rheumatology	NOUN
aji-137	362	3	.	.	PUNCT
aji-137	363	1	2020;58(6	2020;58(6	NUM
aji-137	363	2	):	):	PUNCT
aji-137	363	3	407	407	NUM
aji-137	363	4	-	-	SYM
aji-137	363	5	15	15	NUM
aji-137	363	6	.	.	NOUN
aji-137	364	1	29	29	NUM
aji-137	364	2	.	.	PUNCT
aji-137	364	3	felson	felson	PROPN
aji-137	364	4	dt	dt	PROPN
aji-137	364	5	,	,	PUNCT
aji-137	364	6	anderson	anderson	PROPN
aji-137	364	7	jj	jj	PROPN
aji-137	364	8	,	,	PUNCT
aji-137	364	9	boers	boers	PROPN
aji-137	364	10	m	m	PRON
aji-137	364	11	,	,	PUNCT
aji-137	364	12	bombardier	bombardier	PROPN
aji-137	364	13	c	c	NOUN
aji-137	364	14	,	,	PUNCT
aji-137	364	15	furst	furst	PROPN
aji-137	364	16	d	d	PROPN
aji-137	364	17	,	,	PUNCT
aji-137	364	18	goldsmith	goldsmith	PROPN
aji-137	364	19	c	c	PROPN
aji-137	364	20	,	,	PUNCT
aji-137	364	21	katz	katz	PROPN
aji-137	364	22	lm	lm	PROPN
aji-137	364	23	,	,	PUNCT
aji-137	364	24	lightfoot	lightfoot	PROPN
aji-137	364	25	jr	jr	PROPN
aji-137	364	26	r	r	PROPN
aji-137	364	27	,	,	PUNCT
aji-137	364	28	paulus	paulus	PROPN
aji-137	364	29	h	h	NOUN
aji-137	364	30	,	,	PUNCT
aji-137	364	31	strand	strand	NOUN
aji-137	364	32	v	v	ADP
aji-137	364	33	,	,	PUNCT
aji-137	364	34	tugwell	tugwell	ADJ
aji-137	364	35	p.	p.	PROPN
aji-137	364	36	american	american	PROPN
aji-137	364	37	college	college	PROPN
aji-137	364	38	of	of	ADP
aji-137	364	39	rheumatology	rheumatology	NOUN
aji-137	364	40	preliminary	preliminary	ADJ
aji-137	364	41	definition	definition	NOUN
aji-137	364	42	of	of	ADP
aji-137	364	43	improvement	improvement	NOUN
aji-137	364	44	in	in	ADP
aji-137	364	45	rheumatoid	rheumatoid	NOUN
aji-137	364	46	arthritis	arthritis	NOUN
aji-137	364	47	.	.	PUNCT
aji-137	365	1	arthritis	arthritis	NOUN
aji-137	365	2	and	and	CCONJ
aji-137	365	3	rheumatism	rheumatism	NOUN
aji-137	365	4	:	:	PUNCT
aji-137	365	5	official	official	ADJ
aji-137	365	6	journal	journal	NOUN
aji-137	365	7	of	of	ADP
aji-137	365	8	the	the	DET
aji-137	365	9	american	american	PROPN
aji-137	365	10	college	college	PROPN
aji-137	365	11	of	of	ADP
aji-137	365	12	rheumatology	rheumatology	NOUN
aji-137	365	13	.	.	PUNCT
aji-137	366	1	1995;38(6):727	1995;38(6):727	NUM
aji-137	366	2	-	-	SYM
aji-137	366	3	35	35	NUM
aji-137	366	4	.	.	PUNCT
aji-137	366	5	30	30	NUM
aji-137	366	6	.	.	PUNCT
aji-137	367	1	tanaka	tanaka	PROPN
aji-137	367	2	y	y	PROPN
aji-137	367	3	,	,	PUNCT
aji-137	367	4	emoto	emoto	PROPN
aji-137	367	5	k	k	PROPN
aji-137	367	6	,	,	PUNCT
aji-137	367	7	cai	cai	PROPN
aji-137	368	1	z	z	PROPN
aji-137	368	2	,	,	PUNCT
aji-137	368	3	aoki	aoki	PROPN
aji-137	368	4	t	t	PROPN
aji-137	368	5	,	,	PUNCT
aji-137	368	6	schlichting	schlichting	ADJ
aji-137	368	7	d	d	PROPN
aji-137	368	8	,	,	PUNCT
aji-137	368	9	rooney	rooney	PROPN
aji-137	368	10	t	t	PROPN
aji-137	368	11	,	,	PUNCT
aji-137	368	12	macias	macias	PROPN
aji-137	368	13	w.	w.	PROPN
aji-137	368	14	efficacy	efficacy	PROPN
aji-137	368	15	and	and	CCONJ
aji-137	368	16	safety	safety	NOUN
aji-137	368	17	of	of	ADP
aji-137	368	18	baricitinib	baricitinib	NOUN
aji-137	368	19	in	in	ADP
aji-137	368	20	japanese	japanese	ADJ
aji-137	368	21	patients	patient	NOUN
aji-137	368	22	with	with	ADP
aji-137	368	23	active	active	ADJ
aji-137	368	24	rheumatoid	rheumatoid	NOUN
aji-137	368	25	arthritis	arthritis	NOUN
aji-137	368	26	receiving	receive	VERB
aji-137	368	27	background	background	NOUN
aji-137	368	28	methotrexate	methotrexate	NOUN
aji-137	368	29	therapy	therapy	NOUN
aji-137	368	30	:	:	PUNCT
aji-137	368	31	a	a	DET
aji-137	368	32	12	12	NUM
aji-137	368	33	-	-	PUNCT
aji-137	368	34	week	week	NOUN
aji-137	368	35	,	,	PUNCT
aji-137	368	36	doubleblind	doubleblind	NOUN
aji-137	368	37	,	,	PUNCT
aji-137	368	38	randomized	randomize	VERB
aji-137	368	39	placebocontrolled	placebocontrolle	VERB
aji-137	368	40	study	study	NOUN
aji-137	368	41	.	.	PUNCT
aji-137	369	1	the	the	DET
aji-137	369	2	journal	journal	NOUN
aji-137	369	3	of	of	ADP
aji-137	369	4	rheumatology	rheumatology	NOUN
aji-137	369	5	.	.	PUNCT
aji-137	370	1	2016	2016	NUM
aji-137	370	2	;	;	PUNCT
aji-137	370	3	43(3):504	43(3):504	NOUN
aji-137	370	4	-	-	SYM
aji-137	370	5	11	11	NUM
aji-137	370	6	31	31	NUM
aji-137	370	7	.	.	PUNCT
aji-137	371	1	genovese	genovese	PROPN
aji-137	371	2	mc	mc	PROPN
aji-137	371	3	,	,	PUNCT
aji-137	371	4	kremer	kremer	PROPN
aji-137	371	5	j	j	PROPN
aji-137	371	6	,	,	PUNCT
aji-137	371	7	zamani	zamani	PROPN
aji-137	371	8	o	o	PROPN
aji-137	371	9	,	,	PUNCT
aji-137	371	10	ludivico	ludivico	PROPN
aji-137	371	11	c	c	X
aji-137	371	12	,	,	PUNCT
aji-137	371	13	krogulec	krogulec	PROPN
aji-137	371	14	m	m	PROPN
aji-137	371	15	,	,	PUNCT
aji-137	371	16	xie	xie	PROPN
aji-137	371	17	l	l	PROPN
aji-137	371	18	,	,	PUNCT
aji-137	371	19	beattie	beattie	PROPN
aji-137	371	20	sd	sd	PROPN
aji-137	371	21	,	,	PUNCT
aji-137	371	22	koch	koch	PROPN
aji-137	371	23	ae	ae	PROPN
aji-137	371	24	,	,	PUNCT
aji-137	371	25	cardillo	cardillo	VERB
aji-137	371	26	te	te	PROPN
aji-137	371	27	,	,	PUNCT
aji-137	371	28	rooney	rooney	PROPN
aji-137	371	29	tp	tp	PROPN
aji-137	371	30	,	,	PUNCT
aji-137	371	31	macias	macias	PROPN
aji-137	371	32	wl	wl	PROPN
aji-137	371	33	.	.	PROPN
aji-137	371	34	baricitinib	baricitinib	NOUN
aji-137	371	35	in	in	ADP
aji-137	371	36	patients	patient	NOUN
aji-137	371	37	with	with	ADP
aji-137	371	38	refractory	refractory	NOUN
aji-137	371	39	rheumatoid	rheumatoid	NOUN
aji-137	371	40	arthritis	arthritis	NOUN
aji-137	371	41	.	.	PUNCT
aji-137	372	1	new	new	PROPN
aji-137	372	2	england	england	PROPN
aji-137	372	3	journal	journal	PROPN
aji-137	372	4	of	of	ADP
aji-137	372	5	medicine	medicine	NOUN
aji-137	372	6	.	.	PUNCT
aji-137	373	1	2016;374(13):124352	2016;374(13):124352	X
aji-137	373	2	.	.	PUNCT
aji-137	374	1	gupta	gupta	PROPN
aji-137	374	2	et	et	PROPN
aji-137	374	3	al	al	PROPN
aji-137	374	4	.	.	PROPN
aji-137	374	5	;	;	PUNCT
aji-137	374	6	asian	asian	PROPN
aji-137	374	7	j.	j.	PROPN
aji-137	374	8	immunol	immunol	PROPN
aji-137	374	9	.	.	PROPN
aji-137	374	10	,	,	PUNCT
aji-137	374	11	vol	vol	NOUN
aji-137	374	12	.	.	PROPN
aji-137	375	1	7	7	NUM
aji-137	375	2	,	,	PUNCT
aji-137	375	3	no	no	INTJ
aji-137	375	4	.	.	NOUN
aji-137	375	5	1	1	NUM
aji-137	375	6	,	,	PUNCT
aji-137	375	7	pp	pp	ADJ
aji-137	375	8	.	.	PUNCT
aji-137	376	1	123	123	NUM
aji-137	376	2	-	-	SYM
aji-137	376	3	130	130	NUM
aji-137	376	4	,	,	PUNCT
aji-137	376	5	2024	2024	NUM
aji-137	376	6	;	;	PUNCT
aji-137	376	7	article	article	NOUN
aji-137	376	8	no.aji.120135	no.aji.120135	VERB
aji-137	376	9	130	130	NUM
aji-137	376	10	32	32	NUM
aji-137	376	11	.	.	PUNCT
aji-137	377	1	ummarino	ummarino	PROPN
aji-137	377	2	d.	d.	PROPN
aji-137	377	3	ra	ra	PROPN
aji-137	377	4	-	-	PUNCT
aji-137	377	5	beacon	beacon	NOUN
aji-137	377	6	illuminates	illuminate	VERB
aji-137	377	7	baricitinib	baricitinib	NOUN
aji-137	377	8	.	.	PUNCT
aji-137	378	1	nature	nature	NOUN
aji-137	378	2	reviews	review	VERB
aji-137	378	3	rheumatology	rheumatology	NOUN
aji-137	378	4	.	.	PUNCT
aji-137	379	1	2016;12(6):313-	2016;12(6):313-	NUM
aji-137	379	2	.	.	PUNCT
aji-137	380	1	33	33	NUM
aji-137	380	2	.	.	PUNCT
aji-137	381	1	radu	radu	PROPN
aji-137	381	2	af	af	PROPN
aji-137	381	3	,	,	PUNCT
aji-137	381	4	bungau	bungau	VERB
aji-137	381	5	sg	sg	PROPN
aji-137	381	6	.	.	PUNCT
aji-137	381	7	management	management	NOUN
aji-137	381	8	of	of	ADP
aji-137	381	9	rheumatoid	rheumatoid	NOUN
aji-137	381	10	arthritis	arthritis	NOUN
aji-137	381	11	:	:	PUNCT
aji-137	381	12	an	an	DET
aji-137	381	13	overview	overview	NOUN
aji-137	381	14	.	.	PUNCT
aji-137	382	1	cells	cell	NOUN
aji-137	382	2	.	.	PUNCT
aji-137	383	1	2021;10(11):2857	2021;10(11):2857	X
aji-137	383	2	.	.	PUNCT
aji-137	383	3	disclaimer	disclaimer	ADJ
aji-137	383	4	/	/	SYM
aji-137	383	5	publisher	publisher	NOUN
aji-137	383	6	’s	’s	PART
aji-137	383	7	note	note	NOUN
aji-137	383	8	:	:	PUNCT
aji-137	383	9	the	the	DET
aji-137	383	10	statements	statement	NOUN
aji-137	383	11	,	,	PUNCT
aji-137	383	12	opinions	opinion	NOUN
aji-137	383	13	and	and	CCONJ
aji-137	383	14	data	datum	NOUN
aji-137	383	15	contained	contain	VERB
aji-137	383	16	in	in	ADP
aji-137	383	17	all	all	DET
aji-137	383	18	publications	publication	NOUN
aji-137	383	19	are	be	AUX
aji-137	383	20	solely	solely	ADV
aji-137	383	21	those	those	PRON
aji-137	383	22	of	of	ADP
aji-137	383	23	the	the	DET
aji-137	383	24	individual	individual	ADJ
aji-137	383	25	author(s	author(s	PROPN
aji-137	383	26	)	)	PUNCT
aji-137	383	27	and	and	CCONJ
aji-137	383	28	contributor(s	contributor(s	NOUN
aji-137	383	29	)	)	PUNCT
aji-137	383	30	and	and	CCONJ
aji-137	383	31	not	not	PART
aji-137	383	32	of	of	ADP
aji-137	383	33	the	the	DET
aji-137	383	34	publisher	publisher	NOUN
aji-137	383	35	and/or	and/or	CCONJ
aji-137	383	36	the	the	DET
aji-137	383	37	editor(s	editor(s	NOUN
aji-137	383	38	)	)	PUNCT
aji-137	383	39	.	.	PUNCT
aji-137	384	1	this	this	DET
aji-137	384	2	publisher	publisher	NOUN
aji-137	384	3	and/or	and/or	CCONJ
aji-137	384	4	the	the	DET
aji-137	384	5	editor(s	editor(s	NOUN
aji-137	384	6	)	)	PUNCT
aji-137	384	7	disclaim	disclaim	VERB
aji-137	384	8	responsibility	responsibility	NOUN
aji-137	384	9	for	for	ADP
aji-137	384	10	any	any	DET
aji-137	384	11	injury	injury	NOUN
aji-137	384	12	to	to	ADP
aji-137	384	13	people	people	NOUN
aji-137	384	14	or	or	CCONJ
aji-137	384	15	property	property	NOUN
aji-137	384	16	resulting	result	VERB
aji-137	384	17	from	from	ADP
aji-137	384	18	any	any	DET
aji-137	384	19	ideas	idea	NOUN
aji-137	384	20	,	,	PUNCT
aji-137	384	21	methods	method	NOUN
aji-137	384	22	,	,	PUNCT
aji-137	384	23	instructions	instruction	NOUN
aji-137	384	24	or	or	CCONJ
aji-137	384	25	products	product	NOUN
aji-137	384	26	referred	refer	VERB
aji-137	384	27	to	to	ADP
aji-137	384	28	in	in	ADP
aji-137	384	29	the	the	DET
aji-137	384	30	content	content	NOUN
aji-137	384	31	.	.	PUNCT
aji-137	385	1	_	_	PUNCT
aji-137	386	1	_	_	PUNCT
aji-137	387	1	_	_	PUNCT
aji-137	388	1	_	_	PUNCT
aji-137	389	1	_	_	PUNCT
aji-137	390	1	_	_	PUNCT
aji-137	391	1	_	_	PUNCT
aji-137	392	1	_	_	PUNCT
aji-137	393	1	_	_	PUNCT
aji-137	394	1	_	_	PUNCT
aji-137	395	1	_	_	PUNCT
aji-137	396	1	_	_	PUNCT
aji-137	397	1	_	_	PUNCT
aji-137	398	1	_	_	PUNCT
aji-137	399	1	_	_	PUNCT
aji-137	400	1	_	_	PUNCT
aji-137	401	1	_	_	PUNCT
aji-137	402	1	_	_	PUNCT
aji-137	403	1	_	_	PUNCT
aji-137	404	1	_	_	PUNCT
aji-137	405	1	_	_	PUNCT
aji-137	406	1	_	_	PUNCT
aji-137	407	1	_	_	PUNCT
aji-137	408	1	_	_	PUNCT
aji-137	409	1	_	_	PUNCT
aji-137	410	1	_	_	PUNCT
aji-137	411	1	_	_	PUNCT
aji-137	412	1	_	_	PUNCT
aji-137	413	1	_	_	PUNCT
aji-137	414	1	_	_	PUNCT
aji-137	415	1	_	_	PUNCT
aji-137	416	1	_	_	PUNCT
aji-137	417	1	_	_	PUNCT
aji-137	418	1	_	_	PUNCT
aji-137	419	1	_	_	PUNCT
aji-137	420	1	_	_	PUNCT
aji-137	421	1	_	_	PUNCT
aji-137	422	1	_	_	PUNCT
aji-137	423	1	_	_	PUNCT
aji-137	424	1	_	_	PUNCT
aji-137	425	1	_	_	PUNCT
aji-137	426	1	_	_	PUNCT
aji-137	427	1	_	_	PUNCT
aji-137	428	1	_	_	PUNCT
aji-137	429	1	_	_	PUNCT
aji-137	430	1	_	_	PUNCT
aji-137	431	1	_	_	PUNCT
aji-137	432	1	_	_	PUNCT
aji-137	433	1	_	_	PUNCT
aji-137	434	1	_	_	PUNCT
aji-137	435	1	_	_	PUNCT
aji-137	436	1	_	_	PUNCT
aji-137	437	1	_	_	PUNCT
aji-137	438	1	_	_	PUNCT
aji-137	439	1	_	_	PUNCT
aji-137	440	1	_	_	PUNCT
aji-137	441	1	_	_	PUNCT
aji-137	442	1	_	_	PUNCT
aji-137	443	1	_	_	PUNCT
aji-137	444	1	_	_	PUNCT
aji-137	445	1	_	_	PUNCT
aji-137	446	1	_	_	PUNCT
aji-137	447	1	_	_	PUNCT
aji-137	448	1	_	_	PUNCT
aji-137	449	1	_	_	PUNCT
aji-137	450	1	_	_	PUNCT
aji-137	451	1	_	_	PUNCT
aji-137	452	1	_	_	PUNCT
aji-137	453	1	_	_	PUNCT
aji-137	454	1	_	_	PUNCT
aji-137	455	1	_	_	PUNCT
aji-137	456	1	_	_	PUNCT
aji-137	457	1	_	_	PUNCT
aji-137	458	1	_	_	PUNCT
aji-137	459	1	_	_	PUNCT
aji-137	460	1	_	_	PUNCT
aji-137	461	1	_	_	PUNCT
aji-137	462	1	_	_	PUNCT
aji-137	463	1	_	_	PUNCT
aji-137	464	1	_	_	PUNCT
aji-137	465	1	_	_	PUNCT
aji-137	466	1	©	©	PRON
aji-137	466	2	copyright	copyright	NOUN
aji-137	466	3	(	(	PUNCT
aji-137	466	4	2024	2024	NUM
aji-137	466	5	):	):	PUNCT
aji-137	466	6	author(s	author(s	NOUN
aji-137	466	7	)	)	PUNCT
aji-137	466	8	.	.	PUNCT
aji-137	467	1	the	the	DET
aji-137	467	2	licensee	licensee	NOUN
aji-137	467	3	is	be	AUX
aji-137	467	4	the	the	DET
aji-137	467	5	journal	journal	PROPN
aji-137	467	6	publisher	publisher	NOUN
aji-137	467	7	.	.	PUNCT
aji-137	468	1	this	this	PRON
aji-137	468	2	is	be	AUX
aji-137	468	3	an	an	DET
aji-137	468	4	open	open	ADJ
aji-137	468	5	access	access	NOUN
aji-137	468	6	article	article	NOUN
aji-137	468	7	distributed	distribute	VERB
aji-137	468	8	under	under	ADP
aji-137	468	9	the	the	DET
aji-137	468	10	terms	term	NOUN
aji-137	468	11	of	of	ADP
aji-137	468	12	the	the	DET
aji-137	468	13	creative	creative	ADJ
aji-137	468	14	commons	common	NOUN
aji-137	468	15	attribution	attribution	NOUN
aji-137	468	16	license	license	NOUN
aji-137	468	17	(	(	PUNCT
aji-137	468	18	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-137	468	19	)	)	PUNCT
aji-137	468	20	,	,	PUNCT
aji-137	468	21	which	which	PRON
aji-137	468	22	permits	permit	VERB
aji-137	468	23	unrestricted	unrestricted	ADJ
aji-137	468	24	use	use	NOUN
aji-137	468	25	,	,	PUNCT
aji-137	468	26	distribution	distribution	NOUN
aji-137	468	27	,	,	PUNCT
aji-137	468	28	and	and	CCONJ
aji-137	468	29	reproduction	reproduction	NOUN
aji-137	468	30	in	in	ADP
aji-137	468	31	any	any	DET
aji-137	468	32	medium	medium	NOUN
aji-137	468	33	,	,	PUNCT
aji-137	468	34	provided	provide	VERB
aji-137	468	35	the	the	DET
aji-137	468	36	original	original	ADJ
aji-137	468	37	work	work	NOUN
aji-137	468	38	is	be	AUX
aji-137	468	39	properly	properly	ADV
aji-137	468	40	cited	cite	VERB
aji-137	468	41	.	.	PUNCT
aji-137	469	1	peer	peer	NOUN
aji-137	469	2	-	-	PUNCT
aji-137	469	3	review	review	NOUN
aji-137	469	4	history	history	NOUN
aji-137	469	5	:	:	PUNCT
aji-137	469	6	the	the	DET
aji-137	469	7	peer	peer	NOUN
aji-137	469	8	review	review	NOUN
aji-137	469	9	history	history	NOUN
aji-137	469	10	for	for	ADP
aji-137	469	11	this	this	DET
aji-137	469	12	paper	paper	NOUN
aji-137	469	13	can	can	AUX
aji-137	469	14	be	be	AUX
aji-137	469	15	accessed	access	VERB
aji-137	469	16	here	here	ADV
aji-137	469	17	:	:	PUNCT
aji-137	469	18	https://www.sdiarticle5.com/review-history/120135	https://www.sdiarticle5.com/review-history/120135	PROPN
aji-137	469	19	https://www.sdiarticle5.com/review-history/120135	https://www.sdiarticle5.com/review-history/120135	VERB